Compounds and their use against cancer

The development of specific compounds to selectively inhibit USP1 offers a potent solution for cancer treatment, overcoming the limitations of existing USP1 inhibitors and enhancing cancer therapy by effectively targeting USP1 and modulating DNA repair activity.

WO2024233665A1PCT designated stage expired Publication Date: 2024-11-14TANGO THERAPEUTICS INC

Patent Information

Application Number
PCT/US2024/028376
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2024-05-08
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

There is an unmet need for potent and selective inhibitors of USP1, as existing small molecule inhibitors like GW7647, Pimozide, and C527 have limitations due to potency and off-target pharmacology, and current USP1 inhibitors such as ML323 and those described in various WO applications do not fully address the requirement for effective cancer treatment.

Method used

Development of compounds of Formula (I) or Formula (II) or their pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers, which are designed to selectively inhibit USP1, potentially used in combination with other therapeutic agents for cancer treatment.

Benefits of technology

These compounds provide a therapeutically effective means to inhibit USP1, modulate DNA repair activity, and treat cancer by targeting USP1, addressing the limitations of existing inhibitors and enhancing cancer treatment outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024028376_14112024_PF_FP_ABST
    Figure US2024028376_14112024_PF_FP_ABST
Patent Text Reader

Abstract

Compounds are provided according to Formula (I) and Formula (II) and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, tautomers and stereoisomers, as well as pharmaceutical compositions, wherein Ring A, Ring B, X1, X2, RA, RB, RC, RD, RE, RC, Rc', L, m, n and p are as defined herein. The compounds disclosed herein are contemplated to be useful for the prevention and treatment of a variety of conditions.
Need to check novelty before this filing date? Find Prior Art

Description

COMPOUNDS AND THEIR USE AGAINST CANCER Cross-reference to related application

[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No.63 / 464,915, filed on May 8, 2023, the entire contents of which are incorporated by reference herein. Background

[0002] Ubiquitin is a small, highly conserved protein composed of 76 amino acids that is post-transcriptionally attached to target proteins, including itself, via a concerted three-step enzymatic reaction. This covalent linkage or isopeptide bond primarily occurs between the C- terminal glycine of ubiquitin and the ε-amino group of lysine residue(s) on the target protein (Pickart, C. M., Annu. Rev. Biochem., 2001 : 503-33). The functional consequence of ubiquitination is determined by the number and linkage topology of ubiquitin molecules conjugated to the target protein. For example, proteins exhibiting Lys48-linked polyubiquitin chains are generally targeted to the proteasome for degradation, while monoubiquitination or polyubiquitin chains linked through other lysines regulate several non-proteolytic functions, including cell cycle regulation (Nakayama, K. I. et al., Nat. rev. Cancer, 6(5): 369-81 (2006)), DNA repair (Bergink, S., et al., Nature 458(7237): 461 -7 (2009)), transcription (Conaway, R. C, et al., Science 296(5571): 1254-8 (2002)), and endocytosis (Mukhopadhyay, D., et al., Science 315(5809): 201 -5 (2007)). Similar to other posttranslational modifications, ubiquitination is a reversible process counteracted by a family of enzymes known as deubiquitinases (DUBs). These enzymes are cysteine proteases or metalloproteases that hydrolyze the ubiquitin isopeptide bond (Komander, D., et al., Nat. Rev. Mol. Cell Biol. 10(8): 550-63 (2007)). The human genome encodes close to 100 DUBs.

[0003] DUBs and their substrate proteins are often deregulated in cancers. Targeting specific DUB family members may result in antitumor activity by enhancing the ubiquitination and subsequent degradation of oncogenic substrates, involved in tumor growth, survival, differentiation and maintenance of the tumor microenvironment. (Hussain, S. et. al., "DUBs and cancer: The role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors." Cell Cycle 8, 1688-1697 (2009)). Consequently, several members of the DUB family have been implicated in processes related to human disease, including cancer and neurodegeneration. Among them, USP1 (ubiquitin- specific peptidase 1) has gained increased interest as a novel therapeutic target given its roles in the DNA damage response.

[0004] USP1 is a cysteine isopeptidase of the USP subfamily of deubiquitinases (DUBs). (Nijman, S. M. B., et al. "The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 17, 331-339 (2005)) Full-length human USP1 is composed of 785 amino acids, including a catalytic triad composed of Cys90, His593 and Asp751. (Villamil, M. A., et al, "Serine phosphorylation is critical for the activation of ubiquitin-specific protease 1 and its interaction with WD40-repeat protein UAF1." Biochem.51, 9112-9113 (2012)). USP1 is relatively inactive on its own and full enzymatic activity is achieved only when bound in a heterodimeric complex with USP1 Associated Factor 1 (UAF1), which also binds to and regulates the activity of USP12 and USP46. (Cohn, M. A., et al, "A UAF1 -Containing Multisubunit Protein Complex Regulates the Fanconi Anemia Pathway." Mol. Cell 28, 786- 797 (2007)).

[0005] USP1 deubiquitinates a variety of cellular targets involved in different processes related to cancer. For example, USP1 deubiquitinates PCNA (proliferating cell nuclear antigen), a key protein in translesion synthesis (TLS), and FANCI / FANCD2 (Fanconi anemia group complementation group D2), a key protein complex in the Fanconi anemia (FA) pathway. (Nijman, S. M. B. et al "The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway." Mol Cell 17, 331-339 (2005); Huang, T. T. et al, "Regulation of monoubiquitinated PCNA by DUB autocleavage." Nat. Cell Biol 8, 339-347 (2006)). These DNA damage response (DDR) pathways are essential for repair of DNA damage, including those induced by DNA cross-linking agents such as cisplatin, mitomycin C (MMC), diepoxybutane, ionizing radiation and ultraviolet radiation. In addition, USP1 promotes cancer cell stem maintenance by increasing inhibitor of protein binding (ID) protein stability. Thus, USP1 inhibition may antagonize cancer cell growth by inducing cell cycle arrest and decreasing cancer stem cell maintenance via a decrease in ID protein stability. (Williams, S. A. et al, “USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma.” Cell 146: 918-30 (2011); Lee, J. K. et al, “USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance.” Neuro Oncol.18: 37-47 (2016)).

[0006] The compounds GW7647 and Pimozide have been described as inactivators of USP1. However, both compounds are limited by potency and off-target pharmacology, in part because both of them have noticeable activity against unrelated targets. Another small molecule inhibitor of USP1, C527, which was reported by D’Andrea et al. in WO2011 / 137320, sensitizes cells to both the crosslinking agent, mitomycin C, and the topoisomerase 1 inhibitor, camptothecin. However, C527 shows low micromolar inhibition ofrelated USPs as well as dissimilar DUBs (i.e., UCHL-1 and UCHL-3). Another small molecule USP1-UAF1 inhibitor (ML323) has been more recently disclosed (Dexheimer et al, J. Med. Chem.2014, 57, 8099-8110; Liang et al, Nature Chem. Bio.2015, 10, 298-304; US 9802904 B2). Additional USP1 inhibitors have also been described in WO2017087837, WO2020132269, WO2020139988, WO2021163530, WO2022199652, WO2022214053, WO2022228399, WO2022233263 and WO2022253188. Two applications filed by Tango Therapeutics, WO20222174184 and WO2022197892 also describe USP1 inhibitors.

[0007] The foregoing shows that there exists an unmet need for new selective inhibitors of USP1, and in addition, that inhibition of USP1 with small molecule inhibitors has the potential to be a treatment for cancers and other disorders. For these reasons, there remains a considerable need for potent small molecule inhibitors of USP1. Summary

[0008] In one aspect provided is a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof; wherein:; ; X1and X2are each independently CH or N;Ring A is selected from the group consisting of:andX3wherein X3is CH or N and wherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B; L is selected from the group consisting of –O– and –S–; Ring B is a 5-10 membered heteroaryl or a 3-10 membered heterocyclyl; each RAis independently selected from the group consisting of –D, oxo, halo, – CN, –C1–C6alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, –ORA1and – N(RA1)2; each RA1is independently selected from the group consisting of H, –C1–C6alkyl, –C1–C6haloalkyl and C3–C9cycloalkyl wherein each hydrogen atom of each alkyl and cycloalkyl can be replaced by deuterium; or two instances of RA1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O; each RBis independently selected from the group consisting of halo, –CN, –C1–C6alkyl, –C1–C6alkenyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, C3-C9cycloalkylalkyl, –ORB1, –N(RB1)2, – C(=O)RB1, –C(=O)ORB1, –NRB1C(=O)RB1, –NRB1C(=O)ORB1, –C(=O)N(RB1)2, – OC(=O)N(RB1)2, –S(=O)RB1, –S(=O)2RB1, –SRB1, –S(=O)(=NRB1)RB1, –NRB1S(=O)2RB1and –S(=O)2N(RB1)2, wherein each alkyl, alkenyl, cycloalkyl, heterocyclyl and cycloalkylalkyl of RBcan be partially or fully deuterated and can be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, –OH– and –CH3; each RB1is independently selected from the group consisting of H, –C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl and 3-7 membered heterocyclyl wherein each hydrogen atom of each alkyl, cycloalkyl and heterocyclyl can be replaced by deuterium; or two instances of RB1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O; each RCis independently selected from the group consisting of H, –D, oxo, halo, – CN, –ORC1, –SRC1–NRC12, –C1–C6alkyl, –C1–C6hydroxyalkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl, 3-10 member heterocyclyl and –heteroC1-C4alkyl wherein each alkyl, cycloalkyland heterocyclyl of RCcan partially or fully deuterated and can be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, –OH– and –CH3; each RC1is independently selected from the group consisting of H and –C1–C6alkyl, wherein each hydrogen atom of the alkyl can be independently replaced by deuterium; or two instances of RC1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O; each RDis independently selected from the group consisting of –D, halo, –CN, – C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, –C6-C10aryl, –ORD1, –N(RD1)2, –C(=O)RD1, – C(=O)ORD1, –NRD1C(=O)RD1, –NRD1C(=O)ORD1, –C(=O)N(RD1)2, –OC(=O)N(RD1)2, – S(=O)RD1, –S(=O)2RD1, –SRD1, –S(=O)(=NRD1)RD1, –NRD1S(=O)2RD1and –S(=O)2N(RD1)2, wherein each alkyl, cycloalkyl, heterocyclyl and aryl of RDcan be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, –OH– and –CH3; each RD1is independently selected from the group consisting of H, –C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl and 3-7 membered heterocyclyl, wherein each hydrogen atom of each alkyl, cycloalkyl and heterocyclyl can be replaced by deuterium; or two instances of RD1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O; REis selected from H, –D, halo, –CN, –C1–C6alkyl, –C1-C6alkynyl, –heteroC1– C6alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, –C6-C10aryl, 5-10 member heteroaryl, heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, –ORE1, –SRE1, –N(RE1)2, –C1–C6alkylene–NRE1C(=O)ORE1, – C(=O)RE1, –C(=O)ORE1, –NRE1C(=O)RE1, –NRE1C(=O)ORE1, –C(=O)N(RE1)2, and – OC(=O)N(RE1)2, wherein each alkyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl is optionally substituted at any available position; each RE1is independently selected from H, –C1–C6alkyl (wherein each hydrogen can be independently replaced by deuterium), –heteroC1–C6alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl, 3-7 membered heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, 5-6 membered heteroaryl, arylalkyl and heteroarylalkyl wherein each alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl is optionally substituted at any available position;each Rcand Rc’is independently selected from the group consisting of H, –D, – C1–C6alkyl, –heteroC1-C4alkyl and –C1–C6haloalkyl or Rcand Rc’can be taken together with the atom to which they are attached to form a –C3–C9cycloalkyl; n is 0, 1, 2,3 or 4; m is 0, 1, 2 or 3; and p is 0, 1, 2 or 3.

[0009] In an embodiment, provided are compounds selected from the compounds of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0010] In an embodiment, provided is a pharmaceutical composition comprising a compound as described herein or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceutically acceptable carrier.

[0011] In an embodiment, the pharmaceutical composition comprises a second therapeutic agent.

[0012] In one aspect provided is a method for treating or preventing a disease or disorder sensitive to inhibition of USP1 comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0013] In one aspect provided is a method of treating a disease or disorder sensitive to the inhibition of USP1 comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0014] In one aspect provided is a method for inhibiting USP1 comprising administering to a patient in need thereof an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0015] In one aspect provided is a method for treating or preventing cancer in a patient in need thereof comprising administering to the patient in need thereof a therapeutically effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0016] In one aspect provided is a method for treating cancer in a patient in need thereof comprising administering to the patient in need thereof a therapeutically effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0017] In one aspect provided is a method for treating or preventing a disease or disorder associated with DNA damage comprising administering to a patient in need of a treatment for diseases or disorders associated with DNA damage an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0018] In one aspect provided is a method for treating a disease or disorder associated with DNA damage comprising administering to a patient in need of a treatment for diseases or disorders associated with DNA damage an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0019] In one aspect provided is a method of inhibiting, modulating or reducing DNA repair activity exercised by USP1 comprising administering to a patient in need thereof an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0020] In one aspect provided is a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method for treating or preventing a disease or disorder sensitive to the inhibition of USP1 comprising administering to a patient in need thereof a therapeutically effective amount of the compound or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0021] In one aspect provided is a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method of treating a disease or disorder sensitive to the inhibition of USP1 comprising administering to a patient in need thereof a therapeutically effective amount of the compound or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0022] In one aspect provided is a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method for inhibiting USP1 comprising administering to a patient in need thereof an effective amount of the compound or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0023] In one aspect provided is a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method for treating or preventing cancer in a patient in need thereof comprisingadministering to the patient in need thereof a therapeutically effective amount of the compound or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0024] In one aspect provided is a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method for treating cancer in a patient in need thereof comprising administering to the patient in need thereof a therapeutically effective amount of the compound or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0025] In one aspect provided is a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method for treating or preventing a disease or disorder associated with DNA damage.

[0026] In one aspect provided is a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method for treating a disease or disorder associated with DNA damage.

[0027] In one aspect provided is a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method of inhibiting, modulating or reducing DNA repair activity exercised by USP1 comprising administering to a patient in need thereof an effective amount of the compound or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0028] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof in the manufacturing of a medicament for treating or preventing a disease or disorder sensitive to the inhibition of USP1.

[0029] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof in the manufacturing of a medicament for treating a disease or disorder sensitive to the inhibition of USP1.

[0030] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof in the manufacturing of a medicament for inhibiting USP1.

[0031] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer,or tautomer thereof in the manufacturing of a medicament for treating or preventing cancer in a patient in need thereof.

[0032] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof in the manufacturing of a medicament for treating cancer in a patient in need thereof.

[0033] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof in the manufacturing of a medicament for treating or preventing a disease or disorder associated with DNA damage.

[0034] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof in the manufacturing of a medicament for treating a disease or disorder associated with DNA damage.

[0035] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for inhibiting, modulating or reducing DNA repair activity exercised by USP1.

[0036] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for treating or preventing a disease or disorder sensitive to the inhibition of USP1.

[0037] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for treating a disease or disorder sensitive to the inhibition of USP1.

[0038] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for inhibiting USP1.

[0039] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for treating or preventing cancer in a patient in need thereof.

[0040] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for treating cancer in a patient in need thereof.

[0041] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for treating or preventing a disease or disorder associated with DNA damage.

[0042] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for treating a disease or disorder associated with DNA damage.

[0043] In one aspect, provided is a use of an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for inhibiting, modulating or reducing DNA repair activity exercised by USP1. Detailed Description

[0044] The disclosure herein sets forth exemplary methods, parameters and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments. Definitions

[0045] As used in the present disclosure, the following words and phrases are generally intended to have the meanings as set forth below unless expressly indicated otherwise or the context in which they are used indicates otherwise. Chemical Definitions

[0046] Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March’s Advanced Organic Chemistry, 5thEdition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rdEdition, Cambridge University Press, Cambridge, 1987.

[0047] Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and / or diastereomers. For example, thecompounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Unless stereochemistry is explicitly indicated in a structure, the structure is intended to embrace all possible stereoisomers of the compound depicted. If stereochemistry is explicitly indicated for one portion or portions of a molecule, but not for another portion or portions of a molecule, the structure is intended to embrace all possible stereoisomers for the portion or portions where stereochemistry is not explicitly indicated. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high-pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw–Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p.268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The invention additionally encompasses compounds described herein as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers.

[0048] The “enantiomeric excess” (“e.e.”) or “% enantiomeric excess” (“%e.e.”) of a composition as used herein refers to an excess of one enantiomer relative to the other enantiomer present in the composition. For example, a composition can contain 90% of one enantiomer, e.g., the S enantiomer, and 10% of the other enantiomer, i.e., the R enantiomer. e.e. = (90-10) / 100 = 80%.

[0049] Thus, a composition containing 90% of one enantiomer and 10% of the other enantiomer is said to have an enantiomeric excess of 80%.

[0050] The “diastereomeric excess” (“d.e.”) or “% diastereomeric excess” (“%d.e.”) of a composition as used herein refers to an excess of one diastereomer relative to one or more different diastereomers present in the composition. For example, a composition can contain 90% of one diastereomer, and 10% of one or more different diastereomers. d.e. = (90-10) / 100 = 80%.

[0051] Thus, a composition containing 90% of one diastereomers and 10% of one or more different diastereomers is said to have a diastereomeric excess of 80%.

[0052] In an alternative embodiment, compounds described herein may also comprise one or more isotopic substitutions. For example, hydrogen may be2H (D or deuterium) or3H (T or tritium); carbon may be, for example,13C or14C; oxygen may be, for example,18O; nitrogenmay be, for example,15N, and the like. In other embodiments, a particular isotope (e.g.,3H,13C,14C,18O, or15N) can represent at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 99.9% of the total isotopic abundance of an element that occupies a specific site of the compound.

[0053] In a formula, is a single bond where the stereochemistry of the moieties immediately attached thereto is not specified.

[0054] When a range of values is listed, it is intended to encompass each value and sub– range within the range. For example, “C1–6alkyl” is intended to encompass, C1, C2, C3, C4, C5, C6, C1–6, C1–5, C1–4, C1–3, C1–2, C2–6, C2–5, C2–4, C2–3, C3–6, C3–5, C3–4, C4–6, C4–5, and C5–6alkyl.

[0055] The following terms are intended to have the meanings presented therewith below and are useful in understanding the description and intended scope of the present invention. When describing the invention, which may include compounds, pharmaceutical compositions containing such compounds and methods of using such compounds and compositions, the following terms, if present, have the following meanings unless otherwise indicated. It should also be understood that when described herein any of the moieties defined forth below may be substituted with a variety of substituents, and that the respective definitions are intended to include such substituted moieties within their scope as set out below. Unless otherwise stated, the term “substituted” is to be defined as set out below. It should be further understood that the terms “groups” and “radicals” can be considered interchangeable when used herein. The articles “a” and “an” may be used herein to refer to one or to more than one (i.e. at least one) of the grammatical objects of the article. By way of example “an analogue” means one analogue or more than one analogue.

[0056] The term “unsaturated bond” refers to a double or triple bond.

[0057] The term “unsaturated” or “partially unsaturated” refers to a moiety that includes at least one double or triple bond.

[0058] The term “saturated” refers to a moiety that does not contain a double or triple bond, i.e., the moiety only contains single bonds.

[0059] Affixing the suffix “-ene” to a group indicates the group is a divalent moiety, e.g., alkylene is the divalent moiety of alkyl, alkenylene is the divalent moiety of alkenyl, alkynylene is the divalent moiety of alkynyl, heteroalkylene is the divalent moiety of heteroalkyl, heteroalkenylene is the divalent moiety of heteroalkenyl, heteroalkynylene is thedivalent moiety of heteroalkynyl, carbocyclylene is the divalent moiety of carbocyclyl, heterocyclylene is the divalent moiety of heterocyclyl, arylene is the divalent moiety of aryl, and heteroarylene is the divalent moiety of heteroaryl.

[0060] The term “azido” refers to the radical –N3.

[0061] “Aliphatic” refers to an alkyl, alkenyl, alkynyl, or carbocyclyl group, as defined herein.

[0062] “Cycloalkylalkyl” refers to an alkyl radical in which the alkyl group is substituted with a cycloalkyl group. Typical cycloalkylalkyl groups include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, cyclooctylmethyl, cyclopropylethyl, cyclobutylethyl, cyclopentylethyl, cyclohexylethyl, cycloheptylethyl, and cyclooctylethyl, and the like.

[0063] “Heterocyclylalkyl” refers to an alkyl radical in which the alkyl group is substituted with a heterocyclyl group. Typical heterocyclylalkyl groups include, but are not limited to, pyrrolidinylmethyl, piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyrrolidinylethyl, piperidinylethyl, piperazinylethyl, morpholinylethyl, and the like.

[0064] “Aralkyl” or “arylalkyl” is a subset of alkyl and aryl, as defined herein, and refers to an optionally substituted alkyl group substituted by an optionally substituted aryl group.

[0065] “Alkyl” refers to a radical of a straight–chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms (“C1–20alkyl”). In an embodiment, an alkyl group has 1 to 12 carbon atoms (“C1–12alkyl”). In an embodiment, an alkyl group has 1 to 10 carbon atoms (“C1–10alkyl”). In an embodiment, an alkyl group has 1 to 9 carbon atoms (“C1–9alkyl”). In an embodiment, an alkyl group has 1 to 8 carbon atoms (“C1–8alkyl”). In an embodiment, an alkyl group has 1 to 7 carbon atoms (“C1–7alkyl”). In an embodiment, an alkyl group has 1 to 6 carbon atoms (“C1–6alkyl”, also referred to herein as “lower alkyl”). In an embodiment, an alkyl group has 1 to 5 carbon atoms (“C1–5alkyl”). In an embodiment, an alkyl group has 1 to 4 carbon atoms (“C1–4alkyl”). In an embodiment, an alkyl group has 1 to 3 carbon atoms (“C1–3alkyl”). In an embodiment, an alkyl group has 1 to 2 carbon atoms (“C1–2alkyl”). In an embodiment, an alkyl group has 1 carbon atom (“C1alkyl”). In an embodiment, an alkyl group has 2 to 6 carbon atoms (“C2–6alkyl”). Examples of C1–6alkyl groups include methyl (C1), ethyl (C2), n–propyl (C3), isopropyl (C3), n–butyl (C4), tert–butyl (C4), sec–butyl (C4), iso–butyl (C4), n–pentyl (C5), 3–pentanyl (C5), amyl (C5), neopentyl (C5), 3–methyl–2–butanyl (C5), tertiary amyl (C5), and n–hexyl (C6). Additional examples of alkyl groups include n–heptyl (C7), n–octyl (C8) and the like. Unless otherwise specified, each instance of an alkyl group is independently optionally substituted, i.e., unsubstituted (an“unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents; e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In an embodiment, the alkyl group is unsubstituted C1–10alkyl (e.g., –CH3). In an embodiment, the alkyl group is substituted C1–10alkyl. Common alkyl abbreviations include Me (–CH3), Et (– CH2CH3),iPr (–CH(CH3)2),nPr (–CH2CH2CH3),nBu (–CH2CH2CH2CH3), oriBu (– CH2CH(CH3)2).

[0066] “Alkylene” refers to an alkyl group wherein two hydrogens are removed to provide a divalent radical, and which may be substituted or unsubstituted. Unsubstituted alkylene groups include, but are not limited to, methylene (–CH2-), ethylene (–CH2CH2-), propylene (– CH2CH2CH2-), butylene (–CH2CH2CH2CH2-), pentylene (–CH2CH2CH2CH2CH2-), hexylene (–CH2CH2CH2CH2CH2CH2-), and the like. Exemplary substituted alkylene groups, e.g., substituted with one or more alkyl (methyl) groups, include but are not limited to, substituted methylene (–CH(CH3)-, (–C(CH3)2-), substituted ethylene (–CH(CH3)CH2-,–CH2CH(CH3)-, –C(CH3)2CH2-,–CH2C(CH3)2-), substituted propylene (–CH(CH3)CH2CH2-, – CH2CH(CH3)CH2-, –CH2CH2CH(CH3)-, –C(CH3)2CH2CH2-, –CH2C(CH3)2CH2-, – CH2CH2C(CH3)2-), and the like. When a range or number of carbons is provided for a particular alkylene group, it is understood that the range or number refers to the range or number of carbons in the linear carbon divalent chain. Alkylene groups may be substituted or unsubstituted with one or more substituents as described herein.

[0067] “Alkenyl” refers to a radical of a straight–chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon–carbon double bonds (e.g., 1, 2, 3, or 4 carbon–carbon double bonds), and optionally one or more carbon–carbon triple bonds (e.g., 1, 2, 3, or 4 carbon–carbon triple bonds) (“C2–20alkenyl”). In an embodiment, alkenyl does not contain any triple bonds. In an embodiment, an alkenyl group has 2 to 10 carbon atoms (“C2–10alkenyl”). In an embodiment, an alkenyl group has 2 to 9 carbon atoms (“C2–9alkenyl”). In an embodiment, an alkenyl group has 2 to 8 carbon atoms (“C2–8alkenyl”). In an embodiment, an alkenyl group has 2 to 7 carbon atoms (“C2–7alkenyl”). In an embodiment, an alkenyl group has 2 to 6 carbon atoms (“C2–6alkenyl”). In an embodiment, an alkenyl group has 2 to 5 carbon atoms (“C2–5alkenyl”). In an embodiment, an alkenyl group has 2 to 4 carbon atoms (“C2–4alkenyl”). In an embodiment, an alkenyl group has 2 to 3 carbon atoms (“C2–3alkenyl”). In an embodiment, an alkenyl group has 2 carbon atoms (“C2alkenyl”). The one or more carbon–carbon double bonds can be internal (such as in 2– butenyl) or terminal (such as in 1–butenyl). Examples of C2–4alkenyl groups include ethenyl (C2), 1–propenyl (C3), 2–propenyl (C3), 1–butenyl (C4), 2–butenyl (C4), butadienyl (C4), andthe like. Examples of C2–6alkenyl groups include the aforementioned C2–4alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (C8), octatrienyl (C8), and the like. Unless otherwise specified, each instance of an alkenyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In an embodiment, the alkenyl group is unsubstituted C2–10alkenyl. In an embodiment, the alkenyl group is substituted C2–10alkenyl.

[0068] “Alkynyl” refers to a radical of a straight–chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon–carbon triple bonds (e.g., 1, 2, 3, or 4 carbon–carbon triple bonds), and optionally one or more carbon–carbon double bonds (e.g., 1, 2, 3, or 4 carbon–carbon double bonds) (“C2–20alkynyl”). In an embodiment, alkynyl does not contain any double bonds. In an embodiment, an alkynyl group has 2 to 10 carbon atoms (“C2–10alkynyl”). In an embodiment, an alkynyl group has 2 to 9 carbon atoms (“C2–9alkynyl”). In an embodiment, an alkynyl group has 2 to 8 carbon atoms (“C2–8alkynyl”). In an embodiment, an alkynyl group has 2 to 7 carbon atoms (“C2–7alkynyl”). In an embodiment, an alkynyl group has 2 to 6 carbon atoms (“C2–6alkynyl”). In an embodiment, an alkynyl group has 2 to 5 carbon atoms (“C2–5alkynyl”). In an embodiment, an alkynyl group has 2 to 4 carbon atoms (“C2–4alkynyl”). In an embodiment, an alkynyl group has 2 to 3 carbon atoms (“C2–3alkynyl”). In an embodiment, an alkynyl group has 2 carbon atoms (“C2alkynyl”). The one or more carbon–carbon triple bonds can be internal (such as in 2– butynyl) or terminal (such as in 1–butynyl). Examples of C2–4alkynyl groups include, without limitation, ethynyl (C2), 1–propynyl (C3), 2–propynyl (C3), 1–butynyl (C4), 2– butynyl (C4), and the like. Examples of C2–6alkenyl groups include the aforementioned C2–4alkynyl groups as well as pentynyl (C5), hexynyl (C6), and the like. Additional examples of alkynyl include heptynyl (C7), octynyl (C8), and the like. Unless otherwise specified, each instance of an alkynyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or more substituents; e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In an embodiment, the alkynyl group is unsubstituted C2–10alkynyl. In an embodiment, the alkynyl group is substituted C2–10alkynyl.

[0069] The term “heteroalkyl,” as used herein, refers to an alkyl group, as defined herein, which further comprises 1 or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus and oxidized forms thereof, e.g., SO2) within the parentchain, wherein the one or more heteroatoms is inserted between adjacent carbon atoms within the parent carbon chain and / or one or more heteroatoms is inserted between a carbon atom and the parent molecule, i.e., between the point of attachment. In an embodiment, the heteroalkyl contains 1-2 heteroatoms independently selected from N, O and S and oxidized forms thereof (e.g., SO2). In an embodiment, the heteroalkyl contains 1 heteroatom independently selected from N, O and S and oxidized forms thereof (e.g., SO2). In an embodiment, the heteroalkyl contains 2 heteroatoms independently selected from N, O and S and oxidized forms thereof (e.g., SO2). In an embodiment, a heteroalkyl group refers to a saturated group having from 1 to 10 carbon atoms and 1, 2, 3, or 4 heteroatoms (“heteroC1–10alkyl”). In an embodiment, a heteroalkyl group is a saturated group having 1 to 9 carbon atoms and 1, 2, 3, or 4 heteroatoms (“heteroC1–9alkyl”). In an embodiment, a heteroalkyl group is a saturated group having 1 to 8 carbon atoms and 1, 2, 3, or 4 heteroatoms (“heteroC1–8alkyl”). In an embodiment, a heteroalkyl group is a saturated group having 1 to 7 carbon atoms and 1, 2, 3, or 4 heteroatoms (“heteroC1–7alkyl”). In an embodiment, a heteroalkyl group is a group having 1 to 6 carbon atoms and 1, 2, or 3 heteroatoms (“heteroC1–6alkyl”). In an embodiment, a heteroalkyl group is a saturated group having 1 to 5 carbon atoms and 1 or 2 heteroatoms (“heteroC1–5alkyl”). In an embodiment, a heteroalkyl group is a saturated group having 1 to 4 carbon atoms and 1 or 2 heteroatoms (“heteroC1–4alkyl”). In an embodiment, a heteroalkyl group is a saturated group having 1 to 3 carbon atoms and 1 heteroatom (“heteroC1–3alkyl”). In an embodiment, a heteroalkyl group is a saturated group having 1 to 2 carbon atoms and 1 heteroatom (“heteroC1–2alkyl”). In an embodiment, a heteroalkyl group is a saturated group having 1 carbon atom and 1 heteroatom (“heteroC1alkyl”). In an embodiment, a heteroalkyl group is a saturated group having 2 to 6 carbon atoms and 1 or 2 heteroatoms (“heteroC2–6alkyl”). Unless otherwise specified, each instance of a heteroalkyl group is independently unsubstituted (an “unsubstituted heteroalkyl”) or substituted (a “substituted heteroalkyl”) with one or more substituents. In an embodiment, the heteroalkyl group is an unsubstituted heteroC1–10alkyl. In an embodiment, the heteroalkyl group is a substituted heteroC1–10alkyl. Exemplary heteroalkyl groups include: –CH2OH, –CH2OCH3, –CH2NH2, –CH2NH(CH3), –CH2N(CH3)2, –CH2CH2OH, – CH2CH2OCH3, –CH2CH2NH2, –CH2CH2NH(CH3), –CH2CH2N(CH3)2,–CH2CH2S(O)2CH3.

[0070] “Aryl” refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic array) having 6–14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C6–14aryl”). In an embodiment, an aryl group has six ring carbon atoms (“C6aryl”; e.g.,phenyl). In an embodiment, an aryl group has ten ring carbon atoms (“C10aryl”; e.g., naphthyl such as 1–naphthyl and 2–naphthyl). In an embodiment, an aryl group has fourteen ring carbon atoms (“C14aryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. Particularly aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl. Unless otherwise specified, each instance of an aryl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted aryl”) or substituted (a “substituted aryl”) with one or more substituents. In an embodiment, the aryl group is unsubstituted C6–14aryl. In an embodiment, the aryl group is substituted C6–14aryl.

[0071] In an embodiment, an aryl group is substituted with one or more of groups selected from halo, C1–C8alkyl, C1–C8haloalkyl, cyano, hydroxy, C1–C8alkoxy, and amino.

[0072] Examples of representative substituted aryls include the following:wherein one of R56and R57may be hydrogen and at least one of R56and R57is each independently selected from C1–C8alkyl, C1–C8haloalkyl, 4-10 membered heterocyclyl, alkanoyl, C1–C8alkoxy, heteroaryloxy, alkylamino, arylamino, heteroarylamino, NR58COR59, NR58SOR59NR58SO2R59, COOalkyl, COOaryl, CONR58R59, CONR58OR59, NR58R59, SO2NR58R59, S-alkyl, SOalkyl, SO2alkyl, Saryl, SOaryl, SO2aryl; or R56and R57may be joined to form a cyclic ring (saturated or unsaturated) from 5 to 8 atoms, optionally containing one or more heteroatoms selected from the group N, O, or S. R60and R61are independently hydrogen, C1–C8alkyl, C1–C4haloalkyl, C3–C10cycloalkyl, 4-10 membered heterocyclyl, C6–C10aryl, substituted C6–C10aryl, 5-10 membered heteroaryl, or substituted 5-10 membered heteroaryl.

[0073] “Fused aryl” refers to an aryl having two of its ring carbons in common with a second aryl or heteroaryl ring or with a carbocyclyl or heterocyclyl ring.

[0074] “Heteroaryl” refers to a radical of a 5–10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a cyclic array) having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5–10 memberedheteroaryl”). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings. “Heteroaryl” includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused (aryl / heteroaryl) ring system. Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2–indolyl) or the ring that does not contain a heteroatom (e.g., 5– indolyl).

[0075] In an embodiment, a heteroaryl group is a 5–10 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–10 membered heteroaryl”). In an embodiment, a heteroaryl group is a 5–8 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–8 membered heteroaryl”). In an embodiment, a heteroaryl group is a 5–6 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–6 membered heteroaryl”). In an embodiment, the 5–6 membered heteroaryl has 1–3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In an embodiment, the 5–6 membered heteroaryl has 1–2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In an embodiment, the 5–6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents. In an embodiment, the heteroaryl group is unsubstituted 5–14 membered heteroaryl. In an embodiment, the heteroaryl group is substituted 5–14 membered heteroaryl. In an embodiment, a heteroaryl group is a bicyclic 8-12 membered aromatic ring system having ring carbon atoms and 1-6 ring heteroatoms provided in the aromatic ring system, whereineach heteroatom is independently selected from nitrogen, oxygen, and sulfur (“8-12 membered bicyclic heteroaryl”). In an embodiment, a heteroaryl group is an 8-10 membered bicyclic aromatic ring system having ring carbon atoms and 1-6 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“8-10 membered bicyclic heteroaryl”). In an embodiment, a heteroaryl group is a 9-10 membered bicyclic aromatic ring system having ring carbon atoms and 1-6 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“9-10 membered bicyclic heteroaryl”). Unless otherwise specified, each instance of a heteroaryl group is independently unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents. In an embodiment, the heteroaryl group is an unsubstituted 5-14 membered heteroaryl. In an embodiment, the heteroaryl group is a substituted 5-14 membered heteroaryl.

[0076] Exemplary 5–membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5–membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5–membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5–membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl. Exemplary 6–membered heteroaryl groups containing one heteroatom include, without limitation, pyridinyl. Exemplary 6–membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6–membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7–membered heteroaryl groups containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6–bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6– bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.

[0077] Examples of representative heteroaryls include the following:wherein each Z is selected from carbonyl, N, NR65, O, and S; and R65is independently hydrogen, C1–C8alkyl, C3–C10cycloalkyl, 4-10 membered heterocyclyl, C6–C10aryl, and 5- 10 membered heteroaryl.

[0078] In the structures described herein, a substituent attached to a polycyclic (e.g., bicyclic or tricyclic) cycloalkyl, heterocyclyl, aryl or heteroaryl with a bond that spans two or more rings is understood to mean that the substituent can be attached at any position in each of the rings.

[0079] “Heteroaralkyl” or “heteroarylalkyl” is a subset of “alkyl” and refers to an alkyl group substituted by a heteroaryl group, wherein the point of attachment is on the alkyl moiety.

[0080] The term “carbocyclyl” or “carbocyclic” refers to a radical of a non-aromatic monocyclic, bicyclic, or tricyclic or polycyclic hydrocarbon ring system having from 3 to 14 ring carbon atoms (“C3-14carbocyclyl”) and zero heteroatoms in the non-aromatic ring system. Carbocyclyl groups include fully saturated ring systems (e.g., cycloalkyls), and partially saturated ring systems. In an embodiment, a carbocyclyl group has 3 to 10 ring carbon atoms (“C3-10carbocyclyl”). In an embodiment, a carbocyclyl group has 3 to 8 ring carbon atoms (“C3-8carbocyclyl”). In an embodiment, a carbocyclyl group has 3 to 7 ring carbon atoms (“C3-7carbocyclyl”). In an embodiment, a carbocyclyl group has 3 to 6 ring carbon atoms (“C3-6carbocyclyl”). In an embodiment, a carbocyclyl group has 4 to 6 ring carbon atoms (“C4-6carbocyclyl”). In an embodiment, a carbocyclyl group has 5 to 6 ring carbon atoms (“C5-6carbocyclyl”). In an embodiment, a carbocyclyl group has 5 to 10 ring carbon atoms (“C5-10carbocyclyl”). Exemplary C3-6carbocyclyl groups include, without limitation, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. Exemplary C3-8 carbocyclyl groups include, without limitation, theaforementioned C3-6carbocyclyl groups as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), and the like. Exemplary C3-10carbocyclyl groups include, without limitation, the aforementioned C3-8carbocyclyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro- 1H-indenyl (C9), decahydronaphthalenyl (C10), spiro[4.5]decanyl (C10), and the like.

[0081] As the foregoing examples illustrate, in an embodiment, the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or polycyclic (e.g., containing a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) or tricyclic system (“tricyclic carbocyclyl”)) and can be saturated or can contain one or more carbon-carbon double or triple bonds. “Carbocyclyl” also includes ring systems wherein the carbocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system. Unless otherwise specified, each instance of a carbocyclyl group is independently unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a “substituted carbocyclyl”) with one or more substituents. In an embodiment, the carbocyclyl group is an unsubstituted C3-14carbocyclyl. In an embodiment, the carbocyclyl group is a substituted C3-14carbocyclyl.

[0082] The term “cycloalkyl” as employed herein includes saturated cyclic, bicyclic, tricyclic, or polycyclic hydrocarbon groups having 3 to 14 carbons containing the indicated number of rings and carbon atoms (for example a C3–C14monocyclic, C4–C14bicyclic, C5– C14tricyclic, or C6–C14polycyclic cycloalkyl). In an embodiment “cycloalkyl” is a monocyclic cycloalkyl. In an embodiment, a monocyclic cycloalkyl has 3-14 ring carbon atoms (“C3-14monocyclic cycloalkyl”). In an embodiment, a monocyclic cycloalkyl group has 3 to 10 ring carbon atoms (“C3-10monocyclic cycloalkyl”). In an embodiment, a monocyclic cycloalkyl group has 3 to 8 ring carbon atoms (“C3-8monocyclic cycloalkyl”). In an embodiment, a monocyclic cycloalkyl group has 3 to 6 ring carbon atoms (“C3-6monocyclic cycloalkyl”). In an embodiment, a monocyclic cycloalkyl group has 4 to 6 ring carbon atoms (“C4-6monocyclic cycloalkyl”). In an embodiment, a monocyclic cycloalkyl group has 5 to 6 ring carbon atoms (“C5-6monocyclic cycloalkyl”). In an embodiment, a monocyclic cycloalkyl group has 5 to 10 ring carbon atoms (“C5-10monocyclic cycloalkyl”). Examples of monocyclic C5-6cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C5). Examples of C3-6cycloalkyl groups include the aforementioned C5-6cycloalkyl groupsas well as cyclopropyl (C3) and cyclobutyl (C4). Examples of C3-8cycloalkyl groups include the aforementioned C3-6cycloalkyl groups as well as cycloheptyl (C7) and cyclooctyl (C8).

[0083] In an embodiment “cycloalkyl” is a bicyclic cycloalkyl. In an embodiment, a bicyclic cycloalkyl has 4-14 ring carbon atoms (“C4-14bicyclic cycloalkyl”). In an embodiment, a bicyclic cycloalkyl group has 4 to 12 ring carbon atoms (“C4-12bicyclic cycloalkyl”). In an embodiment, a bicyclic cycloalkyl group has 4 to 10 ring carbon atoms (“C4-10bicyclic cycloalkyl”). In an embodiment, a bicyclic cycloalkyl group has 5 to 10 ring carbon atoms (“C5-10bicyclic cycloalkyl”). In an embodiment, a bicyclic cycloalkyl group has 6 to 10 ring carbon atoms (“C6-10bicyclic cycloalkyl”). In an embodiment, a bicyclic cycloalkyl group has 8 to 10 ring carbon atoms (“C8-10bicyclic cycloalkyl”). In an embodiment, a bicyclic cycloalkyl group has 7 to 9 ring carbon atoms (“C7-9bicyclic cycloalkyl”). Examples of bicyclic cycloalkyls include bicyclo[1.1.0]butane (C4), bicyclo[1.1.1]pentane (C5), spiro[2.2] pentane (C5), bicyclo[2.1.0]pentane (C5), bicyclo[2.1.1]hexane (C6), bicyclo[3.1.0]hexane (C6), spiro[2.3] hexane (C6), bicyclo[2.2.1]heptane (norbornane) (C7), bicyclo[3.2.0]heptane (C7), bicyclo[3.1.1]heptane (C7), bicyclo[3.1.1]heptane (C7), bicyclo[4.1.0]heptane (C7), spiro[2.4] heptane (C7), spiro [3.3] heptane (C7), bicyclo[2.2.2]octane (C8), bicyclo[4.1.1]octane (C8)octahydropentalene (C8), bicyclo[3.2.1]octane (C8), bicyclo[4.2.0]octane (C8), spiro[2.5]octane (C8), spiro[3.4]octane (C8), bicyclo[3.3.1]nonane (C9), octahydro-1H-indene (C9), bicyclo[4.2.1]nonane (C9), spiro[3.5]nonane (C9), spiro[4.4]nonane (C9), bicyclo[3.3.2]decane (C10), bicyclo[4.3.1]decane (C10), spiro[4.5]decane (C10), bicyclo[3.3.3]undecane (C11), decahydronaphthalene (C10), bicyclo[4.3.2]undecane (C11), spiro[5.5]undecane (C11) and bicyclo[4.3.3]dodecane (C12).

[0084] In an embodiment “cycloalkyl” is a tricyclic cycloalkyl. In an embodiment, a tricyclic cycloalkyl has 6-14 ring carbon atoms (“C6-14tricyclic cycloalkyl”). In an embodiment, a tricyclic cycloalkyl group has 8 to 12 ring carbon atoms (“C8-12 tricyclic cycloalkyl”). In an embodiment, a tricyclic cycloalkyl group has 10 to 12 ring carbon atoms (“C10-12tricyclic cycloalkyl. Examples of tricyclic cycloalkyls include adamantine (C12). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents. In an embodiment, the cycloalkyl group is an unsubstituted C3-14cycloalkyl. In an embodiment, the cycloalkyl group is a substituted C3-14cycloalkyl

[0085] “Heterocyclyl” or “heterocyclic” refers to a radical of a 3– to 10–membered non– aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, andsilicon (“3–10 membered heterocyclyl”). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”), and can be saturated or can be partially unsaturated. Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings. “Heterocyclyl” also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system. Unless otherwise specified, each instance of heterocyclyl is independently optionally substituted, i.e., unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents. In an embodiment, the heterocyclyl group is unsubstituted 3–10 membered heterocyclyl. In an embodiment, the heterocyclyl group is substituted 3–10 membered heterocyclyl.

[0086] In an embodiment, a heterocyclyl group is a 5–10 membered non–aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“5–10 membered heterocyclyl”). In an embodiment, a heterocyclyl group is a 5–8 membered non– aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–8 membered heterocyclyl”). In an embodiment, a heterocyclyl group is a 5–6 membered non–aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–6 membered heterocyclyl”). In an embodiment, the 5–6 membered heterocyclyl has 1–3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In an embodiment, the 5–6 membered heterocyclyl has 1–2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In an embodiment, the 5–6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.

[0087] Exemplary 3–membered heterocyclyl groups containing one heteroatom include, without limitation, aziridinyl, oxiranyl, thiorenyl. Exemplary 4–membered heterocyclyl groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl. Exemplary 5–membered heterocyclyl groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl,dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl–2,5–dione. Exemplary 5– membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5–membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6–membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6–membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl. Exemplary 6– membered heterocyclyl groups containing two heteroatoms include, without limitation, triazinanyl. Exemplary 7–membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8–membered heterocyclyl groups containing one heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary 5-membered heterocyclyl groups fused to a C6aryl ring (also referred to herein as a 5,6-bicyclic heterocyclic ring) include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like. Exemplary bicyclic heterocyclyl groups include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, tetrahydrobenzothienyl, tetrahydrobenzofuranyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridinyl, decahydro-1,8-naphthyridinyl, octahydropyrrolo[3,2-b]pyrrole, indolinyl, phthalimidyl, naphthalimidyl, chromanyl, chromenyl, 1H-benzo[e][1,4]diazepinyl, 1,4,5,7-tetrahydropyrano[3,4-b]pyrrolyl, 5,6-dihydro-4H-furo[3,2-b]pyrrolyl, 6,7-dihydro- 5H-furo[3,2-b]pyranyl, 5,7-dihydro-4H-thieno[2,3-c]pyranyl, 2,3-dihydro-1H-pyrrolo[2,3- b]pyridinyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 4,5,6,7-tetrahydro-1H-pyrrolo[2,3-b]pyridinyl, 4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl, 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl, 1,2,3,4- tetrahydro-1,6-naphthyridinyl, and the like. Exemplary 6-membered heterocyclyl groups fused to an aryl ring (also referred to herein as a 6,6-bicyclic heterocyclic ring) include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.

[0088] “Nitrogen-containing heterocyclyl” group means a 4– to 7– membered non-aromatic cyclic group containing at least one nitrogen atom, for example, but without limitation, morpholine, piperidine (e.g., 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), pyrrolidine (e.g., 2-pyrrolidinyl and 3-pyrrolidinyl), azetidine, pyrrolidone, imidazoline, imidazolidinone, 2- pyrazoline, pyrazolidine, piperazine, and N-alkyl piperazines such as N-methyl piperazine. Particular examples include azetidine, piperidone and piperazone.

[0089] “Hetero” when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the hydrocarbyl groups described above such as alkyl, e.g., heteroalkyl, cycloalkyl, e.g., heterocyclyl, aryl, e.g., heteroaryl, cycloalkenyl, e.g., cycloheteroalkenyl, and the like having from 1 to 5, and particularly from 1 to 3 heteroatoms.

[0090] “Acyl” refers to a radical –C(=O)R20, where R20is hydrogen, substituted or unsubstitued alkyl, substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstitued heteroaryl, as defined herein. “Alkanoyl” is an acyl group wherein R20is a group other than hydrogen. Representative acyl groups include, but are not limited to, formyl (–CHO), acetyl (–C(=O)CH3), cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl (–C(=O)Ph), benzylcarbonyl (–C(=O)CH2Ph), ––C(=O)– C1–C8alkyl, –C(=O)-(CH2)t(C6–C10aryl), –C(=O)-(CH2)t(5-10 membered heteroaryl), – C(=O)-(CH2)t(C3–C10cycloalkyl), and –C(=O)-(CH2)t(4-10 membered heterocyclyl), wherein t is an integer from 0 to 4. In an embodiment, R21is C1–C8alkyl, substituted with halo or hydroxy; or C3–C10cycloalkyl, 4-10 membered heterocyclyl, C6–C10aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl, each of which is substituted with unsubstituted C1– C4alkyl, halo, unsubstituted C1–C4alkoxy, unsubstituted C1–C4haloalkyl, unsubstituted C1– C4hydroxyalkyl, or unsubstituted C1–C4haloalkoxy or hydroxy.

[0091] The term aminoalkyl refers to a substituted alkyl group wherein one or more of the hydrogen atoms are independently replaced by an –NH2group.

[0092] The term hydroxyalkyl refers to a substituted alkyl group wherein one or more of the hydrogen atoms are independently replaced by an –OH group.

[0093] The terms “alkylamino” and “dialkylamino” refer to −NH(alkyl) and−N(alkyl)2radicals respectively. In an embodiment the alkylamino is a−NH(C1−C4alkyl). In an embodiment the alkylamino is methylamino, ethylamino, propylamino, isopropylamino, n- butylamino, iso-butylamino, sec-butylamino or tert-butylamino. In an embodiment the dialkylamino is −N(C1−C6alkyl)2. In an embodiment the dialkylamino is a dimethylamino, a methylethylamino, a diethylamino, a methylpropylamino, a methylisopropylamino, a methylbutylamino, a methylisobutylamino or a methyltertbutylamino.

[0094] The term “aryloxy” refers to an –O–aryl radical. In an embodiment the aryloxy group is phenoxy.

[0095] The term “haloalkoxy” refers to alkoxy structures that are substituted with one or more halo groups or with combinations thereof. For example, the term “fluoroalkoxy” includes haloalkoxy groups, in which the halo is fluorine. In an embodiment haloalkoxy groups are difluoromethoxy and trifluoromethoxy.

[0096] “Alkoxy” refers to the group –OR29where R29is substituted or unsubstituted alkyl, substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstitued heteroaryl. Particular alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n- hexoxy, and 1,2-dimethylbutoxy. Particular alkoxy groups are lower alkoxy, i.e. with between 1 and 6 carbon atoms. Further particular alkoxy groups have between 1 and 4 carbon atoms.

[0097] In an embodiment, R29is a group that has 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, in particular 1 substituent, selected from the group consisting of amino, substituted amino, C6–C10aryl, aryloxy, carboxyl, cyano, C3–C10cycloalkyl, 4-10 membered heterocyclyl, halogen, 5-10 membered heteroaryl, hydroxyl, nitro, thioalkoxy, thioaryloxy, thiol, alkyl-S(O)-, aryl–S(O)-, alkyl–S(O)2– and aryl-S(O)2-. Exemplary ’substituted alkoxy’ groups include, but are not limited to, –O– (CH2)t(C6–C10aryl), –O–(CH2)t(5-10 membered heteroaryl), –O–(CH2)t(C3–C10cycloalkyl), and –O–(CH2)t(4-10 membered heterocyclyl), wherein t is an integer from 0 to 4 and any aryl, heteroaryl, cycloalkyl or heterocyclyl groups present, may themselves be substituted by unsubstituted C1–C4alkyl, halo, unsubstituted C1–C4alkoxy, unsubstituted C1–C4haloalkyl, unsubstituted C1–C4hydroxyalkyl, or unsubstituted C1–C4haloalkoxy or hydroxy. Particular exemplary ’substituted alkoxy’ groups are –OCF3, –OCH2CF3, –OCH2Ph, –OCH2- cyclopropyl, –OCH2CH2OH, and –OCH2CH2NMe2.

[0098] “Amino” refers to the radical –NH2.

[0099] “Oxo group” refers to –C(=O)–.

[0100] “Substituted amino” refers to an amino group of the formula –N(R38)2wherein R38is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstitued alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstitued carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstitued heteroaryl, or an amino protecting group, wherein at least one of R38is not a hydrogen. In an embodiment, each R38is independently selected from hydrogen, C1–C8alkyl, C3–C8alkenyl, C3–C8alkynyl, C6–C10aryl, 5-10 membered heteroaryl, 4-10 membered heterocyclyl, or C3–C10cycloalkyl; or C1–C8alkyl, substituted with halo or hydroxy; C3–C8alkenyl, substituted with halo or hydroxy; C3–C8alkynyl, substituted with halo or hydroxy, or -(CH2)t(C6–C10aryl), - (CH2)t(5-10 membered heteroaryl), -(CH2)t(C3–C10cycloalkyl), or -(CH2)t(4-10 membered heterocyclyl), wherein t is an integer between 0 and 8, each of which is substituted by unsubstituted C1–C4alkyl, halo, unsubstituted C1–C4alkoxy, unsubstituted C1–C4haloalkyl, unsubstituted C1–C4hydroxyalkyl, or unsubstituted C1–C4haloalkoxy or hydroxy; or both R38groups are joined to form an alkylene group.

[0101] Exemplary “substituted amino” groups include, but are not limited to, –NR39–C1–C8alkyl, –NR39-(CH2)t(C6–C10aryl), –NR39-(CH2)t(5-10 membered heteroaryl), –NR39- (CH2)t(C3–C10cycloalkyl), and –NR39-(CH2)t(4-10 membered heterocyclyl), wherein t is an integer from 0 to 4, for instance 1 or 2, each R39independently represents H or C1–C8alkyl; and any alkyl groups present, may themselves be substituted by halo, substituted or unsubstituted amino, or hydroxy; and any aryl, heteroaryl, cycloalkyl, or heterocyclyl groups present, may themselves be substituted by unsubstituted C1–C4alkyl, halo, unsubstituted C1– C4alkoxy, unsubstituted C1–C4haloalkyl, unsubstituted C1–C4hydroxyalkyl, or unsubstituted C1–C4haloalkoxy or hydroxy. For the avoidance of doubt the term ’substituted amino’ includes the groups alkylamino, substituted alkylamino, alkylarylamino, substituted alkylarylamino, arylamino, substituted arylamino, dialkylamino, and substituted dialkylamino as defined below. Substituted amino encompasses both monosubstituted amino and disubstituted amino groups.

[0102] In an embodiment, the substituent present on the nitrogen atom is a nitrogen protecting group (also referred to herein as an “amino protecting group”). Nitrogen protecting groups include, but are not limited to, −OH, −ORaa, −N(Rcc)2, −C(=O)Raa, −C(=O)N(Rcc)2, −CO2Raa, −SO2Raa, −C(=NRcc)Raa, −C(=NRcc)ORaa, −C(=NRcc)N(Rcc)2, −SO2N(Rcc)2, −SO2Rcc, −SO2ORcc, −SORaa, −C(=S)N(Rcc)2, −C(=O)SRcc, −C(=S)SRcc, −C1-10alkyl (e.g., aralkyl, heteroaralkyl), −C2-10alkenyl, −C2-10alkynyl, heteroC1-10alkyl, heteroC2-10alkenyl, heteroC2-10alkynyl, C3-10carbocyclyl, 3-14 membered heterocyclyl, C6-14aryl, and 5-14 membered heteroaryl groups, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups, and wherein Raa, Rbb, Rccand Rddare as defined herein. Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rdedition, John Wiley & Sons, 1999, incorporated herein by reference.In the definition of nitrogen protecting groups, each instance of Raais, independently, selected from −C1-10alkyl, −C1-10perhaloalkyl, −C2-10alkenyl, −C2-10alkynyl, heteroC1-10alkyl, heteroC2-10alkenyl, heteroC2-10alkynyl, C3-10carbocyclyl, 3-14 membered heterocyclyl, C6-14aryl, and 5-14 membered heteroaryl, or two Raagroups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; each instance of Rbbis, independently, selected from hydrogen, −OH, −ORaa, −N(Rcc)2, −CN, −C(=O)Raa, −C(=O)N(Rcc)2, −CO2Raa, −SO2Raa, −C(=NRcc)ORaa, −C(=NRcc)N(Rcc)2, −SO2N(Rcc)2, −SO2Rcc, −SO2ORcc, −SORaa, −C(=S)N(Rcc)2, −C(=O)SRcc, −C(=S)SRcc, −P(=O)(Raa)2, −P(=O)(ORcc)2, −P(=O)(N(Rcc)2)2, −C1-10alkyl, −C1-10perhaloalkyl, −C2-10alkenyl, −C2-10alkynyl, heteroC1-10alkyl, heteroC2-10alkenyl, heteroC2-10alkynyl, C3-10carbocyclyl, 3-14 membered heterocyclyl, C6-14aryl, and 5-14 membered heteroaryl, or two Rbbgroups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; wherein X−is a counterion. each instance of Rccis, independently, selected from hydrogen, −C1-10alkyl, −C1-10perhaloalkyl, −C2-10alkenyl, −C2-10alkynyl, heteroC1-10alkyl, heteroC2-10alkenyl, heteroC2-10alkynyl, C3-10carbocyclyl, 3-14 membered heterocyclyl, C6-14aryl, and 5-14 membered heteroaryl, or two Rccgroups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; each instance of Rddis, independently, selected from halogen, −CN, −NO2, −N3, −SO2H, −SO3H, −OH, −ORee, −ON(Rff)2, −N(Rff)2, −N(Rff)3+X−, −N(ORee)Rff, −SH, −SRee, −SSRee, −C(=O)Ree, −CO2H, −CO2Ree, −OC(=O)Ree, −OCO2Ree, −C(=O)N(Rff)2, −OC(=O)N(Rff)2, −NRffC(=O)Ree, −NRffCO2Ree, −NRffC(=O)N(Rff)2, −C(=NRff)ORee, −OC(=NRff)Ree, −OC(=NRff)ORee, −C(=NRff)N(Rff)2, −OC(=NRff)N(Rff)2, −NRffC(=NRff)N(Rff)2, −NRffSO2Ree, −SO2N(Rff)2, −SO2Ree, −SO2ORee, −OSO2Ree, −S(=O)Ree, −Si(Ree)3, −OSi(Ree)3, −C(=S)N(Rff)2, −C(=O)SRee, −C(=S)SRee, −SC(=S)SRee, −P(=O)(ORee)2, −P(=O)(Ree)2, −OP(=O)(Ree)2, −OP(=O)(ORee)2, −C1-6alkyl, −C1-6perhaloalkyl, −C2-6alkenyl, −C2-6alkynyl, heteroC1-6alkyl, heteroC2-6alkenyl, heteroC2-6alkynyl, C3-10carbocyclyl, 3-10 membered heterocyclyl, C6-10aryl, 5-10 memberedheteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgggroups, or two geminal Rddsubstituents can be joined to form =O or =S; wherein X−is a counterion; each instance of Reeis, independently, selected from −C1-6alkyl, −C1-6perhaloalkyl, −C2-6alkenyl, −C2-6alkynyl, heteroC1-6alkyl, heteroC2-6alkenyl, heteroC2-6alkynyl, C3-10carbocyclyl, C6-10aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgggroups; each instance of Rffis, independently, selected from hydrogen, −C1-6alkyl, −C1-6perhaloalkyl, −C2-6alkenyl, −C2-6alkynyl, heteroC1-6alkyl, heteroC2-6alkenyl, heteroC2-6alkynyl, C3-10carbocyclyl, 3-10 membered heterocyclyl, C6-10aryl and 5-10 membered heteroaryl, or two Rffgroups are joined to form a 3-10 membered heterocyclyl or 5-10 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgggroups; and each instance of Rggis, independently, halogen, −CN, −NO2, −N3, −SO2H, −SO3H, −OH, −OC1-6alkyl, −ON(C1-6alkyl)2, −N(C1-6alkyl)2, −N(C1-6alkyl)3+X−, −NH(C1-6alkyl)2+X−, −NH2(C1-6alkyl)+X−, −NH3+X−, −N(OC1-6alkyl)(C1-6alkyl), −N(OH)(C1-6alkyl), −NH(OH), −SH, −SC1-6alkyl, −SS(C1-6alkyl), −C(=O)(C1-6alkyl), −CO2H, −CO2(C1-6alkyl), −OC(=O)(C1-6alkyl), −OCO2(C1-6alkyl), −C(=O)NH2, −C(=O)N(C1-6alkyl)2, −OC(=O)NH(C1-6alkyl), −NHC(=O)(C1-6alkyl), −N(C1-6alkyl)C(=O)(C1-6alkyl), −NHCO2(C1-6alkyl), −NHC(=O)N(C1-6alkyl)2, −NHC(=O)NH(C1-6alkyl), −NHC(=O)NH2, −C(=NH)O(C1-6alkyl), −OC(=NH)(C1-6alkyl), −OC(=NH)OC1-6alkyl, −C(=NH)N(C1-6alkyl)2, −C(=NH)NH(C1-6alkyl), −C(=NH)NH2, −OC(=NH)N(C1-6alkyl)2, −OC(NH)NH(C1-6alkyl), −OC(NH)NH2, −NHC(NH)N(C1-6alkyl)2, −NHC(=NH)NH2, −NHSO2(C1-6alkyl), −SO2N(C1-6alkyl)2, −SO2NH(C1-6alkyl), −SO2NH2, −SO2C1-6alkyl, −SO2OC1-6alkyl, −OSO2C1-6alkyl, −SOC1-6alkyl, −Si(C1-6alkyl)3, −OSi(C1-6alkyl)3−C(=S)N(C1-6alkyl)2, −C(=S)NH(C1-6alkyl), −C(=S)NH2, −C(=O)S(C1-6alkyl), −C(=S)SC1-6alkyl, −SC(=S)SC1-6alkyl, −P(=O)(OC1-6alkyl)2, −P(=O)(C1-6alkyl)2, −OP(=O)(C1-6alkyl)2, −OP(=O)(OC1-6alkyl)2, −C1-6alkyl, −C1-6perhaloalkyl, −C2-6alkenyl, −C2-6alkynyl, heteroC1-6alkyl, heteroC2-6alkenyl, heteroC2-6alkynyl, C3-10carbocyclyl, C6-10aryl, 3-10 memberedheterocyclyl, 5-10 membered heteroaryl; or two geminal Rggsubstituents can be joined to form =O or =S; wherein X−is a counterion.

[0103] For example, nitrogen protecting groups such as amide groups (e.g., −C(=O)Raa) include, but are not limited to, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3- pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide, o- nitrophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N’- dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o- nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o- phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o- nitrocinnamide, N-acetylmethionine derivative, o-nitrobenzamide and o- (benzoyloxymethyl)benzamide.

[0104] Nitrogen protecting groups such as carbamate groups (e.g., −C(=O)ORaa) include, but are not limited to, methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluorenylmethyl carbamate, 2,7-di-t- butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2- trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1- methylethyl carbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate, 1,1-dimethyl-2,2- dibromoethyl carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1-methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc), 1-(3,5-di-t-butylphenyl)-1- methylethyl carbamate (t-Bumeoc), 2-(2’– and 4’-pyridyl)ethyl carbamate (Pyoc), 2-(N,N- dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC or Boc), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitobenzyl carbamate, p-bromobenzyl carbamate, p- chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3- dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4- dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2- triphenylphosphonioisopropyl carbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate, m- chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4- dimethoxy-6-nitrobenzyl carbamate, phenyl (o-nitrophenyl)methyl carbamate, t-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p- decyloxybenzyl carbamate, 2,2-dimethoxyacylvinyl carbamate, o-(N,N- dimethylcarboxamido)benzyl carbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isobornyl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p’-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1- methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, 1-methyl-1-(3,5- dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1- methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4- (trimethylammonium)benzyl carbamate, and 2,4,6-trimethylbenzyl carbamate.

[0105] Nitrogen protecting groups such as sulfonamide groups (e.g., −S(=O)2Raa) include, but are not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4- methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6- dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4- methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6- trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β- trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4’,8’- dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.

[0106] Other nitrogen protecting groups include, but are not limited to, phenothiazinyl-(10)- acyl derivative, N’-p-toluenesulfonylaminoacyl derivative, N’-phenylaminothioacyl derivative, N-benzoylphenylalanyl derivative, N-acetylmethionine derivative, 4,5-diphenyl-3- oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5- dimethylpyrrole, N-1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5- substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5- triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl- 4-nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N- [(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N- 2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2- picolylamino N’-oxide, N-1,1-dimethylthiomethyleneamine, N-benzylideneamine, N-p- methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2- pyridyl)mesityl]methyleneamine, N-(N’,N’-dimethylaminomethylene)amine, N,N’- isopropylidenediamine, N-p-nitrobenzylideneamine, N-salicylideneamine, N-5- chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N- cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine, N-borane derivative, N-diphenylborinic acid derivative, N-[phenyl(pentaacylchromium– or tungsten)acyl]amine, N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4- dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4- methoxybenzenesulfenamide, triphenylmethylsulfenamide, and 3-nitropyridinesulfenamide (Npys).

[0107] In an embodiment, the substituent present on an oxygen atom is an oxygen protecting group (also referred to herein as an “hydroxyl protecting group”). Oxygen protecting groups include, but are not limited to, −Raa, −N(Rbb)2, −C(=O)SRaa, −C(=O)Raa, −CO2Raa, −C(=O)N(Rbb)2, −C(=NRbb)Raa, −C(=NRbb)ORaa, −C(=NRbb)N(Rbb)2, −S(=O)Raa, −SO2Raa, −Si(Raa)3, −P(Rcc)2, −P(Rcc)3+X−, −P(ORcc)2, −P(ORcc)3+X−, −P(=O)(Raa)2, −P(=O)(ORcc)2, and −P(=O)(N(Rbb)2)2, wherein Raa, Rbb, and Rccare as defined herein. Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rdedition, John Wiley & Sons, 1999, incorporated herein by reference.

[0108] Exemplary oxygen protecting groups include, but are not limited to, methyl, methoxymethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p- methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2- methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2- (trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3- bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4- methoxytetrahydrothiopyranyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4- methoxypiperidin-4-yl (CTMP), 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, 1- (2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1- benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t- butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), p- methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6- dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N- oxido, diphenylmethyl, p,p’-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, α- naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p- methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4’- bromophenacyloxyphenyl)diphenylmethyl, 4,4′,4″-tris(4,5- dichlorophthalimidophenyl)methyl, 4,4′,4″-tris(levulinoyloxyphenyl)methyl, 4,4′,4″- tris(benzoyloxyphenyl)methyl, 3-(imidazol-1-yl)bis(4′,4″-dimethoxyphenyl)methyl, 1,1- bis(4-methoxyphenyl)-1′-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10- oxo)anthryl, 1,3-benzodithiolan-2-yl, benzisothiazolyl S,S-dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t-butyldimethylsilyl (TBDMS), t- butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4- oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6- trimethylbenzoate (mesitoate), methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), ethyl carbonate, 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec), 2-(triphenylphosphonio) ethyl carbonate (Peoc), isobutyl carbonate, vinyl carbonate, allyl carbonate, t-butyl carbonate (BOC or Boc), p- nitrophenyl carbonate, benzyl carbonate, p-methoxybenzyl carbonate, 3,4-dimethoxybenzyl carbonate, o-nitrobenzyl carbonate, p-nitrobenzyl carbonate, S-benzyl thiocarbonate, 4- ethoxy-1-napththyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4- nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2- (methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4- (1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate, o- (methoxyacyl)benzoate, α-naphthoate, nitrate, alkyl N,N,N’,N’- tetramethylphosphorodiamidate, alkyl N-phenylcarbamate, borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts).

[0109] In an embodiment, the substituent present on a sulfur atom is a sulfur protecting group (also referred to as a “thiol protecting group”). Sulfur protecting groups include, but are not limited to, −Raa, −N(Rbb)2, −C(=O)SRaa, −C(=O)Raa, −CO2Raa, −C(=O)N(Rbb)2, −C(=NRbb)Raa, −C(=NRbb)ORaa, −C(=NRbb)N(Rbb)2, −S(=O)Raa, −SO2Raa, −Si(Raa)3, −P(Rcc)2, −P(Rcc)3+X−, −P(ORcc)2, −P(ORcc)3+X−, −P(=O)(Raa)2, −P(=O)(ORcc)2, and −P(=O)(N(Rbb)2)2, wherein Raa, Rbb, and Rccare as defined herein. Sulfur protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rdedition, John Wiley & Sons, 1999, incorporated herein by reference.

[0110] The term “leaving group” is given its ordinary meaning in the art of synthetic organic chemistry and refers to an atom or a group capable of being displaced by a nucleophile. Examples of suitable leaving groups include, but are not limited to, halogen (such as F, Cl, Br, or I (iodine)), alkoxycarbonyloxy, aryloxycarbonyloxy, alkanesulfonyloxy, arenesulfonyloxy, alkyl-carbonyloxy (e.g., acetoxy), arylcarbonyloxy, aryloxy, methoxy, N,O-dimethylhydroxylamino, pixyl, and haloformates. In an embodiment, the leaving group is halogen, alkanesulfonyloxy, arenesulfonyloxy, diazonium, alkyl diazenes, aryl diazenes, alkyl triazenes, aryl triazenes, nitro, alkyl nitrate, aryl nitrate, alkyl phosphate, aryl phosphate, alkyl carbonyl oxy, aryl carbonyl oxy, alkoxcarbonyl oxy, aryoxcarbonyl oxy ammonia, alkyl amines, aryl amines, hydroxyl group, alkyloxy group, or aryloxy. In some cases, the leaving group is a sulfonic acid ester, such as toluenesulfonate (tosylate, –OTs), methanesulfonate (mesylate, –OMs), p-bromobenzenesulfonyloxy (brosylate, –OBs), – OS(=O)2(CF2)3CF3(nonaflate, –ONf), or trifluoromethanesulfonate (triflate, –OTf). In some cases, the leaving group is a brosylate, such as p-bromobenzenesulfonyloxy. In some cases, the leaving group is a nosylate, such as 2-nitrobenzenesulfonyloxy. In an embodiment, the leaving group is a sulfonate-containing group. In an embodiment, the leaving group is a tosylate group. The leaving group may also be a phosphineoxide (e.g., formed during a Mitsunobu reaction) or an internal leaving group such as an epoxide or cyclic sulfate. Othernon-limiting examples of leaving groups are water, ammonia, alcohols, ether moieties, thioether moieties, zinc halides, magnesium moieties, diazonium salts, and copper moieties.

[0111] “Carboxy” refers to the radical –C(=O)OH.

[0112] “Cyano” refers to the radical –CN.

[0113] “Halo” or “halogen” refers to fluoro (F), chloro (Cl), bromo (Br), and iodo (I). In an embodiment, the halo group is either fluoro or chloro.

[0114] “Haloalkyl” refers to an alkyl radical in which the alkyl group is substituted with one or more halogens. Typical haloalkyl groups include, but are not limited to, trifluoromethyl (– CF3), difluoromethyl (–CHF2), fluoromethyl (–CH2F), chloromethyl (–CH2Cl), dichloromethyl (–CHCl2), tribromomethyl (–CH2Br), and the like.

[0115] “Hydroxy” refers to the radical –OH.

[0116] “Nitro” refers to the radical –NO2.

[0117] “Thioketo” refers to the group =S.

[0118] Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups, as defined herein, are optionally substituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” carbocyclyl, “substituted” or “unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or “substituted” or “unsubstituted” heteroaryl group). In general, the term “substituted”, whether preceded by the term “optionally” or not, means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. The term “substituted” is contemplated to include substitution with all permissible substituents of organic compounds, any of the substituents described herein that results in the formation of a stable compound. The present invention contemplates any and all such combinations in order to arrive at a stable compound. For purposes of this disclosure, heteroatoms such as nitrogen may have hydrogen substituents and / or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety.

[0119] Exemplary carbon atom substituents include, but are not limited to, halogen, –CN, – NO2, –N3, –SO2H, –SO3H, –OH, –ORaa, –ON(Rbb)2, –N(Rbb)2, –N(Rbb)3+X–, –N(ORcc)Rbb, –SH, –SRaa, –SSRcc, –C(=O)Raa, –CO2H, –CHO, –C(ORcc)2, –CO2Raa, –OC(=O)Raa, – OCO2Raa, –C(=O)N(Rbb)2, –OC(=O)N(Rbb)2, –NRbbC(=O)Raa, –NRbbCO2Raa, – NRbbC(=O)N(Rbb)2, –C(=NRbb)Raa, –C(=NRbb)ORaa, –OC(=NRbb)Raa, –OC(=NRbb)ORaa, – C(=NRbb)N(Rbb)2, –OC(=NRbb)N(Rbb)2, –NRbbC(=NRbb)N(Rbb)2, –C(=O)NRbbSO2Raa, – NRbbSO2Raa, –SO2N(Rbb)2, –SO2Raa, –SO2ORaa, –OSO2Raa, –S(=O)Raa, –S(=O)(=NRbb)Raa, – OS(=O)Raa, –Si(Raa)3, –OSi(Raa)3–C(=S)N(Rbb)2, –C(=O)SRaa, –C(=S)SRaa, –SC(=S)SRaa, – SC(=O)SRaa, –OC(=O)SRaa, –SC(=O)ORaa, –SC(=O)Raa, –P(=O)2Raa, –OP(=O)2Raa, – P(=O)(Raa)2, –OP(=O)(Raa)2, –OP(=O)(ORcc)2, –P(=O)2N(Rbb)2, –OP(=O)2N(Rbb)2, – P(=O)(NRbb)2, –OP(=O)(NRbb)2, –NRbbP(=O)(ORcc)2, –NRbbP(=O)(NRbb)2, –P(Rcc)2, – P(Rcc)3, –OP(Rcc)2, –OP(Rcc)3, –B(Raa)2, –B(ORcc)2, –BRaa(ORcc), C1–10alkyl, C1–10haloalkyl, C2–10alkenyl, C2–10alkynyl, C3–10carbocyclyl, 3–14 membered heterocyclyl, C6–14aryl, and 5–14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; or two geminal hydrogens on a carbon atom are replaced with the group =O, =S, =NN(Rbb)2, =NNRbbC(=O)Raa, =NNRbbC(=O)ORaa, =NNRbbS(=O)2Raa, =NRbb, or =NORcc; each instance of Raais, independently, selected from C1–10alkyl, C1–10haloalkyl, C2–10alkenyl, C2–10alkynyl, C3–10carbocyclyl, 3–14 membered heterocyclyl, C6–14aryl, and 5–14 membered heteroaryl, or two Raagroups are joined to form a 3–14 membered heterocyclyl or 5–14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; each instance of Rbbis, independently, selected from hydrogen, –OH, –ORaa, – N(Rcc)2, –CN, –C(=O)Raa, –C(=O)N(Rcc)2, –CO2Raa, –SO2Raa, –C(=NRcc)ORaa, – C(=NRcc)N(Rcc)2, –SO2N(Rcc)2, –SO2Rcc, –SO2ORcc, –SORaa, –C(=S)N(Rcc)2, –C(=O)SRcc, – C(=S)SRcc, –P(=O)2Raa, –P(=O)(Raa)2, –P(=O)2N(Rcc)2, –P(=O)(NRcc)2, C1–10alkyl, C1–10haloalkyl, C2–10alkenyl, C2–10alkynyl, C3–10carbocyclyl, 3–14 membered heterocyclyl, C6–14aryl, and 5–14 membered heteroaryl, or two Rbbgroups are joined to form a 3–14 membered heterocyclyl or 5–14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; each instance of Rccis, independently, selected from hydrogen, C1–10alkyl, C1–10haloalkyl, C2–10alkenyl, C2–10alkynyl, C3–10carbocyclyl, 3–14 membered heterocyclyl, C6–14aryl, and 5–14 membered heteroaryl, or two Rccgroups are joined to form a 3–14 membered heterocyclyl or 5–14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl,carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; each instance of Rddis, independently, selected from halogen, –CN, –NO2, –N3, – SO2H, –SO3H, –OH, –ORee, –ON(Rff)2, –N(Rff)2, –N(Rff)3+X–, –N(ORee)Rff, –SH, –SRee, – SSRee, –C(=O)Ree, –CO2H, –CO2Ree, –OC(=O)Ree, –OCO2Ree, –C(=O)N(Rff)2, – OC(=O)N(Rff)2, –NRffC(=O)Ree, –NRffCO2Ree, –NRffC(=O)N(Rff)2, –C(=NRff)ORee, – OC(=NRff)Ree, –OC(=NRff)ORee, –C(=NRff)N(Rff)2, –OC(=NRff)N(Rff)2, – NRffC(=NRff)N(Rff)2,–NRffSO2Ree, –SO2N(Rff)2, –SO2Ree, –SO2ORee, –OSO2Ree, –S(=O)Ree, –Si(Ree)3, –OSi(Ree)3, –C(=S)N(Rff)2, –C(=O)SRee, –C(=S)SRee, –SC(=S)SRee, –P(=O)2Ree, – P(=O)(Ree)2, –OP(=O)(Ree)2, –OP(=O)(ORee)2, C1–6alkyl, C1–6haloalkyl, C2–6alkenyl, C2–6alkynyl, C3–10carbocyclyl, 3–10 membered heterocyclyl, C6–10aryl, 5–10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgggroups, or two geminal Rddsubstituents can be joined to form =O or =S; each instance of Reeis, independently, selected from C1–6alkyl, C1–6haloalkyl, C2–6alkenyl, C2–6alkynyl, C3–10carbocyclyl, C6–10aryl, 3–10 membered heterocyclyl, and 3–10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgggroups; each instance of Rffis, independently, selected from hydrogen, C1–6alkyl, C1–6haloalkyl, C2–6alkenyl, C2–6alkynyl, C3–10carbocyclyl, 3–10 membered heterocyclyl, C6–10aryl and 5–10 membered heteroaryl, or two Rffgroups are joined to form a 3–14 membered heterocyclyl or 5–14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgggroups; and each instance of Rggis, independently, halogen, –CN, –NO2, –N3, –SO2H, –SO3H, – OH, –OC1–6alkyl, –ON(C1–6alkyl)2, –N(C1–6alkyl)2, –N(C1–6alkyl)3+X–, –NH(C1–6alkyl)2+X–, –NH2(C1–6alkyl)+X–, –NH3+X–, –N(OC1–6alkyl)(C1–6alkyl), –N(OH)(C1–6alkyl), –NH(OH), –SH, –SC1–6alkyl, –SS(C1–6alkyl), –C(=O)(C1–6alkyl), –CO2H, –CO2(C1–6alkyl), –OC(=O)(C1–6alkyl), –OCO2(C1–6alkyl), –C(=O)NH2, –C(=O)N(C1–6alkyl)2, – OC(=O)NH(C1–6alkyl), –NHC(=O)(C1–6alkyl), –N(C1–6alkyl)C(=O)(C1–6alkyl), – NHCO2(C1–6alkyl), –NHC(=O)N(C1–6alkyl)2, –NHC(=O)NH(C1–6alkyl), –NHC(=O)NH2, – C(=NH)O(C1–6alkyl),–OC(=NH)(C1–6alkyl), –OC(=NH)OC1–6alkyl, –C(=NH)N(C1–6alkyl)2, –C(=NH)NH(C1–6alkyl), –C(=NH)NH2, –OC(=NH)N(C1–6alkyl)2, –OC(NH)NH(C1–6alkyl), –OC(NH)NH2, –NHC(NH)N(C1–6alkyl)2, –NHC(=NH)NH2, –NHSO2(C1–6alkyl), –SO2N(C1–6alkyl)2, –SO2NH(C1–6alkyl), –SO2NH2,–SO2C1–6alkyl, –SO2OC1–6alkyl, – OSO2C1–6alkyl, –SOC1–6alkyl, –Si(C1–6alkyl)3, –OSi(C1–6alkyl)3–C(=S)N(C1–6alkyl)2, C(=S)NH(C1–6alkyl), C(=S)NH2, –C(=O)S(C1–6alkyl), –C(=S)SC1–6alkyl, –SC(=S)SC1–6alkyl, –P(=O)2(C1–6alkyl), –P(=O)(C1–6alkyl)2, –OP(=O)(C1–6alkyl)2, –OP(=O)(OC1–6alkyl)2, C1–6alkyl, C1–6haloalkyl, C2–6alkenyl, C2–6alkynyl, C3–10carbocyclyl, C6–10aryl, 3– 10 membered heterocyclyl, 5–10 membered heteroaryl; or two geminal Rggsubstituents can be joined to form =O or =S; wherein X–is a counterion.

[0120] A “counterion” or “anionic counterion” is a negatively charged group associated with a cationic quaternary amino group in order to maintain electronic neutrality. Exemplary counterions include halide ions (e.g., F–, Cl–, Br–, I–), NO3–, ClO4–, OH–, H2PO4–, HSO4–, SO4-2, sulfonate ions (e.g., methansulfonate, trifluoromethanesulfonate, p–toluenesulfonate, benzenesulfonate, 10–camphor sulfonate, naphthalene–2–sulfonate, naphthalene–1–sulfonic acid–5–sulfonate, ethan–1–sulfonic acid–2–sulfonate, and the like), and carboxylate ions (e.g., acetate, ethanoate, propanoate, benzoate, glycerate, lactate, tartrate, glycolate, and the like).

[0121] Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quarternary nitrogen atoms. Exemplary nitrogen atom substitutents include, but are not limited to, hydrogen, –OH, –ORaa, –N(Rcc)2, –CN, – C(=O)Raa, –C(=O)N(Rcc)2, –CO2Raa, –SO2Raa, –C(=NRbb)Raa, –C(=NRcc)ORaa, – C(=NRcc)N(Rcc)2, –SO2N(Rcc)2, –SO2Rcc, –SO2ORcc, –SORaa, –C(=S)N(Rcc)2, –C(=O)SRcc, – C(=S)SRcc, –P(=O)2Raa, –P(=O)(Raa)2, –P(=O)2N(Rcc)2, –P(=O)(NRcc)2, C1–10alkyl, C1–10haloalkyl, C2–10alkenyl, C2–10alkynyl, C3–10carbocyclyl, 3–14 membered heterocyclyl, C6–14aryl, and 5–14 membered heteroaryl, or two Rccgroups attached to a nitrogen atom are joined to form a 3–14 membered heterocyclyl or 5–14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups, and wherein Raa, Rbb, Rccand Rddare as defined above.

[0122] These and other exemplary substituents are described in more detail in the Detailed Description, Examples, and Claims. The invention is not intended to be limited in any manner by the above exemplary listing of substituents. Other definitions

[0123] The term "about," as used herein, includes the recited number ± 10%. Thus, "about 10" means 9 to 11. As is understood by one skilled in the art, reference to "about" a value orparameter herein includes (and describes) instances that are directed to that value or parameter per se. For example, description referring to "about X" includes description of "X."

[0124] "USP1" and "ubiquitin-specific peptidase 1" as used herein refer to any native polypeptide or USP1 -encoding polynucleotide. The term "USP1" encompasses " full- length," unprocessed USP1 polypeptide as well as any forms of USP1 that result from processing within the cell (e g., removal of the signal peptide). The term also encompasses naturally occurring variants of USP1, e.g., those encoded by splice variants and allelic variants. The USP1 polypeptides described herein can be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods. Human USP1 sequences are known and include, for example, the sequences publicly available as UniProt No.094782 (including isoforms). As used herein, the term "human USP1 protein" refers to USP1 protein comprising the amino acid sequence as set forth in SEQ ID NO: 1 in U S. provisional patent application no.62 / 857,986 filed June 6, 2019.

[0125] USP1 is a deubiquitinating enzyme that acts as part of a complex with UAF1. USP1’s "deubiquitinase activity" includes its ability to deubiquitinate as part of the USP1- UAF1 complex.

[0126] The term "specifically binds" to a protein or domain of a protein is a term that is well understood in the art, and methods to determine such specific binding are also well known in the art. A molecule is said to exhibit "specific binding" or "preferential binding" if it reacts or associates more frequently, more rapidly, with greater duration and / or with greater affinity with a particular protein or domain of a protein than it does with alternative proteins or domains. It should be understood that a molecule that specifically or preferentially binds to a first protein or domain may or may not specifically or preferentially bind to a second protein or domain. As such, "specific binding" or "preferential binding" does not necessarily require (although it can include) exclusive binding. Generally, but not necessarily, reference to binding means preferential binding. For example, a USP1 inhibitor that specifically binds to USP1, UAF1, and / or the USP1-UAF1 complex may not bind to other deubiquitinases, other USP proteins, or other UAF1 complexes (e.g., USP46-UAF1) or may bind to other deubiquitinases, other USP proteins, or other UAF1 complexes (e.g., USP46-UAF1) with a reduced affinity as compared to binding to USP1.

[0127] The terms "reduction" or "reduce" or "inhibition" or "inhibit" refer to a decrease or cessation of any phenotypic characteristic or to the decrease or cessation in the incidence, degree, or likelihood of that characteristic. To "reduce" or "inhibit" is to decrease, reduce orarrest an activity, function, and / or amount as compared to a reference. In an embodiment, by "reduce" or "inhibit" is meant the ability to cause an overall decrease of 20% or greater. In an embodiment, by "reduce" or "inhibit" is meant the ability to cause an overall decrease of 50% or greater. In an embodiment, by "reduce" or "inhibit" is meant the ability to cause an overall decrease of 75%, 85%, 90%, 95%, or greater. In an embodiment, the amount noted above is inhibited or decreased over a period of time, relative to a control over the same period of time.

[0128] In an embodiment inhibiting USP1 proteins is the inhibition of one or more activities or functions of USP1 proteins. It should be appreciated that the activity or function of the one or more USP1 proteins may be inhibited in vitro or in vivo. Non limiting examples of activities and functions of USP1 include deubiquitinase activity, and formation of a complex with UAF l and are described herein. Examplary levels of inhibition of the activity of one or more USP1 proteins include at least 10% inhibiton, at least 20% inhibition, at least 30% inhibition, at least 40% inhibition, at least 50% inhibition, at least 60% inhibition, at least 70% inhibition, at least 80% inhibition, at least 90% inhibition, and up to 100% inhibition.

[0129] As used herein, the term "loss of function" mutation refers to a mutation that results in the absence of a gene, decreased expression of a gene, or the production of a gene product (e.g. protein) having decreased activity or no activity. Loss of function mutations include for example, missense mutations, nucleotide insertions, nucleotide deletions, and gene deletions. Loss of function mutations also include dominant negative mutations. Thus, cancer cells with a loss of function mutation in a gene encoding BRCA1 or BRCA2 include cancer cells that contain missense mutations in a gene encoding BRCA1 or BRCA2as well as cancer cells that lack a gene encoding BRCA1 or BRCA2.

[0130] As used herein, the term “salt” refers to any and all salts and encompasses pharmaceutically acceptable salts.

[0131] The term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al., describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1–19. Pharmaceutically acceptable salts of the compounds disclosed herein include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid,phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2–hydroxy–ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2– naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3–phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p–toluenesulfonate, undecanoate, valerate salts, and the like. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1–4alkyl)4salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.

[0132] A “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle–aged adult or senior adult)) and / or a non-human animal, e.g., a mammal such as primates (e.g., cynomologus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In an embodiment, the subject is a human. In an embodiment, the subject is a non-human animal. The terms “human,” “patient,” and “subject” are used interchangeably herein.

[0133] Disease, disorder, and condition are used interchangeably herein.

[0134] As used herein, and unless otherwise specified, the terms “treat,” “treating” and “treatment” contemplate an action that occurs while a subject is suffering from the specified disease, disorder or condition, which reduces the severity of the disease, disorder or condition, or retards or slows the progression of the disease, disorder or condition (“therapeutic treatment”), and also contemplates an action that occurs before a subject begins to suffer from the specified disease, disorder or condition (“prophylactic treatment”). In an embodiment, the compounds provided herein are contemplated to be used in methods of therapeutic treatment wherein the action occurs while a subject is suffering from the specified disease, disorder or condition and results in a reduction in the severity of the disease, disorderor condition, or retardation or slowing of the progression of the disease, disorder or condition. In an alternate embodiment, the compounds provided herein are contemplated to be used in methods of prophylactic treatment wherein the action occurs before a subject begins to suffer from the specified disease, disorder or condition and results in preventing a disease, disorder or condition, or one or more symptoms associated with the disease, disorder or condition, or preventing the recurrence of the disease, disorder or condition.

[0135] In general, the “effective amount” of a compound refers to an amount sufficient to elicit the desired biological response. As will be appreciated by those of ordinary skill in this art, the effective amount of a compound disclosed herein may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, health, and condition of the subject. An effective amount encompasses therapeutic and prophylactic treatment. An effective amount encompasses therapeutic and prophylactic treatment (i.e., encompasses a “therapeutically effective amount” and a “prophylactically effective amount”).

[0136] As used herein, and unless otherwise specified, a “therapeutically effective amount” of a compound is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder or condition, or to delay or minimize one or more symptoms associated with the disease, disorder or condition. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the disease, disorder or condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.

[0137] As used herein, and unless otherwise specified, a “prophylactically effective amount” of a compound is an amount sufficient to prevent a disease, disorder or condition, or one or more symptoms associated with the disease, disorder or condition, or prevent its recurrence. A prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the disease, disorder or condition. The term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.

[0138] The term "container" means any receptacle and closure therefore suitable for storing, shipping, dispensing, and / or handling a pharmaceutical product.

[0139] The term "insert" or "package insert" means information accompanying a pharmaceutical product that provides a description of how to administer the product, along with the safety and efficacy data required to allow the physician, pharmacist, and patient to make an informed decision regarding use of the product. The package insert generally is regarded as the "label" for a pharmaceutical product. Compounds

[0140] As generally described herein, provided are compounds (e.g., compounds of Formula (I), (II) or a compound of Table 1 or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers or tautomers thereof) that are ubiquitin-specific peptidase 1 (USP1) inhibitors useful for treating diseases and disorders (e.g., cancers) associated with USP1.

[0141] Provided herein are compounds of Formula (I) and Formula (II). Unless the context requires otherwise, reference throughout this specification to “a compound of Formula (I) and / or a compound of Formula (II)” refers to all embodiments of Formula (I), including, for example, compounds of Formula (I), Formula (I-a), Formula (I-b), Formula (I-c), Formula (I- d), Formula (I-d-1), Formula (I-e), Formula (I-f), Formula (I-f-1), Formula (II) as well as the compounds of Table 1.

[0142] In an embodiment, provided are compounds of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. In an embodiment, including any of the numbered embodiments described herein, the compounds are provided as free base or pharmaceutically acceptable salts. In an embodiment, including any of the numbered embodiments described herein, the compounds are provided as free base. In an embodiment, including any of the numbered embodiments described herein, the compounds are provided as pharmaceutically acceptable salts.

[0143] In an embodiment, provided is a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof; wherein:Ring A is selected from the group consisting of:wherein X3is CH or N and wherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B; L is selected from the group consisting of –O– and –S–; Ring B is a 5-10 membered heteroaryl or a 3-10 membered heterocyclyl; each RAis independently selected from the group consisting of –D, oxo, halo, – CN, –C1–C6alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, –ORA1and – N(RA1)2; each RA1is independently selected from the group consisting of H, –C1–C6alkyl, –C1–C6haloalkyl and C3–C9cycloalkyl wherein each hydrogen atom of each alkyl and cycloalkyl can be replaced by deuterium; or two instances of RA1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O; each RBis independently selected from the group consisting of halo, –CN, –C1–C6alkyl, –C1–C6alkenyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, C3-C9cycloalkylalkyl, –ORB1, –N(RB1)2, – C(=O)RB1, –C(=O)ORB1, –NRB1C(=O)RB1, –NRB1C(=O)ORB1, –C(=O)N(RB1)2, – OC(=O)N(RB1)2, –S(=O)RB1, –S(=O)2RB1, –SRB1, –S(=O)(=NRB1)RB1, –NRB1S(=O)2RB1and –S(=O)2N(RB1)2, wherein each alkyl, alkenyl, cycloalkyl, heterocyclyl and cycloalkylalkyl of RBcan be partially or fully deuterated and can be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, –OH– and –CH3; each RB1is independently selected from the group consisting of H, –C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl and 3-7 membered heterocyclyl wherein each hydrogen atom of each alkyl, cycloalkyl and heterocyclyl can be replaced by deuterium; or two instances of RB1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O; each RCis independently selected from the group consisting of H, –D, oxo, halo, – CN, –ORC1, –SRC1–NRC12, –C1–C6alkyl, –C1–C6hydroxyalkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl, 3-10 member heterocyclyl and –heteroC1-C4alkyl wherein each alkyl, cycloalkyl and heterocyclyl of RCcan partially or fully deuterated and can be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, –OH– and –CH3; each RC1is independently selected from the group consisting of H and –C1–C6alkyl, wherein each hydrogen atom of the alkyl can be independently replaced by deuterium; or two instances of RC1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O; each RDis independently selected from the group consisting of –D, halo, –CN, – C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, –C6-C10aryl, –ORD1, –N(RD1)2, –C(=O)RD1, – C(=O)ORD1, –NRD1C(=O)RD1, –NRD1C(=O)ORD1, –C(=O)N(RD1)2, –OC(=O)N(RD1)2, – S(=O)RD1, –S(=O)2RD1, –SRD1, –S(=O)(=NRD1)RD1, –NRD1S(=O)2RD1and –S(=O)2N(RD1)2, wherein each alkyl, cycloalkyl, heterocyclyl and aryl of RDcan be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, –OH– and –CH3; each RD1is independently selected from the group consisting of H, –C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl and 3-7 membered heterocyclyl, wherein each hydrogen atom of each alkyl, cycloalkyl and heterocyclyl can be replaced by deuterium; or two instances of RD1on a nitrogen atom can be taken together with the nitrogento which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O; REis selected from H, –D, halo, –CN, –C1–C6alkyl, –C1-C6alkynyl, –heteroC1– C6alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, –C6-C10aryl, 5-10 member heteroaryl, heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, –ORE1, –SRE1, –N(RE1)2, –C1–C6alkylene–NRE1C(=O)ORE1, – C(=O)RE1, –C(=O)ORE1, –NRE1C(=O)RE1, –NRE1C(=O)ORE1, –C(=O)N(RE1)2, and – OC(=O)N(RE1)2, wherein each alkyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl is optionally substituted at any available position; each RE1is independently selected from H, –C1–C6alkyl (wherein each hydrogen can be independently replaced by deuterium), –heteroC1–C6alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl, 3-7 membered heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, 5-6 membered heteroaryl, arylalkyl and heteroarylalkyl wherein each alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl is optionally substituted at any available position; each Rcand Rc’is independently selected from the group consisting of H, –D, – C1–C6alkyl, –heteroC1-C4alkyl and –C1–C6haloalkyl or Rcand Rc’can be taken together with the atom to which they are attached to form a –C3–C9cycloalkyl; n is 0, 1, 2,3 or 4; m is 0, 1, 2 or 3; and p is 0, 1, 2 or 3.

[0144] In an embodiment, provided is a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof wherein X1, X2, Ring A, L, Ring B, RA, RB, RC, RD, RE, Rc, Rc’, n, m and p are as defined in any of the embodiments described herein. In an embodiment, the compound is of Formula (I). In an embodiment, the compound is of Formula (II).

[0145] As generally defined herein, Ring A is selected from the group consisting of:wherein X3is as defined in any of the embodiments described herein, wherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0146] As generally defined herein, X3is CH or N. In an embodiment, X3is CH. In an embodiment, X3is N.

[0147] In an embodiment, Ring A is selected from the group consisting ofandwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0148] In an embodiment, Ring A iswherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0149] In an embodiment, Ring A iswherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0150] In an embodiment, Ring A iswherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0151] In an embodiment, Ring A is optionally substituted at any available position. In an embodiment, Ring A is substituted with 0, 1, 2, 3 or 4 instances of RA, wherein each RAis independently as defined in any of the embodiments described herein. In an embodiment, Ring A is substituted with 0, 1, 2 or 3 instances of RA, wherein each RAis independently as defined in any of the embodiments described herein. In an embodiment, Ring A is unsubstituted. In an embodiment, Ring A is substituted with 1 or 2 instances of RA, wherein each RAis independently as defined in any of the embodiments described herein. In an embodiment, Ring A is substituted with 1 instance of RA, wherein each RAis independently as defined in any of the embodiments described herein. In an embodiment, Ring A is substituted with 2 instances of RA, wherein each RAis independently as defined in any of the embodiments described herein. In an embodiment, Ring A is substituted with 3 instances of RA, wherein each RAis independently as defined in any of the embodiments described herein.

[0152] In an embodiment, the moiety representedgroup consistingpoint connects to CRcRc’and the right attachment point connects to Ring B.

[0153] In an embodiment, the moiety representedgroup consistingwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0154] In an embodiment, the moiety representedgroup consisting, wherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B. (RA)nRing A

[0155] In an embodiment, the moiety represented asis, wherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0156] In an embodiment, the moiety representedwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B. (RA)n

[0157] In an embodiment, the moiety represented asis, wherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0158] In an embodiment, the moiety representedwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0159] In an embodiment, the moiety representedwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0160] In an embodiment, the moiety representedwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0161] In an embodiment, the moiety representedwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.(RA)nRing A

[0162] In an embodiment, the moiety represented asiwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B. (RA)nRing A

[0163] In an embodiment, the moiety represented asiwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0164] In an embodiment, the moiety representedwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0165] In an embodiment, the moiety representedwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.(RA)nRing A

[0166] In an embodiment, the moiety represented as is, wherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0167] In an embodiment, the moiety representedwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0168] In an embodiment, the moiety representedwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0169] In an embodiment, the moiety representedwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0170] In an embodiment, the moiety representedwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0171] In an embodiment, the moiety representedwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0172] In an embodiment, the moiety representedwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0173] In an embodiment, the moiety representedwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0174] In an embodiment, the moiety represented as, wherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0175] In an embodiment, the moiety represented as,wherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

[0176] As generally defined herein, X1is selected from N and CH. In an embodiment, X1is N. In an embodiment, X1is CH.

[0177] As generally defined herein, X2is selected from N and CH. In an embodiment, X2is N. In an embodiment, X2is CH.

[0178] In an embodiment, X1is N and X2is CH. In an embodiment, X1and X2are both N. In an embodiment, X1and X2are both CH.

[0179] In an embodiment,. In an embodiment,. In an embodiment,

[0180] In an embodiment, the moiety represented asis selected from the group consistingwherein each R1and R2are as defined in any of the embodiments described herein.

[0181] In an embodiment, the moiety represented asis selected from the

[0182] In an embodiment, the moiety represented asis selected from the

[0183] In an embodiment, the moiety represented asis selected from the group consisting

[0184] In an embodiment, the moiety representedembodiment, the moiety representedembodiment, the moiety representedembodiment, the moiety representedembodiment, the moiety representedembodiment, the moiety represented as

[0185] As generally defined herein, Ring B is a 5-10 membered heteroaryl or a 3-10 membered heterocyclyl.

[0186] In an embodiment, Ring B is a 3-7 member monocyclic heterocyclyl containing 1-3 heteroatoms selected from O, N and S (e.g., azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl).

[0187] In an embodiment, Ring B is a 5-6 member monocyclic heteroaryl containing 1-3 heteroatoms selected from O, N and S (e.g., pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, furanyl, thiophenyl, oxazolyl, thiadiazolyl, oxadiazolyl and triazolyl). In an embodiment, Ring B is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxadiazolyl and triazolyl.

[0188] In an embodiment, Ring B is selected from the group consisting of pyridinyl, pyrazolyl and imidazolyl. In an embodiment, Ring B is selected from the group consisting of pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, pyrazin-2-yl, pyrazin-3-yl, pyridazin-3-yl, pyridazin-4-yl, pyridazin-5-yl, pyridazin-6-yl, pyrrol-2-yl, pyrazol-1-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-2-yl, thiazol-4- yl, thiazol-5-yl, thiadiazol-3-yl, thiadiazol-5-yl, oxadiazol-3-yl, oxadiazol-5-yl, 1,2,3 triazol- 1-yl and 1,2,5 thiazol-4-yl. In an embodiment, Ring B is selected from the group consisting of pyridin-2-yl, pyrazol-1-yl and imidazol-2-yl.

[0189] In an embodiment, Ring B is a 6-member monocyclic heteroaryl containing 1-3 nitrogen atoms (e.g., pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl).

[0190] In an embodiment, Ring B is pyridinyl (e.g., pyridin-2-yl, pyridin-3-yl, pyridin-4-yl), pyrimidinyl, (e.g., pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl), pyrazinyl (e.g., pyrazin-2-yl, pyrazin-3-yl) or pyridazinyl (e.g., pyridazin-3-yl, pyridazin-4-yl, pyridazin-5-yl, pyridazin-6-yl). In an embodiment, Ring B is a 5 member monocyclic heteroaryl containing 1-3 heteroatoms selected from O, N and S.

[0191] In an embodiment, Ring B is selected from pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, furanyl, thiophenyl, oxazolyl, thiadiazolyl, oxadiazolyl and triazolyl. In an embodiment, Ring B is selected from pyrrolyl (e.g., pyrrol-2-yl), pyrazolyl (e.g., pyrazol-1-yl, pyrazol-4-yl, pyrazol-5-yl) , imidazolyl (e.g., imidazol-2-yl), thiazolyl (e.g., thiazol-4-yl, thiazol-5-yl), thiadiazolyl (e.g., thiadiazol-3-yl, thiadiazol-5-yl), oxadiazolyl (e.g., oxadiazol-3-yl, oxadiazol-5-yl) and triazolyl (e.g., 1,2,3 triazol-1-yl, 1,2,5 thiazol-4-yl). In an embodiment, Ring B is pyrrolyl (e.g., pyrrol-2-yl).

[0192] In an embodiment, Ring B is selected from imidazolyl (e.g., imidazol-2-yl) and pyrazolyl (e.g., pyrazol-1-yl). In an embodiment, Ring B is pyrazolyl (e.g., pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl). In an embodiment, Ring B is pyrazol-1-yl. In an embodiment, Ring B is imidazolyl (e.g., imidazol-2-yl, imidazol-4-yl, imidazol-5-yl). In an embodiment, Ring B is imidazol-2-yl. In an embodiment, Ring B is thiazolyl (e.g., thiazol-2- yl, thiazol-4-yl, thiazol-5-yl). In an embodiment, Ring B is furanyl (e.g., furan-2-yl, furan-3- yl). In an embodiment, Ring B is thiophenyl (e.g., thiophen-2-yl, thiophen-3-yl). In an embodiment, Ring B is oxazolyl (e.g., oxazol-2-yl, oxazol-4-yl, oxazol-5-yl). In an embodiment, Ring B is thiadiazolyl. In an embodiment, Ring B is oxadiazolyl.

[0193] In an embodiment, Ring B as defined in any of the above embodiments is optionally substituted at any available position. In an embodiment, Ring B is substituted with 0, 1, 2 or 3 instances of RB, wherein each RBis independently as defined in any of the embodiments described herein. In an embodiment, Ring B is substituted with 0, 1 or 2 instances of RB, wherein each RBis independently as defined in any of the embodiments described herein. In an embodiment, Ring B is unsubstituted. In an embodiment, Ring B is substituted with 1 or 2 instances of RB, wherein each RBis independently as defined in any of the embodiments described herein. In an embodiment, Ring B is substituted with 1 instance of RB, wherein each RBis independently as defined in any of the embodiments described herein. In an embodiment, Ring B is substituted with 2 instances of RB, wherein each RBis independently as defined in any of the embodiments described herein. In an embodiment, Ring B is substituted with 3 instances of RB, wherein each RBis independently as defined in any of the embodiments described herein.

[0195] In an embodiment, the moiety representedselected from the group.(RB)pB

[0196] In an embodiment, the moiety represented byis selected from the group consisting(RB)pB

[0197] In an embodiment, the moiety represented byis selected from the group consisting

[0198] In an embodiment, the moiety represented byembodiment, the moiety represented byembodiment, the moiety represented byembodiment, the moiety represented byembodiment, the moiety represented byembodiment, the moiety represented by. ,mbodiment, the moiety representedmbodiment, the moiety represented)pmbodiment, the moiety represented byisembodiment, the moiety representedIn an embodiment, the moiety representedembodiment, the moiety representedthe moiety representedembodiment, the moiety

[0199] As generally defined herein, L is selected from the group consisting of –O– and –S–.

[0200] In an embodiment, L is –O–. In an embodiment, L is –S–.

[0201] As generally defined herein, each Rcand Rc’is independently selected from the group consisting of H, –D, –C1–C6alkyl, –heteroC1-C4alkyl and –C1–C6haloalkyl or Rcand Rc’canbe taken together with the atom to which they are attached to form a –C3–C9cycloalkyl (e.g., cyclopropyl)

[0202] In an embodiment, Rcand Rc’are each independently selected from H, –Me, –CF3and –CHF2or are taken together to form a cyclopropyl.

[0203] In an embodiment, Rcand Rc’are each independently selected from H and –Me or are taken together to form a cyclopropyl.

[0204] In an embodiment, Rcand Rc’are each independently selected from H and –Me.

[0205] In an embodiment, Rcand Rc’are both H.

[0206] In an embodiment, Rcis H and Rc’is –Me.

[0207] In an embodiment, Rcand Rc’are each independently –C1–C6alkyl (e.g., –Me, –Et, – Pr, –iPr, –nBu, –sec-Bu, –iso-Bu, –tBu). In an embodiment, Rcand Rc’are each independently –Me. In an embodiment, Rcand Rc’are each independently –Et. In an embodiment Rcand Rc’are each independently –Pr. In an embodiment, Rcand Rc’are each independently –iPr.

[0208] In an embodiment, Rcand Rc’are each independently –heteroC1-C4alkyl. In an embodiment, Rcand Rc’are each independently methoxymethyl (–CH2OCH3). In an embodiment, Rcand Rc’are each independently hydroxymethyl (–CH2OH). In an embodiment, Rcand Rc’are each independently aminomethyl (e.g., –CH2NH2, –CH2NHCH3, –CH2N(CH3)2.

[0209] In an embodiment, Rcand Rc’are each independently –C1–C6haloalkyl. In an embodiment, Rcand Rc’are each independently trifluoromethyl (–CF3). In other embodiments, Rcand Rc’are each independently difluoromethyl (–CHF2).

[0210] In an embodiment, Rcand Rc’are taken together with the carbon to which they are attached to form a –C3–C9cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl). In an embodiment, Rcand Rc’are taken together with the carbon to which they are attached to form a cyclopropyl. In an embodiment, Rcand Rc’are taken together with the carbon to which they are attached to form a cyclobutyl. In an embodiment, Rcand Rc’are taken together with the carbon to which they are attached to form a cyclopentyl. In an embodiment, Rcand Rc’are taken together with the carbon to which they are attached to form a cyclohexyl.

[0211] As generally defined herein, n is 0, 1, 2, 3 or 4. In an embodiment, n is selected from 0, 1, 2 or 3. In an embodiment, n is selected from 0, 1 or 2. In an embodiment, n is selected from 0 or 1. In an embodiment n is 0. In an embodiment, n is 1 or 2. In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3. In an embodiment, n is 4

[0212] As generally defined herein, m is 0, 1, 2 or 3. In an embodiment, m is selected from 0, 1 or 2. In an embodiment, m is selected from 0 or 1. In an embodiment m is 0. In an embodiment, m is 1 or 2. In an embodiment, m is 1. In an embodiment, m is 2.

[0213] As generally defined herein, p is 0, 1, 2 or 3. In an embodiment, p is selected from 1, 2 or 3. In an embodiment, p is selected from 0, 1 or 2. In an embodiment, p is selected from 0 or 1. In an embodiment p is 0. In an embodiment, p is 1 or 2. In an embodiment, p is 2 or 3. In an embodiment, p is 1. In an embodiment, p is 2. In an embodiment, p is 3. As generally defined herein, each RAis independently selected from –D, oxo, halo, – CN, –C1–C6alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, –ORA1and – N(RA1)2, wherein each RA1is as defined in any of the embodiments described herein. In an embodiment, each RAis independently selected from –D, oxo, halo (e.g., –F, –Cl), –C1–C6alkyl (e.g., –Me, –Et, –Pr, –iPr, –nBu, –tBu), –OH and –O–C1–C6alkyl (e.g., –OMe, –OEt, – OPr, –OiPr, –OnBu, –OtBu). In an embodiment, each RAis independently selected from In an embodiment, each RAis independently selected from C1-C6alkyl, C1-C6haloalkyl, –OC1-C3alkyl, and halo.

[0214] In an embodiment, each RAis independently selected from oxo and halo. In an embodiment, each RAis independently selected from –F, –Cl, –Me, –OH and –OMe. In an embodiment, each RAis independently selected from –F, –Cl, –CH3, –Et,–CH2CF3, –OCH3and –OEt. In an embodiment, each RAis independently selected from oxo and –F. In an embodiment, each RAis independently oxo. In an embodiment, each RAis independently –F.

[0215] As generally defined herein, each RA1is independently selected from the group consisting of H, –C1–C6alkyl, –C1–C6haloalkyl and C3–C9cycloalkyl wherein each hydrogen atom of each alkyl and cycloalkyl can be replaced by deuterium; or two instances of RA1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O. In an embodiment, RA1is H. In an embodiment, RA1is –C1–C6alkyl (e.g., –Me, –Et, –Pr, –iPr, –nBu, –tBu). In an embodiment, RA1is –Me. In an embodiment RA1is –C1–C6haloalkyl (e.g., –CF3, –CHF2, –CF2CH3, – CH2CF3). In an embodiment, RA1is –CF3.

[0216] As generally defined herein, each RBis independently selected from the group consisting of halo, –CN, –C1–C6alkyl, –C1–C6alkenyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, C3-C9cycloalkylalkyl, –ORB1, –N(RB1)2, –C(=O)RB1, –C(=O)ORB1, –NRB1C(=O)RB1, – NRB1C(=O)ORB1, –C(=O)N(RB1)2, –OC(=O)N(RB1)2, –S(=O)RB1, –S(=O)2RB1, –SRB1, –S(=O)(=NRB1)RB1, –NRB1S(=O)2RB1and –S(=O)2N(RB1)2, wherein each alkyl, alkenyl, cycloalkyl, heterocyclyl and cycloalkylalkyl of RBcan be partially or fully deuterated and can be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, – OH– and –CH3, and wherein RB1is as defined in any of the embodiments described herein.

[0217] In an embodiment, RBis selected from halo (e.g., –F, –Cl, –Br), –CN, –OH, –C1–C6alkyl including partially or fully deuterated alkyl (e.g., –Me, –CD3, –Et, –Pr, –iPr, –nBu, –tBu), –C1–C6hydroxyalkyl (e.g.¸–CH2OH), –OC1–C6alkyl (e.g., –OMe, –OEt, –OPr, –OiPr, –OnBu, –OtBu), –COO(C1-C6alkyl) (e.g., –COOEt), –CONH2.

[0218] In an embodiment, each RBis independently selected from the group consisting of halo, –CN, –C1-C6alkyl including partially or fully deuterated alkyl, –C1-C6haloalkyl, –C1- C6hydroxyalkyl, C3-C10cycloalkyl, ORB1, –C(O)(NRB1)2and –C(O)ONRB1, wherein each RB1is as defined in any of the embodiments described herein.

[0219] In an embodiment, each RBis independently selected from the group consisting of halo, –C1-C6alkyl including partially or fully deuterated alkyl, –C1-C6alkenyl, –C1-C6haloalkyl, -heteroC1-C4alkyl, –C3-C10cycloalkyl (substituted with 0, 1 or 2 instances of F), 4-7 member heterocyclyl (substituted with 0 or 1 instances of methyl), C3-C10cycloalkylalkyl and ORB1, wherein each RB1is as defined in any of the embodiments described herein.

[0220] In an embodiment, each RBis independently selected from the group consisting of – Cl, –CH3, –CD3,–Et, –iPr, –CH=CHCH3, –CH2CF3,–CH(CH3)CF3, –CF3, –CHF2, –OCH3, – OEt, cyclopropyl, 2,2-difluorocyclopropyl, 1-Me-azetidin-3-yl, oxetan-3-yl, tetrahydropyran- 4-yl, –CH2CH2OCH3,–OCH(CH3)CH2OCH3, –CH2-cyclopropyl.

[0221] In an embodiment, each RBis independently selected from the group consisting of – Cl, –CH3, –CD3, –Et, –iPr , –CF3, –OCH3and cyclopropyl.

[0222] In an embodiment, each RBis independently selected from the group consisting of – Cl, –CH3, –Et, –iPr , –CF3, –OCH3and cyclopropyl.

[0223] In an embodiment, each RBis independently selected from the group consisting of – CH3, –Et, –iPr, –CF3and cyclopropyl.

[0224] In an embodiment, RBis selected from the group consisting of –Me, –Et, –iPr, and cyclopropyl. In an embodiment, RBis selected from the group consisting of –Me, –Et, and cyclopropyl.

[0225] In an embodiment, RBis halo (e.g., fluoro, chloro, bromo, iodo). In an embodiment, RBis –Cl. In an embodiment, RBis –F. In an embodiment, RBis –Br. In an embodiment, RBis –I.

[0226] In an embodiment, RBis –CN.

[0227] In an embodiment, RBis –C1–C6alkyl including partially or fully deuterated alkyl (e.g., –Me, –CD3, –Et, –Pr, –iPr, –nBu, –sec-Bu, –iso-Bu, –tBu). In an embodiment, RBis – Me. In an embodiment, RBis –CD3. In an embodiment, RBis –Et. In an embodiment RBis – Pr. In an embodiment, RBis –iPr.

[0228] In an embodiment, RBis –heteroC1-C4alkyl. In an embodiment, RBis methoxymethyl (–CH2OCH3). In an embodiment RBis –CH2CH2OMe. In an embodiment, RBis aminomethyl (e.g., –CH2NH2, –CH2NHCH3, –CH2N(CH3)2. In an embodiment, RBis – CH2N(CH3)CH2CH3.

[0229] In an embodiment, RBis –C1–C6haloalkyl (e.g., –CF3, –CHF2, –CH2CH2F, – CH2CHF2, –CH2CF3, –CF2CH3). In an embodiment, RBis trifluoromethyl (–CF3). In other embodiments, RBis difluoromethyl (–CHF2). In an embodiment, RBis –CH2CH2F. In other embodiments, RBis –CH2CHF2,

[0230] In an embodiment, RBis –C1–C6hydroxyalkyl (e.g., –CH2OH, –CH2CH2OH). In an embodiment, RBis hydroxyethyl (–CH2CH2OH).

[0231] In an embodiment, RBis –C3–C10cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl). In an embodiment, RBis cyclopropyl. In an embodiment RBis cyclobutyl. In an embodiment, RBis cyclopentyl. In an embodiment, RBis cyclohexyl.

[0232] In an embodiment, RBis 3-10 membered heterocyclyl (e.g., oxetanyl, tetrahydropyranyl, tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl, 6-oxa-1-azaspiro[3.3]heptanyl, 6-oxa-1-azaspiro[3.4]octanyl). In an embodiment, RBis oxetanyl. In an embodiment, RBis tetrahydropyranyl. In an embodiment, RBis tetrahydrofuranyl. In an embodiment, RBis azetidinyl (e.g., N-methyl azetidin-3-yl). In an embodiment, RBis pyrrolidinyl. In an embodiment, RBis piperidinyl. In an embodiment, RBis piperazinyl. In an embodiment, RBis morpholinyl. In an embodiment, RBis azepanyl. In an embodiment, RBis 6-oxa-1-azaspiro[3.3]heptanyl. In an embodiment, RBis 6-oxa-1- azaspiro[3.4]octanyl.

[0233] In an embodiment, RBis –ORB1wherein each RB1is as defined in any of the embodiments described herein (e.g., hydroxy (–OH), methoxy, difluoromethoxy (–OCHF2), trifluoromethoxy (–OCF3), –OCH(CH3)CF3, –OCH2CF3, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclobutyloxy, ). In an embodiment, RBis hydroxy. In an embodiment, RBis methoxy. In an embodiment, RBis ethoxy. In an embodiment, RBis propoxy. In an embodiment, RBis isopropoxy. In an embodiment RBis difluoromethoxy (–OCHF2). In an embodiment, RBis trifluoromethoxy (–OCF3). In an embodiment, RBis –OCH(CH3)CF3. In an embodiment, RBis –OCH2CF3. In an embodiment, RBis cyclopropyloxy.

[0234] In an embodiment, RBis –N(RB1)2wherein each RB1is as defined in any of the embodiments described herein (e.g., –NH2, –NHRB1, –N(CH3)RB1). In an embodiment, RBis –NH2. In an embodiment, RBis –NHRB1(e.g., –NHMe, –NHEt, –NHPr, –NHiPr, – NHcyclopropyl, –NHcyclobutyl). In an embodiment, RBis –N(CH3)RB1(e.g., –NMe2, – N(CH3)Et, –N(CH3)Pr, –N(CH3)iPr, –N(CH3)cyclopropyl, –N(CH3)cyclobutyl).

[0235] In an embodiment, RBis –C(=O)RB1or –C(=O)ORB1wherein each RB1is as defined in any of the embodiments described herein. In an embodiment, RBis –C(=O)RB1wherein RB1is as described herein. In an embodiment, RBis –C(=O)alkyl. In an embodiment, RBis – C(O)CH3, –C(O)cyclopropyl, –C(O)cyclobutyl, –C(O)tBu, –C(O)iPr, –C(O)Pr, –C(O)iBu, or –C(=O)OMe. In an embodiment, RBis acetyl (–C(=O)Me). In an embodiment, RBis – C(=O)ORB1. In an embodiment, RBis –COOH. In an embodiment, RBis COOMe.

[0236] In an embodiment, RBis –NRB1C(=O)RB1wherein each RB1is as defined in any of the embodiments described herein. In an embodiment, RBis –NHC(=O)RB1(e.g., –NHC(=O)Me, –NHC(=O)Et, –NHC(=O)Pr, –NHC(=O)iPr, –NHC(=O)Bu, –NHC(=O)tBu, – NHC(=O)Cyclopropyl, –NHC(=O)Cyclobutyl). In an embodiment, RBis –N(CH3)C(=O)RB1(e.g., –N(CH3)C(=O)Me, –N(CH3)C(=O)Et, –N(CH3)C(=O)Pr, –N(CH3)C(=O)iPr, – N(CH3)C(=O)Bu, –N(CH3)C(=O)tBu, –N(CH3)C(=O)Cyclopropyl, – N(CH3)C(=O)Cyclobutyl).

[0237] In an embodiment, RBis –NRB1C(=O)ORB1wherein each RB1is as defined in any of the embodiments described herein. In an embodiment, RBis –NHC(=O)ORB1(e.g., – NHC(=O)OMe, –NHC(=O)OEt, –NHC(=O)OPr, –NHC(=O)OiPr, –NHC(=O)OBu, – NHC(=O)OtBu, –NHC(=O)OCyclopropyl, –NHC(=O)OCyclobutyl). In an embodiment, RBis –N(CH3)C(=O)ORB1(e.g., –N(CH3)C(=O)OMe, –N(CH3)C(=O)OEt, –N(CH3)C(=O)OPr, –N(CH3)C(=O)OiPr, –N(CH3)C(=O)OBu, –N(CH3)C(=O)OtBu, – N(CH3)C(=O)OCyclopropyl, –N(CH3)C(=O)OCyclobutyl).

[0238] In an embodiment, RBis –C(=O)N(RB1)2wherein each RB1is as defined in any of the embodiments described herein (e.g., –C(=O)NH2, –C(=O)NHRB1, –C(=O)N(CH3)RB1). In an embodiment, RBis –C(=O)NH2. In an embodiment, RBis –C(=O)NHRB1(e.g., – C(=O)NHMe, –C(=O)NHEt, –C(=O)NHPr, –C(=O)NHiPr, –C(=O)NHBu, –C(=O)NHtBu, – C(=O)NHCyclopropyl, –C(=O)NHCyclobutyl). In an embodiment, RBis –C(=O)N(CH3)RB1(e.g., –C(=O)NMe2, –C(=O)N(CH3)Et, –C(=O)N(CH3)Pr, –C(=O)N(CH3)iPr, – C(=O)N(CH3)Bu, –C(=O)N(CH3)tBu, –C(=O)N(CH3)Cyclopropyl, – C(=O)N(CH3)Cyclobutyl).

[0239] In an embodiment, RBis –OC(=O)N(RB1)2wherein each RB1is as defined in any of the embodiments described herein. In an embodiment, RBis –OC(=O)NHRB1(e.g., – OC(=O)NHMe, –OC(=O)NHEt, –OC(=O)NHPr, –OC(=O)NHiPr, –OC(=O)NHBu, – OC(=O)NHtBu, –OC(=O)NHCyclopropyl, –OC(=O)NHCyclobutyl). In an embodiment, RBis –OC(=O)N(CH3)RB1(e.g., –OC(=O)NMe2, –OC(=O)N(CH3)Et, –OC(=O)N(CH3)Pr, – OC(=O)N(CH3)iPr, –OC(=O)N(CH3)Bu, –OC(=O)N(CH3)tBu, – OC(=O)N(CH3)Cyclopropyl, –OC(=O)N(CH3)Cyclobutyl).

[0240] In an embodiment, RBis -S(=O)RB1wherein each RB1is as defined in any of the embodiments described herein. In an embodiment, RBis –S(=O)alkyl (e.g., –S(=O)Me, – S(=O)Et, –S(=O)Pr, –S(=O)iPr). In an embodiment, RBis –S(=O)cycloalkyl (e.g., – S(=O)cyclopropyl, –S(=O)cyclobutyl, –S(=O)cyclopentyl, –S(=O)cyclohexyl).

[0241] In an embodiment, RBis -S(=O)2RB1wherein each RB1is as defined in any of the embodiments described herein. In an embodiment, RBis –S(=O)2alkyl (e.g., –S(=O)2Me, – S(=O)2Et, –S(=O)2Pr, –S(=O)2iPr). In an embodiment, RBis –S(=O)2cycloalkyl (e.g., – S(=O)2cyclopropyl, –S(=O)2cyclobutyl, –S(=O)2cyclopentyl, –S(=O)2cyclohexyl). In an embodiment, RBis S(=O)2aryl (e.g., S(=O)2phenyl).

[0242] In an embodiment, RBis –SRB1wherein each RB1is as defined in any of the embodiments described herein. In an embodiment, RBis –Salkyl (e.g., –SMe, –SEt, –SPr, – SiPr). In an embodiment, RBis –Scycloalkyl (e.g., –Scyclopropyl, –Scyclobutyl, – Scyclopentyl, –Scyclohexyl). In an embodiment, RBis –Saryl (e.g., Sphenyl).

[0243] In an embodiment, RBis -S(=O)(=NRB1)RB1wherein each RB1is as defined in any of the embodiments described herein. In an embodiment, RBis –S(=O)(=NH)RB1(e.g., – S(=O)(=NH)Me, –S(=O)(=NH)Et, –S(=O)(=NH)Pr, –S(=O)(=NH)iPr, –S(=O)(=NH)Bu, – S(=O)(=NH)tBu, –S(=O)(=NH)Cyclopropyl, –S(=O)(=NH)Cyclobutyl). In an embodiment, RBis –S(=O)(=NCH3)RB1(e.g., –S(=O)(=NCH3)Me, –S(=O)(=NCH3)Et, –S(=O)(=NCH3)Pr, –S(=O)(=NCH3)iPr, –S(=O)(=NCH3)Bu, –S(=O)(=NCH3)tBu, –S(=O)(=NCH3)Cyclopropyl, –S(=O)(=NCH3)Cyclobutyl).

[0244] In an embodiment, RBis –NRB1S(=O)2RB1. In an embodiment, RBis –NHS(=O)2alkyl (e.g., –NHS(=O)2Me, –NHS(=O)2Et, –NHS(=O)2Pr, –NHS(=O)2iPr). In an embodiment, RBis –NHS(=O)2cycloalkyl (e.g., –NHS(=O)2cyclopropyl, –NHS(=O)2cyclobutyl, – NHS(=O)2cyclopentyl, –NHS(=O)2cyclohexyl). In an embodiment, RBis – N(CH3)S(=O)2alkyl (e.g., –N(CH3)S(=O)2Me, –N(CH3)S(=O)2Et, –N(CH3)S(=O)2Pr, – N(CH3)S(=O)2iPr). In an embodiment, RBis –N(CH3)S(=O)2cycloalkyl (e.g., –N(CH3)S(=O)2cyclopropyl, –N(CH3)S(=O)2cyclobutyl, –N(CH3)S(=O)2cyclopentyl, – N(CH3)S(=O)2cyclohexyl).

[0245] In an embodiment, RBis -S(=O)2N(RB1)2wherein each RB1is as defined in any of the embodiments described herein (e.g., –S(=O)2NH2, –S(=O)2NHRB1, –S(=O)2N(CH3)RB1). In an embodiment, RBis -S(=O)2NH2. In an embodiment, RBis -S(=O)2NHRB1(e.g., – S(=O)2NHMe, –S(=O)2NHEt, –S(=O)2NHPr, –S(=O)2NHiPr, –S(=O)2NHcyclopropyl, – S(=O)2NHcyclobutyl). In an embodiment, RBis -S(=O)2N(CH3)RB1(e.g., –S(=O)2NMe2, – S(=O)2N(CH3)Et, –S(=O)2N(CH3)Pr, –S(=O)2N(CH3)iPr, –S(=O)2N(CH3)cyclopropyl, – S(=O)2N(CH3)cyclobutyl).

[0246] As generally defined herein, each RB1is independently selected from the group consisting of H, –C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl and 3-7 membered heterocyclyl wherein each hydrogen atom of each alkyl, cycloalkyl and heterocyclyl can be replaced by deuterium; or two instances of RB1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O.

[0247] In an embodiment, each RB1is independently selected from the group consisting of H and –C1–C6alkyl.

[0248] In an embodiment, each RB1is independently selected from the group consisting of H, –Me and –Et.

[0249] In an embodiment, each RB1is independently H.

[0250] In an embodiment, each RB1is independently –C1–C6alkyl (e.g., –Me, –Et, –Pr, –iPr, –nBu, –tBu, –sec-Bu, –iso-Bu). In an embodiment, each RB1is independently –Me. In an embodiment, each RB1is independently –Et. In an embodiment, each RB1is independently – Pr. In an embodiment, each RB1is independently –iPr.

[0251] In an embodiment, each RB1is independently –heteroC1-C4alkyl. In an embodiment, each RB1is independently methoxymethyl (–CH2OCH3). In an embodiment, each RB1is independently hydroxymethyl (–CH2OH). In an embodiment, each RB1is independently aminomethyl (e.g., –CH2NH2, –CH2NHCH3, –CH2N(CH3)2.

[0252] In an embodiment, each RB1is independently –C1–C6haloalkyl. In an embodiment, each RB1is independently trifluoromethyl (–CF3). In other embodiments, each RB1is independently difluoromethyl (–CHF2). In an embodiment, each RB1is –CH(CH3)CF3. In an embodiment, each RB1is –CH2CF3.

[0253] In an embodiment, each RB1is independently –C3–C9cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl). In an embodiment, each RB1is independently cyclopropyl. In an embodiment each RB1is independently cyclobutyl. In an embodiment, each RB1is independently cyclopentyl. In an embodiment, each RB1is independently cyclohexyl.

[0254] In an embodiment, each RB1is independently 3-7 membered heterocyclyl (e.g., oxetanyl, tetrahydropyranyl, tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl).

[0255] As generally defined herein, each RCis independently selected from the group consisting of H, –D, oxo, halo, –CN, –ORC1, –SRC1–NRC12, –C1–C6alkyl, –C1–C6hydroxyalkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl, 3-10 member heterocyclyl and – heteroC1-C4alkyl wherein each alkyl, cycloalkyl and heterocyclyl of RCcan be partially or fully deuterated and can be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, –OH– and –CH3, wherein each RC1is as defined in any of the embodiments described herein.

[0256] In an embodiment, each RCis independently selected from the group consisting of H, –ORC1, –SRC1, –C1-C6alkyl including partially or fully deuterated alkyl, –C1-C6haloalkyl – C1-C6hydroxyalkyl and C3-C9cycloalkyl.

[0257] In an embodiment, each RCis independently selected from the group consisting of H, –C1-C3alkyl including partially or fully deuterated alkyl and –C1-C3hydroxyalkyl.

[0258] In an embodiment, each RCis independently selected from the group consisting of H, –CH3, –Et, –iPr, –CF3, CH2OH, –CH(OH)CH3, –OMe, –SMe and cyclopropyl.

[0259] In an embodiment, each RCis independently selected from the group consisting of H, –CH3, CH2OH and –CH(OH)CH3.

[0260] In an embodiment, each RCis –CH3.

[0261] In an embodiment, RCis –CH(OH)CH3.

[0262] In an embodiment, RCis –CH2OH.

[0263] In an embodiment, RCis H.

[0264] As generally defined herein, each RC1is independently selected from the group consisting of H and –C1–C6alkyl, wherein each hydrogen atom of the alkyl can be independently replaced by deuterium; or two instances of RC1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O. In an embodiment, RC1is H. In an embodiment, RC1is –Me.

[0265] As generally defined herein, each RDis independently selected from consisting of –D, halo, –CN, –C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3– C10cycloalkyl, 3-10 membered heterocyclyl, –C6-C10aryl, –ORD1, –N(RD1)2, –C(=O)RD1, – C(=O)ORD1, –NRD1C(=O)RD1, –NRD1C(=O)ORD1, –C(=O)N(RD1)2, –OC(=O)N(RD1)2, – S(=O)RD1, –S(=O)2RD1, –SRD1, –S(=O)(=NRD1)RD1, –NRD1S(=O)2RD1and –S(=O)2N(RD1)2, wherein each alkyl, cycloalkyl, heterocyclyl and aryl of RDcan be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, –OH– and –CH3and wherein each RD1is as defined in any of the embodiments described herein.

[0266] In an embodiment, each RDis independently selected from the group consisting of – C1-C6alkyl, ORD1and C3-C10cycloalkyl.

[0267] In an embodiment, each RC1is independently selected from the group consisting of H, –CH3, –Et and –CD3.

[0268] In an embodiment, each RDis independently selected from the group consisting of – ORD1and C3-C10cycloalkyl wherein each RD1is as defined in any of the embodiments described herein.

[0269] In an embodiment, each RDis independently selected from the group consisting of –n- Pr, –iPr, –OCH3, –OCD3, –OEt, –OCHF2, –OCH2F and cyclopropyl.

[0270] In an embodiment, each RDis independently selected from the group consisting of – OCH3, –OCD3, –OEt, –OCHF2, –OCH2F and cyclopropyl.

[0271] In an embodiment, each RDis independently selected from the group consisting of – OCH3, –OCD3, –OCHF2and cyclopropyl.

[0272] In an embodiment, each RDis independently selected from the group consisting of – OCH3and cyclopropyl.

[0273] In an embodiment RDis –D.

[0274] In an embodiment, RDis halo (e.g., fluoro, chloro, bromo, iodo). In an embodiment, RDis –Cl. In an embodiment, RDis –F. In an embodiment, RDis –Br. In an embodiment, RDis –I.

[0275] In an embodiment, RDis –CN.

[0276] In an embodiment, RDis –C1–C6alkyl (e.g., –Me, –Et, –Pr, –iPr, –nBu, –sec-Bu, –iso- Bu, –tBu). In an embodiment, RDis –Me. In an embodiment, RDis –Et. In an embodiment RDis –Pr. In an embodiment, RDis –iPr.

[0277] In an embodiment, RDis –heteroC1-C4alkyl. In an embodiment, RDis methoxymethyl (–CH2OCH3). In an embodiment, RDis aminomethyl (e.g., –CH2NHCH2CH3, –CH2N(CH3)CH2CF3, –CH2N(CH3)CH2CH3, –CH2N(CH3)2–CH2NH2, –CH2NHCH3, – CH2N(CH3)2).

[0278] In an embodiment, RDis –C1–C6haloalkyl (e.g., –CF3, –CHF2, –CF2CH3, –CH2CF3). In an embodiment, RDis trifluoromethyl (–CF3). In other embodiments, RDis difluoromethyl (–CHF2).

[0279] In an embodiment, RDis –C1–C6hydroxyalkyl (e.g., –CH2OH, –CH2CH2OH, – CH(OH)CH3, –C(OH)(CH3)2). In an embodiment, RDis hydroxymethyl (–CH2OH). In an embodiment, RDis –CH(OH)CH3. In an embodiment, RDis –C(OH)(CH3)2.

[0280] In an embodiment, RDis –C3–C10cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl), each of which can be optionally substituted. In an embodiment, RDis optionally substituted cyclopropyl (e.g., cyclopropyl substituted with 0 or 1 instances of – CN). In an embodiment RDis cyclobutyl. In an embodiment, RDis cyclopentyl. In an embodiment, RDis cyclohexyl.

[0281] In an embodiment, RDis 3-10 membered heterocyclyl (e.g., oxetanyl, tetrahydropyranyl, tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl, 6-oxa-1-azaspiro[3.3]heptanyl, 6-oxa-1-azaspiro[3.4]octanyl), each of which can be optionally substituted. In an embodiment, RDis oxetanyl. In an embodiment, RDis tetrahydropyranyl. In an embodiment, RDis tetrahydrofuranyl. In an embodiment, RDis azetidinyl (e.g., azetidinyl substituted with 0 or 1 instances of halo or methyl). In an embodiment, RDis pyrrolidinyl. In an embodiment, RDis piperidinyl. In an embodiment, RDis piperazinyl. In an embodiment, RDis morpholinyl. In an embodiment, RDis azepanyl.

[0282] In an embodiment, RDis –C6-C10aryl (e.g., phenyl, naphthyl). In an embodiment, RDis substituted phenyl (e.g., phenyl substituted with 0 or 1 instances of halo (e.g., –Cl, –F)). In an embodiment RDis 2-chloro-phenyl.

[0283] In an embodiment, RDis –ORD1wherein each RD1is as defined in any of the embodiments described herein (e.g., hydroxy (–OH), methoxy, difluoromethoxy (–OCHF2), trifluoromethoxy (–OCF3), –OCH(CH3)CF3, –OCH2CF3, ethoxy, propoxy, isopropoxy, – OCH2CH(CH3)3, cyclopropyloxy, cyclobutyloxy). In an embodiment, RDis hydroxy. In an embodiment, RDis methoxy. In an embodiment, RDis ethoxy. In an embodiment, RDis propoxy. In an embodiment, RDis isopropoxy. In an embodiment RDis fluoromethoxy (– OCH2F).In an embodiment RDis difluoromethoxy (–OCHF2). In an embodiment, RDis trifluoromethoxy (–OCF3). In an embodiment, RDis –OCH(CH3)CF3. In an embodiment, RDis –OCH2CF3. In an embodiment, RDis cyclopropyloxy.

[0284] In an embodiment, RDis –N(RD1)2wherein each RD1is as defined in any of the embodiments described herein (e.g., –NH2, –NHRD1, –N(CH3)RD1). In an embodiment, RDis –NH2. In an embodiment, RDis –NHRD1(e.g., –NHMe, –NHEt, –NHPr, –NHiPr, – NHcyclopropyl, –NHcyclobutyl). In an embodiment, RDis –N(CH3)RD1(e.g., –NMe2, – N(CH3)Et, –N(CH3)Pr, –N(CH3)iPr, –N(CH3)cyclopropyl, –N(CH3)cyclobutyl).

[0285] In an embodiment, RDis –C(=O)RD1or –C(=O)ORD1wherein each RD1is as defined in any of the embodiments described herein. In an embodiment, RDis –C(=O)RD1wherein each RD1is as defined in any of the embodiments described herein. In an embodiment, RDis –C(=O)alkyl. In an embodiment, RDis –C(O)CH3, –C(O)cyclopropyl, –C(O)cyclobutyl, – C(O)tBu, –C(O)iPr, –C(O)Pr, –C(O)iBu, or –C(=O)OMe. In an embodiment, RDis acetyl (– C(=O)Me). In an embodiment, RDis –C(=O)ORD1. In an embodiment, RDis –COOH. In an embodiment, RDis COOMe.

[0286] In an embodiment, RDis –NRD1C(=O)RD1wherein each RD1is as defined in any of the embodiments described herein. In an embodiment, RDis –NHC(=O)RD1(e.g., –NH, – NHC(=O)Me, –NH, –NHC(=O)Et, –NH, –NHC(=O)Pr, –NH, –NHC(=O)iPr, –NH, – NHC(=O)Bu, –NH, –NHC(=O)tBu, –NH, –NHC(=O)Cyclopropyl, –NH, – NHC(=O)Cyclobutyl). In an embodiment, RDis –N(CH3)C(=O)RD1(e.g., –N(CH3)C(=O)Me, –N(CH3)C(=O)Et, –N(CH3)C(=O)Pr, –N(CH3)C(=O)iPr, –N(CH3)C(=O)Bu, – N(CH3)C(=O)tBu, –N(CH3)C(=O)Cyclopropyl, –N(CH3)C(=O)Cyclobutyl).

[0287] In an embodiment, RDis –NRD1C(=O)ORD1wherein each RD1is as defined in any of the embodiments described herein. In an embodiment, RDis –NHC(=O)ORD1(e.g., –NH, – NHC(=O)OMe, –NH, –NHC(=O)OEt, –NH, –NHC(=O)OPr, –NH, –NHC(=O)OiPr, –NH, – NHC(=O)OBu, –NH, –NHC(=O)OtBu, –NH, –NHC(=O)OCyclopropyl, –NH, – NHC(=O)OCyclobutyl). In an embodiment, RDis –N(CH3)C(=O)ORD1(e.g., – N(CH3)C(=O)OMe, –N(CH3)C(=O)OEt, –N(CH3)C(=O)OPr, –N(CH3)C(=O)OiPr, – N(CH3)C(=O)OBu, –N(CH3)C(=O)OtBu, –N(CH3)C(=O)OCyclopropyl, – N(CH3)C(=O)OCyclobutyl).

[0288] In an embodiment, RDis –C(=O)N(RD1)2wherein each RD1is as defined in any of the embodiments described herein (e.g., –C(=O)NH2, –C(=O)NHRD1, –C(=O)N(CH3)RD1). In an embodiment, RDis –C(=O)NH2. In an embodiment, RDis –C(=O)NHRD1(e.g., – C(=O)NHMe, –C(=O)NHEt, –C(=O)NHPr, –C(=O)NHiPr, –C(=O)NHBu, –C(=O)NHtBu, – C(=O)NHCyclopropyl, –C(=O)NHCyclobutyl). In an embodiment, RDis –C(=O)N(CH3)RD1(e.g., –C(=O)NMe2, –C(=O)N(CH3)Et, –C(=O)N(CH3)Pr, –C(=O)N(CH3)iPr, –C(=O)N(CH3)Bu, –C(=O)N(CH3)tBu, –C(=O)N(CH3)Cyclopropyl, – C(=O)N(CH3)Cyclobutyl).

[0289] In an embodiment, RDis –OC(=O)N(RD1)2wherein each RD1is as defined in any of the embodiments described herein. In an embodiment, RDis –OC(=O)NHRD1(e.g., – OC(=O)NHMe, –OC(=O)NHEt, –OC(=O)NHPr, –OC(=O)NHiPr, –OC(=O)NHBu, – OC(=O)NHtBu, –OC(=O)NHCyclopropyl, –OC(=O)NHCyclobutyl). In an embodiment, RDis –OC(=O)N(CH3)RD1(e.g., –OC(=O)NMe2, –OC(=O)N(CH3)Et, –OC(=O)N(CH3)Pr, – OC(=O)N(CH3)iPr, –OC(=O)N(CH3)Bu, –OC(=O)N(CH3)tBu, – OC(=O)N(CH3)Cyclopropyl, –OC(=O)N(CH3)Cyclobutyl).

[0290] In an embodiment, RDis -S(=O)RD1wherein each RD1is as defined in any of the embodiments described herein. In an embodiment, RDis –S(=O)alkyl (e.g., –S(=O)Me, – S(=O)Et, –S(=O)Pr, –S(=O)iPr). In an embodiment, RDis –S(=O)cycloalkyl (e.g., – S(=O)cyclopropyl, –S(=O)cyclobutyl, –S(=O)cyclopentyl, –S(=O)cyclohexyl).

[0291] In an embodiment, RDis -S(=O)2RD1wherein each RD1is as defined in any of the embodiments described herein. In an embodiment, RDis –S(=O)2alkyl (e.g., –S(=O)2Me, – S(=O)2Et, –S(=O)2Pr, –S(=O)2iPr). In an embodiment, RDis –S(=O)2cycloalkyl (e.g., – S(=O)2cyclopropyl, –S(=O)2cyclobutyl, –S(=O)2cyclopentyl, –S(=O)2cyclohexyl). In an embodiment, RDis S(=O)2aryl (e.g., S(=O)2phenyl).

[0292] In an embodiment, RDis –SRD1wherein each RD1is as defined in any of the embodiments described herein. In an embodiment, RDis –Salkyl (e.g., –SMe, –SEt, –SPr, – SiPr). In an embodiment, RDis –Scycloalkyl (e.g., –Scyclopropyl, –Scyclobutyl, – Scyclopentyl, –Scyclohexyl). In an embodiment, RDis –Saryl (e.g., Sphenyl).

[0293] In an embodiment, RDis -S(=O)(=NRD1)RD1wherein each RD1is as defined in any of the embodiments described herein. In an embodiment, RDis –S(=O)(=NH)RD1(e.g., – S(=O)(=NH)Me, –S(=O)(=NH)Et, –S(=O)(=NH)Pr, –S(=O)(=NH)iPr, –S(=O)(=NH)Bu, – S(=O)(=NH)tBu, –S(=O)(=NH)Cyclopropyl, –S(=O)(=NH)Cyclobutyl). In an embodiment, RDis –S(=O)(=NCH3)RD1(e.g., –S(=O)(=NCH3)Me, –S(=O)(=NCH3)Et, –S(=O)(=NCH3)Pr, –S(=O)(=NCH3)iPr, –S(=O)(=NCH3)Bu, –S(=O)(=NCH3)tBu, –S(=O)(=NCH3)Cyclopropyl, –S(=O)(=NCH3)Cyclobutyl).

[0294] In an embodiment, RDis –NRD1S(=O)2RD1wherein each RD1is as defined in any of the embodiments described herein. In an embodiment, RDis –NHS(=O)2alkyl (e.g., – NHS(=O)2Me, –NHS(=O)2Et, –NHS(=O)2Pr, –NHS(=O)2iPr). In an embodiment, RDis – NHS(=O)2cycloalkyl (e.g., –NHS(=O)2cyclopropyl, –NHS(=O)2cyclobutyl, – NHS(=O)2cyclopentyl, –NHS(=O)2cyclohexyl). In an embodiment, RDis –N(CH3)S(=O)2alkyl (e.g., –N(CH3)S(=O)2Me, –N(CH3)S(=O)2Et, –N(CH3)S(=O)2Pr, – N(CH3)S(=O)2iPr). In an embodiment, RDis –N(CH3)S(=O)2cycloalkyl (e.g., – N(CH3)S(=O)2cyclopropyl, –N(CH3)S(=O)2cyclobutyl, –N(CH3)S(=O)2cyclopentyl, – N(CH3)S(=O)2cyclohexyl).

[0295] In an embodiment, RDis -S(=O)2N(RD1)2wherein each RD1is as defined in any of the embodiments described herein (e.g., –S(=O)2NH2, –S(=O)2NHRD1, –S(=O)2N(CH3)RD1). In an embodiment, RDis -S(=O)2NH2. In an embodiment, RDis -S(=O)2NHRD1(e.g., – S(=O)2NHMe, –S(=O)2NHEt, –S(=O)2NHPr, –S(=O)2NHiPr, –S(=O)2NHcyclopropyl, – S(=O)2NHcyclobutyl). In an embodiment, RDis -S(=O)2N(CH3)RD1(e.g., –S(=O)2NMe2, – S(=O)2N(CH3)Et, –S(=O)2N(CH3)Pr, –S(=O)2N(CH3)iPr, –S(=O)2N(CH3)cyclopropyl, – S(=O)2N(CH3)cyclobutyl).

[0296] As generally defined herein, each RD1is independently selected from the group consisting of H, –C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl and 3-7 membered heterocyclyl, wherein each hydrogen atom of each alkyl, cycloalkyl and heterocyclyl can be replaced by deuterium; or two instances of RD1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O.

[0297] In an embodiment, each RD1is independently selected from H, –C1–C6alkyl (e.g., – Me, –Et, –Pr, –iPr, –nBu, –sec-Bu, –iso-Bu, –tBu), –C1–C6haloalkyl (e.g., –CF3, –CHF2, – CH2CF3, –CH(CH3)CF3) and C3–C9cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl) wherein each hydrogen atom of the alkyl can be independently replaced by deuterium.

[0298] In an embodiment, each RD1is independently selected from the group consisting of H, –C1-C6alkyl and –C1-C6haloalkyl wherein each hydrogen atom of the alkyl can be independently replaced with deuterium.

[0299] In an embodiment, each RD1is independently selected from the group consisting of H, –C1-C3alkyl and –C1-C3haloalkyl wherein each hydrogen atom of the alkyl can be independently replaced with deuterium.

[0300] In an embodiment, each RD1is independently selected from the group consisting of – C1-C3alkyl and –C1-C3haloalkyl wherein each hydrogen atom of the alkyl can be independently replaced with deuterium.

[0301] In an embodiment, each RD1is independently –C1-C3alkyl wherein each hydrogen atom of the alkyl can be independently replaced with deuterium.

[0302] In an embodiment, each RD1is independently selected from the group consisting of – CH3,–Et, –CD3, –CH2F and –CHF2.

[0303] In an embodiment, each RD1is independently selected from the group consisting of – CH3, –CD3and –CHF2.

[0304] In an embodiment, each RD1is independently selected from the group consisting of – CH3and –CD3.

[0305] In an embodiment, each RD1is independently H.

[0306] In an embodiment, each RD1is independently –C1–C6alkyl (e.g., –Me, –Et, –Pr, –iPr, –nBu, –tBu, –sec-Bu, –iso-Bu) wherein each hydrogen atom of the alkyl can be independently replaced with deuterium. In an embodiment, each RD1is independently –Me. In an embodiment, each RD1is independently –CD3. In an embodiment, each RD1is independently –Et. In an embodiment, each RD1is independently –Pr. In an embodiment, each RD1is independently –iPr.

[0307] In an embodiment, each RD1is independently –heteroC1-C4alkyl. In an embodiment, each RD1is independently methoxymethyl (–CH2OCH3). In an embodiment, each RD1is independently aminomethyl (e.g., –CH2NH2, –CH2NHCH3, –CH2N(CH3)2.

[0308] In an embodiment, each RD1is independently –C1–C6haloalkyl. In an embodiment, each RD1is independently trifluoromethyl (–CF3). In other embodiments, each RD1is independently difluoromethyl (–CHF2). In other embodiments, each RD1is independently fluoromethyl (–CH2F). In an embodiment, each RD1is –CH(CH3)CF3. In an embodiment, each RD1is –CH2CF3.

[0309] In an embodiment, each RD1is independently –C3–C9cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl). In an embodiment, each RD1is independently cyclopropyl. In an embodiment each RD1is independently cyclobutyl. In an embodiment, each RD1is independently cyclopentyl. In an embodiment, each RD1is independently cyclohexyl.

[0310] In an embodiment, each RD1is independently 3-7 membered heterocyclyl (e.g., oxetanyl, tetrahydropyranyl, tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl).

[0311] As generally defined herein, each REis selected from H, –D, halo, –CN, –C1–C6alkyl, –C1-C6alkynyl, –heteroC1–C6alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, –C6-C10aryl, 5-10 member heteroaryl, heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, –ORE1, –SRE1, –N(RE1)2, –C1– C6alkylene–NRE1C(=O)ORE1, –C(=O)RE1, –C(=O)ORE1, –NRE1C(=O)RE1, –NRE1C(=O)ORE1, –C(=O)N(RE1)2, and –OC(=O)N(RE1)2, wherein each alkyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl is optionally substituted at any available position and wherein RE1is as defined in any of the embodiments described herein.

[0312] In an embodiment, REis selected from H, –D, halo, –CN, –C1–C6alkyl, –C1-C6alkynyl, –heteroC1–C4alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3- 10 membered heterocyclyl, –C6-C10aryl, 5-10 member heteroaryl, heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, –ORE1, –SRE1, –N(RE1)2, –C1–C6alkylene– NRE1C(=O)ORE1, –C(=O)RE1, –C(=O)ORE1, –NRE1C(=O)RE1, –NRE1C(=O)ORE1, – C(=O)N(RE1)2, and –OC(=O)N(RE1)2, wherein each alkyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl is substituted at any available position with 0, 1 or 2 substituents independently selected from – F, –Cl–, –Me, –Et, –CN, –OH, –OMe –NCH3, –NH2and –CF3, and wherein RE1is as defined in any of the embodiments described herein.

[0313] In an embodiment, REis selected from H, –D, halo, –C1–C6alkyl, –heteroC1–C4alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, 5-10 member heteroaryl, heterocyclylalkyl, –ORE1, –SRE1, –N(RE1)2, and –C1–C6alkylene– NRE1C(=O)ORE1, wherein each alkyl, haloalkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and heterocyclylalkyl is substituted at any available position with 0 or 1 substituents independently selected from –F, –Cl–, –Me, –Et, –CN, –OH, –OMe –NCH3, – NH2and –CF3, and wherein RE1is as defined in any of the embodiments described herein.

[0314] In an embodiment, REis selected from H, halo, –CN, –C1–C6alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, 5-10 member heteroaryl, –ORE1, –SRE1, –N(RE1)2, –C1–C6alkylene–NRE1C(=O)ORE1and –C(=O)N(RE1)2wherein each alkyl, haloalkyl, cycloalkyl, heterocyclyl and heteroaryl is substituted at any available position with 0 or 1 substituents independently selected from –CN, –OH, –NCH3, – NH2, –CF3and –F, and wherein RE1is as defined in any of the embodiments described herein.

[0315] In an embodiment, REis selected from H, –D, halo, –C1–C6alkyl (substituted with 0 or 1 instances of –CN), –C1–C6haloalkyl (substituted with 0 or 1 instances of OH, –NH2or – NHCH3), heteroC1–C4alkyl, –C1–C6hydroxyalkyl (substituted with 0 or 1 instances of –CF3), –C1–C6alkylene–NHC(=O)O(C1-C6alkyl), –C3–C10cycloalkyl (substituted with 0 or 1 instances of –CF3), 3-10 member heterocyclyl (substituted with 0 or 1 instances of –F), 5-10 member heteroaryl, –CH2-heterocyclyl, –NH2, –NH(C1-C6alkyl), –N(C1-C6alkyl)2, – NH(heteroC1–C4alkyl), –OH, –S(C1–C6alkyl), –Ocycloalkylalkyl (substituted with 0 or 1instances of –CF3), -Oarylalkyl, –O(C1–C6haloalkyl) and –O(C1–C6alkyl) (wherein each hydrogen can be independently replaced by deuterium).

[0316] In an embodiment, REis selected from H, –D, –F, –Cl, –Me, –Et, –iPr, –tBu, –CHF2, – CH2CF3, –CH2CHF2, –CF3, –CH2OMe, –CH(CF3)NH2, –CH(CF3)NHCH3, –CH(OH)CF3, – C(OH)(CH3)2, –CH(OH)CH3, –CH2CN,–C(CN)(CH3)2, –CH2CH2CH2NHC(=O)OC(CH3)3, cyclopropyl, 1-CF3-cyclopropyl, cyclobutyl, cyclopentyl, 3-F-oxetan-3-yl, tetrahydrofuran-3-–O-tetrahydrofuran-3-yl, –OCH2CH(NH2)CF3, –OCF3, –OCH2CHF2, –OCH2F, –OCHF2, – OCH2CF3, –OMe, –OCD3, –OEt and –OiPr.

[0317] In an embodiment, REis selected from H, –D, –CN, –F, –Cl, –Me, –Et, –Pr, –iPr, –nBu, –tBu, –CF3, –CHF2, –C(=O)NH2, –OH and –OMe.

[0318] In an embodiment, REis selected from H, –F, –Cl, –Me –OCD3and –OMe .

[0319] In an embodiment, REis selected from H, –Me, –OCD3and –OMe .

[0320] In an embodiment, REis selected from H, –Me and –OMe.

[0321] In an embodiment, REis H. In an embodiment, REis –D.

[0322] In an embodiment, REis halo (e.g., fluoro, chloro, bromo, iodo). In an embodiment, REis –Cl. In an embodiment, REis –F. In an embodiment, REis –Br. In an embodiment, REis –I.

[0323] In an embodiment, REis –CN.

[0324] In an embodiment, REis –C1–C6alkyl, optionally substituted (e.g., –Me, –Et, –Pr, –iPr, –nBu, –sec-Bu, –iso-Bu, –tBu, -CH2CN, –C(CN)(CH3)2). In an embodiment, REis –Me. In an embodiment, REis –Et. In an embodiment REis –Pr. In an embodiment, REis –iPr. In an embodiment, REis –tBu. In an embodiment, REis -CH2CN. In an embodiment, REis – C(CN)(CH3)2.

[0325] In an embodiment, REis –heteroC1–C6alkyl. In an embodiment, REis methoxymethyl (–CH2OCH3). In an embodiment REis –CH2CH2OMe. In an embodiment, REis aminomethyl (e.g., –CH2NH2, –CH2NHCH3, –CH2N(CH3)2. In an embodiment, REis – CH2N(CH3)CH2CH3.

[0326] In an embodiment, REis –C1–C6haloalkyl (e.g., optionally substituted, e.g., substituted at any available position with 0, 1 or 2 instances of –OH) (e.g., –CF3, – CH(OH)CF3, –CH(CF3)NH2, –CH(CF3)NHCH3, –CHF2, –CH2CH2F, –CH2CHF2, –CH2CF3, –CF2CH3). In an embodiment, REis trifluoromethyl (–CF3). In other embodiments, REis difluoromethyl (–CHF2). In an embodiment, REis –CH2CH2F. In other embodiments, REis – CH2CHF2. In an embodiment, REis –CH(OH)CF3.

[0327] In an embodiment, REis –C1–C6hydroxyalkyl, optionally substituted (e.g., with 0 or 1 instances of CF3) (e.g., –CH2OH, –CH2CH2OH, –C(OH)(CH3)2, –CH(OH)CH3, – CH(OH)CF3). In an embodiment, REis hydroxymethyl (–CH2OH,). In an embodiment, REis hydroxyethyl (–CH2CH2OH). In an embodiment, REis –C(OH)(CH3)2. In an embodiment, REis –CH(OH)CH3. In an embodiment, REis –CH(OH)CF3.

[0328] In an embodiment, REis optionally substituted –C3–C10cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl) (e.g., substituted with 0-1 instances of -CF3). In an embodiment, REis cyclopropyl. In an embodiment, REis 1-CF3-cyclopropyl. In an embodiment REis cyclobutyl. In an embodiment, REis cyclopentyl. In an embodiment, REis cyclohexyl.

[0329] In an embodiment, REis optionally substituted 3-10 membered heterocyclyl (e.g., oxetanyl, tetrahydropyranyl, tetrahydrofuranyl, azetidinyl, pyrrolidinyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, azepanyl, 6-oxa-1-azaspiro[3.3]heptanyl, 6-oxa-1- azaspiro[3.4]octanyl)(e.g., substituted with 0 or 1 instances of halo (e.g., –F) or –Me). In an embodiment, REis oxetanyl (e.g, oxetan-3-yl, 3-F-oxetan-3-yl). In an embodiment, REis tetrahydropyranyl. In an embodiment, REis tetrahydrofuranyl (e.g., tetrahydrofuran-3-yl). In an embodiment, REis azetidinyl (e.g., N-methyl azetidin-3-yl). In an embodiment, REis pyrrolidinyl (e.g.,E. In an embodiment, R is dihydropyrrolyl (e.g.In an embodiment, REis piperidinyl. In an embodiment, REis piperazinyl. In an embodiment, REis morpholinyl. In an embodiment, REis azepanyl. In an embodiment, REis 6-oxa-1- azaspiro[3.3]heptanyl. In an embodiment, REis 6-oxa-1-azaspiro[3.4]octanyl.

[0330] In an embodiment, REis independently a 5-10 member heteroaryl (e.g., a 5-6 member monocyclic heteroaryl or an 8-10 member bicyclic heteroaryl containing 1-3 heteroatoms independently selected from N, O and S). In an embodiment, REis independently a 5-6 member monocyclic heteroaryl (e.g., a 5-member monocyclic heteroaryl containing 1-3 heteroatoms independently selected from O, N and S, a 6-member monocyclic heteroaryl containing 1-3 N heteroatoms). In an embodiment, REis independently a 5-member monocyclic heteroaryl (e.g., pyrazolyl, pyrolyl, thiophenyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, thiadiazolyl, oxadiazolyl). In an embodiment, REis independently thiophenyl (e.g., thiophen-2-yl, thiophen-3-yl). In an embodiment, REis independently pyrolyl (e.g., pyrol-2-yl, pyrol-3-yl). In an embodiment, REis independently pyrazolyl (e.g. pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl). In an embodiment, REis independently oxazolyl (e.g., oxazol-2-yl, oxazol-4-yl, oxazol-5-yl). In an embodiment, REis independently thiazolyl (e.g., thiazol-2-yl, thiazol-4-yl, thiazol-5-yl). In an embodiment, REis independently isothiazolyl (e.g., isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl). In an embodiment, REis independently a 6-member monocyclic heteroaryl (e.g., pyridyl, pyrimidinyl, triazinyl, pyrazinyl, pyridazinyl). In an embodiment, REis independently pyridinyl (e.g., pyridin-2-yl, pyridin-3-yl, pyridin-4-yl). In an embodiment, REis independently pyrimidinyl (e.g, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl). In an embodiment, REis independently pyrazinyl.

[0331] In an embodiment REis cycloalkylalkyl (e.g., cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl). In an embodiment, REis heterocyclylalkyl (e.g., oxetanylmethyl, aziridinylmethyl, tetrahydrofuranylmethyl, pyrrolidinylmethyl, tetrahydropyranylmethyl, piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, azepanylmethyl).

[0332] In an embodiment, REis arylalkyl. In an embodiment, REis benzyl.

[0333] In an embodiment, REis heteroarylalkyl (e.g., pyridinylmethyl, thiazolylmethyl, triazolylmethyl, pyrazolylmethyl).

[0334] In an embodiment, REis –ORE1(e.g., hydroxy (–OH), methoxy, –OCD3, difluoromethoxy (–OCHF2), trifluoromethoxy (–OCF3), –OCH(CH3)CF3, –OCH2CF3, - OCH2F, OCH2CHF2, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclobutyloxy, benzyloxy,, –O-oxetan-3-yl, –O-tetrahydrofuran-3-yl, –OCH2CH(NH2)CF3). In an embodiment, REis hydroxy. In an embodiment, REis methoxy. In an embodiment, REisethoxy. In an embodiment, REis propoxy. In an embodiment, REis isopropoxy. In an embodiment REis fluoromethoxy (–OCH2F).In an embodiment REis difluoromethoxy (– OCHF2). In an embodiment, REis trifluoromethoxy (–OCF3). In an embodiment, REis – OCH(CH3)CF3. In an embodiment, REis –OCH2CF3. In an embodiment, REis cyclopropyloxy. In an embodiment, REis. In an embodiment, REis –OCD3. In an embodiment, REis OCH2F. In an embodiment, REis OCH2CHF2. In an embodiment, REis benzyloxy. In an embodiment, REis –O-oxetan-3-yl. In an embodiment, REis –O- tetrahydrofuran-3-yl. In an embodiment, REis –OCH2CH(NH2)CF3).

[0335] In an embodiment, REis –SRE1(e.g., –SMe).

[0336] In an embodiment, REis –N(RE1)2(e.g., –NH2, –NHRE1, –N(CH3)RE1). In an embodiment, REis –NH2. In an embodiment, REis –NHRE1(e.g., –NHMe, –NHEt, –NHPr, – NHiPr, –NHcyclopropyl, –NHcyclobutyl,–NHCH2CH2OCH3, –NHCH2CH2CH2OCH3–,embodiment, REis –N(CH3)RE1(e.g., –NMe2, –N(CH3)Et, –N(CH3)Pr, – N(CH3)iPr, –N(CH3)cyclopropyl, –N(CH3)cyclobutyl).

[0337] In an embodiment, REis –C(=O)RE1or –C(=O)ORE1. In an embodiment, REis – C(=O)RE1wherein RE1is as described herein. In an embodiment, REis –C(=O)alkyl. In an embodiment, REis –C(O)CH3, –C(O)cyclopropyl, –C(O)cyclobutyl, –C(O)tBu, –C(O)iPr, – C(O)Pr, –C(O)iBu, or –C(=O)OMe. In an embodiment, REis acetyl (–C(=O)Me). In an embodiment, REis –C(=O)ORE1. In an embodiment, REis –COOH. In an embodiment, REis COOMe.

[0338] In an embodiment, REis –NRE1C(=O)RE1. In an embodiment, REis –NHC(=O)RE1(e.g., –NHC(=O)Me, –NHC(=O)Et, –NHC(=O)Pr, –NHC(=O)iPr, –NHC(=O)Bu, – NHC(=O)tBu, –NHC(=O)Cyclopropyl, –NHC(=O)Cyclobutyl). In an embodiment, REis – N(CH3)C(=O)RE1(e.g., –N(CH3)C(=O)Me, –N(CH3)C(=O)Et, –N(CH3)C(=O)Pr, – N(CH3)C(=O)iPr, –N(CH3)C(=O)Bu, –N(CH3)C(=O)tBu, –N(CH3)C(=O)Cyclopropyl, – N(CH3)C(=O)Cyclobutyl).

[0339] In an embodiment, REis –NRE1C(=O)ORE1. In an embodiment, REis –NHC(=O)ORE1(e.g., –NHC(=O)OMe, –NHC(=O)OEt, –NHC(=O)OPr, –NHC(=O)OiPr, –NHC(=O)OBu, –NHC(=O)OtBu, –NHC(=O)OCyclopropyl, –NHC(=O)OCyclobutyl). In an embodiment, REis –N(CH3)C(=O)ORE1(e.g., –N(CH3)C(=O)OMe, –N(CH3)C(=O)OEt, –N(CH3)C(=O)OPr, –N(CH3)C(=O)OiPr, –N(CH3)C(=O)OBu, –N(CH3)C(=O)OtBu, – N(CH3)C(=O)OCyclopropyl, –N(CH3)C(=O)OCyclobutyl).

[0340] In an embodiment, REis –C(=O)N(RE1)2(e.g., –C(=O)NH2, –C(=O)NHRE1, – C(=O)N(CH3)RE1). In an embodiment, REis –C(=O)NH2. In an embodiment, REis – C(=O)NHRE1(e.g., –C(=O)NHMe, –C(=O)NHEt, –C(=O)NHPr, –C(=O)NHiPr, – C(=O)NHBu, –C(=O)NHtBu, –C(=O)NHCyclopropyl, –C(=O)NHCyclobutyl). In an embodiment, REis –C(=O)N(CH3)RE1(e.g., –C(=O)NMe2, –C(=O)N(CH3)Et, – C(=O)N(CH3)Pr, –C(=O)N(CH3)iPr, –C(=O)N(CH3)Bu, –C(=O)N(CH3)tBu, – C(=O)N(CH3)Cyclopropyl, –C(=O)N(CH3)Cyclobutyl).

[0341] In an embodiment, REis –OC(=O)N(RE1)2. In an embodiment, REis –OC(=O)NHRE1(e.g., –OC(=O)NHMe, –OC(=O)NHEt, –OC(=O)NHPr, –OC(=O)NHiPr, –OC(=O)NHBu, – OC(=O)NHtBu, –OC(=O)NHCyclopropyl, –OC(=O)NHCyclobutyl). In an embodiment, REis –OC(=O)N(CH3)RE1(e.g., –OC(=O)NMe2, –OC(=O)N(CH3)Et, –OC(=O)N(CH3)Pr, – OC(=O)N(CH3)iPr, –OC(=O)N(CH3)Bu, –OC(=O)N(CH3)tBu, – OC(=O)N(CH3)Cyclopropyl, –OC(=O)N(CH3)Cyclobutyl).

[0342] –In an embodiment, REis –C1–C6alkylene–NRE1C(=O)ORE1(e.g., –C1–C6alkylene– NHC(=O)O(C1-C6alkyl)). In an embodiment, REis –CH2–NHC(=O)O(C1-C6alkyl) (e.g., – CH2NHC(=O)OC(CH3)3). In an embodiment, REis –CH2CH2–NHC(=O)O(C1-C6alkyl) (e.g., –CH2CH2NHC(=O)OC(CH3)3). In an embodiment, REis –CH2CH2CH2–NHC(=O)O(C1- C6alkyl) (e.g., –CH2CH2CH2NHC(=O)OC(CH3)3)

[0343] As generally defined herein, each RE1is independently selected from independently selected from H, –C1–C6alkyl (wherein each hydrogen can be independently replaced by deuterium), –heteroC1–C6alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl, 3-7 membered heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, 5-6 membered heteroaryl, arylalkyl and heteroarylalkyl wherein each alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl is optionally substituted at any available position.

[0344] In an embodiment, each RE1is independently selected from H, –C1–C6alkyl (wherein each hydrogen can be independently replaced by deuterium), –heteroC1–C6alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl, 3-7 membered heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, 5-6 membered heteroaryl, arylalkyl and heteroarylalkyl wherein each alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl andheteroarylalkyl is substituted at any available position with 0, 1 or 2 substituents independently selected from –F, –Cl–, –Me, –Et, –CN, –OH, –OMe –NCH3, –NH2and –CF3.

[0345] . In an embodiment, each RE1is independently substituted with 0 or 1 instance of CF3.

[0346] In an embodiment, each RE1is independently selected from –C1–C6alkyl (wherein each hydrogen can be independently replaced with deuterium), –C1–C6haloalkyl, –heteroC1- C4alkyl, –C3-C9cycloalkyl, 3-7 membered heterocyclyl, cycloalkylalkyl, heterocyclylalkyl and arylalkyl, wherein each alkyl, haloalkyl, heteroalkyl, cycloalkyl, heterocyclyl, cycloalkylalkyl and arylalkyl is independently substituted at any available position with 0 or 1 substituents independently selected from –NH2and –CF3.

[0347] In an embodiment, each RE1is independently selected from –C1–C6alkyl (wherein each hydrogen can be independently replaced with deuterium)(e.g., –Me, –CD3, –Et, –iPr), – C1–C6haloalkyl (e.g., –CH2CHF2, –CH2F, –CHF2, –CH2CF3), –heteroC1–C6alkyl (e.g., – CH2CH2OCH3, –CH2CH2CH2OCH3), benzyl and CH2Cyclopropyl (substituted with 0 or 1 instance of –CF3).

[0348] In an embodiment, each RE1is independently selected from H, –C1–C6alkyl (e.g., – Me, –Et, –Pr, –iPr, –nBu, –tBu, –sec-Bu, –iso-Bu) and –C1–C6haloalkyl (e.g., –CHF2, –CF3, – CH(CH3)CF3, –CH2CF3).

[0349] In an embodiment, each RE1is independently selected from the group consisting of – Me, –CD3, –Et, –iPr, CH2CHF2, –CF3, –CHF2, –CH2F, Bn, cyclopropyl, oxetan-3-yl, tetrahydrofuran-3-yl, CH2-1-CF3-cyclopropyl, CH2CH(NH2)CF3,,– CH2CH2CH2OMe and –CH2CH2OMe.

[0350] In an embodiment, each RE1is independently selected from –Me, –CD3, –Et, –iPr, CH2CHF2, –CH2F, –CHF2, –CH2CF3, –CH2CH2OCH3, –CH2CH2CH2OCH3, benzyl, – F3CCH2Cyclopropyl and (substituted with 0 or 1 instance of –CF3).

[0351] In an embodiment, each RE1is independently selected from –Me, –CD3, –Et, –iPr, CH2CHF2, –CH2F, –CHF2and –CH2CF3.

[0352] In an embodiment, each RE1is independently H.

[0353] In an embodiment, each RE1is independently –C1–C6alkyl (wherein each hydrogen can be independently replaced with deuterium)(e.g., –Me, –CD3, –Et, –Pr, –iPr, –nBu, –tBu, – sec-Bu, –iso-Bu). In an embodiment, each RE1is independently –Me. In an embodiment each RE1is independently –CD3. In an embodiment, each RE1is independently –Et. In anembodiment, each RE1is independently –Pr. In an embodiment, each RE1is independently –iPr.

[0354] In an embodiment, each RE1is independently –heteroC1–C6alkyl (e.g., –CH2OH, – CH2OCH3, –CH2CH2OCH3, –CH2CH2CH2OCH3. In an embodiment, each RE1is independently methoxymethyl (–CH2OCH3). In an embodiment, each RE1is independently hydroxymethyl (–CH2OH). In an embodiment, each RE1is independently –CH2CH2OCH3. In an embodiment, each RE1is independently –CH2CH2CH2OCH3. In an embodiment, each RE1is independently aminomethyl (e.g., –CH2NH2, –CH2NHCH3, –CH2N(CH3)2.

[0355] In an embodiment, each RE1is independently –C1–C6haloalkyl (e.g., –CF3, – CH2CHF2, –CH2F, –CHF2, –CH2CF3), optionally substituted with 0-1 instances of NH2. In an embodiment, each RE1is independently trifluoromethyl (–CF3). In other embodiments, each RE1is independently difluoromethyl (–CHF2). In an embodiment, each RE1is independently – CH2CHF2. In an embodiment, each RE1is independently –CH2F. In an embodiment, each RE1is –CH(CH3)CF3. In an embodiment, each RE1is –CH2CF3. In an embodiment, each RE1is CH2CH(NH2)CF3.

[0356] In an embodiment, each RE1is independently –C3–C9cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl) optionally substituted (e.g., substituted with 0, 1 or 2 instances of halo (e.g., –F, –Cl), –CN, –Me, –Et–, –iPr, –OH, –OMe, –NH2, –CF3). In an embodiment, each RE1is independently cyclopropyl. In an embodiment each RE1is independently cyclobutyl. In an embodiment, each RE1is independently cyclopentyl. In an embodiment, each RE1is independently cyclohexyl.

[0357] In an embodiment, each RE1is independently 3-10 membered heterocyclyl (e.g., oxetanyl, tetrahydropyranyl, tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl) optionally substituted (e.g., substituted with 0, 1 or 2 instances of halo (e.g., –F, –Cl), –CN, –Me, –Et–, –iPr, –OH, –OMe, –NH2, –CF3). In an embodiment, each RE1is independently oxetan-3-yl. In an embodiment, each RE1is independently tetrahydrofuran-3-yl.

[0358] In an embodiment, RE1is independently heteroaryl, optionally substituted (e.g., substituted with 0, 1 or 2 instances of halo (e.g., –F, –Cl), –CN, –Me, –Et–, –iPr, –OH, – OMe, –NH2, –CF3). In an embodiment, RE1is independently a 5-10 member heteroaryl (e.g., a 5-6 member monocyclic heteroaryl or an 8-10 member bicyclic heteroaryl containing 1-3 heteroatoms independently selected from N, O and S). In an embodiment, RE1is independently a 5-6 member monocyclic heteroaryl (e.g., a 5-member monocyclic heteroaryl containing 1-3 heteroatoms independently selected from O, N and S, a 6-member monocyclicheteroaryl containing 1-3 N heteroatoms). In an embodiment, RE1is independently a 5- member monocyclic heteroaryl (e.g., pyrazolyl, pyrolyl, thiophenyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, thiadiazolyl, oxadiazolyl). In an embodiment, RE1is independently thiophenyl (e.g., thiophen-2-yl, thiophen-3-yl). In an embodiment, RE1is independently pyrazolyl (e.g. pyrazol-1-yl, pyrazol-3-yl, pyrazol-5-yl). In an embodiment, RE1is independently thiazolyl (e.g., thiazol-2-yl, thiazol-4-yl, thiazol-5-yl). In an embodiment, RE1is independently a 6-member monocyclic heteroaryl (e.g., pyridyl, pyrimidinyl, triazinyl, pyrazinyl, pyridazinyl). In an embodiment, RE1is independently pyridinyl (e.g., pyridin-2-yl, pyridin-3-yl, pyridin-4-yl). In an embodiment, RE1is independently pyrimidinyl (e.g, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl).

[0359] In an embodiment, RE1is independently aryl, optionally substituted (e.g., substituted with 0, 1 or 2 instances of halo (e.g., –F, –Cl), –CN, –Me, –Et–, –iPr, –OH, –OMe, –NH2, – CF3). In an embodiment, RE1is independently 6-10 member mono or bicyclic aryl. In an embodiment, RE1is independently phenyl.

[0360] In an embodiment each RE1is independently cycloalkylalkyl (e.g., cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl), optionally substituted (e.g., substituted with 0, 1 or 2 instances of halo (e.g., –F, –Cl), –CN, –Me, –Et–, –iPr, –OH, –OMe, –NH2, –CF3). In an embodiment, each RE1is independently substituted with 0 or 1 instance of CF3. In an embodiment, each RE1is independently cyclopropylmethyl (–CH2Cyclopropyl), optionally substituted (e.g., substituted with 0, 1 or 2 instances of halo (e.g., –F, –Cl), –CN, –Me, –Et–, –iPr, –OH, –OMe, –NH2, –CF3). In an embodiment, each RE1is independently cyclopropylmethyl (–CH2Cyclopropyl) substituted with 0 or 1 instance of CF3(–CH2-1-CF3-cyclopropyl). In an embodiment, each RE1is independently heterocyclylalkyl (e.g., oxetanylmethyl, aziridinylmethyl, tetrahydrofuranylmethyl, pyrrolidinylmethyl, tetrahydropyranylmethyl, piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, azepanylmethyl, thiomorpholinmethyl, thiomorpholinethyl, thiomorpholindioxide ethyl) optionally substituted (e.g., substituted with 0, 1 or 2 instances of halo (e.g., –F, –Cl), –CN, –Me, –Et–, –iPr, –OH, –OMe, –NH2, –CF3).

[0361] In an embodiment, each RE1is independently arylalkyl optionally substituted (e.g., substituted with 0, 1 or 2 instances of halo (e.g., –F, –Cl), –CN, –Me, –Et–, –iPr, –OH, – OMe, –NH2, –CF3). In an embodiment, each RE1is independently benzyl.

[0362] In an embodiment, each RE1is independently heteroarylalkyl (e.g., pyridinylmethyl, thiazolylmethyl, triazolylmethyl, pyrazolylmethyl), optionally substituted (e.g., substituted with 0, 1 or 2 instances of halo (e.g., –F, –Cl), –CN, –Me, –Et–, –iPr, –OH, –OMe, –NH2, – CF3).

[0363] As generally defined herein, each R1is independently selected from the group consisting of –D, halo, –CN, –C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, –C6-C10aryl, –ORa1, – N(Ra1)2, –C(=O)Ra1, –C(=O)ORa1, –NRa1C(=O)Ra1, –NRa1C(=O)ORa1, –C(=O)N(Ra1)2, – OC(=O)N(Ra1)2, –S(=O)Ra1, –S(=O)2Ra1, –SRa1, –S(=O)(=NRa1)Ra1, –NRa1S(=O)2Ra1and – S(=O)2N(Ra1)2, wherein each alkyl, cycloalkyl, heterocyclyl and aryl of R1can be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, –OH– and –CH3wherein each Ra1is as defined in any of the embodiments described herein.

[0364] In an embodiment, each R1is independently selected from halo, –C1–C6alkyl, phenyl substituted with 0 to 1 instances of halo, –C1–C6haloalkyl, –C1–C6hydroxyalkyl and –C3– C10cycloalkyl.

[0365] In an embodiment, each R1is independently selected from Cl, –Me, –iPr, –CF3, – CHF2, –CF2CH3, 2-chlorophenyl, cyclopropyl, –CH(OH)CH3and –C(CH3)2OH.

[0366] In an embodiment, each R1is independently selected from –iPr, –CF3and cyclopropyl.

[0367] In an embodiment, each R1is independently selected from –iPr and cyclopropyl.

[0368] In an embodiment, R1is H. In an embodiment R1is –D.

[0369] In an embodiment, R1is halo (e.g., fluoro, chloro, bromo, iodo). In an embodiment, R1is –Cl. In an embodiment, R1is –F. In an embodiment, R1is –Br. In an embodiment, R1is –I.

[0370] In an embodiment, R1is –CN.

[0371] In an embodiment, R1is –C1–C6alkyl (e.g., –Me, –Et, –Pr, –iPr, –nBu, –sec-Bu, –iso- Bu, –tBu, –C(CH3)CH2CH3,). In an embodiment, R1is –Me. In an embodiment, R1is –Et. In an embodiment R1is –Pr. In an embodiment, R1is –iPr. In an embodiment, R1is - C(CH3)CH2CH3.

[0372] In an embodiment, R1is –heteroC1-C4alkyl. In an embodiment, R1is methoxymethyl (–CH2OCH3). In an embodiment, R1is aminomethyl (e.g., –CH2NH2, –CH2NHCH3, – CH2NHCH2CH3, –CH2N(CH3)2). In an embodiment, R1is –CH2N(CH3)CH2CH3. In an embodiment, R1is –CH2N(CH3)CH2CF3.

[0373] In an embodiment, R1is –C1–C6haloalkyl (e.g., –CF3, –CHF2, –CF2CH3, –CH2CF3) . In an embodiment, R1is trifluoromethyl (–CF3). In other embodiments, R1is difluoromethyl (–CHF2). In other embodiments, R1is –CH2CF3. In an embodiment, R1is –CF2CH3.

[0374] In an embodiment, R1is –C1–C6hydroxyalkyl (e.g., –CH2OH, –CH(OH)CH3, – C(OH)(CH3)2). In an embodiment, R1is hydroxymethyl (–CH2OH).

[0375] In an embodiment, R1is –C3–C10cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl). In an embodiment, R1is cyclopropyl (e.g., substituted with 0 or 1 instance of –CN). In an embodiment R1is cyclobutyl. In an embodiment, R1is cyclopentyl. In an embodiment, R1is cyclohexyl.

[0376] In an embodiment, R1is an optionally substituted 3-10 membered heterocyclyl (e.g., oxetanyl, tetrahydropyranyl, tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl, 6-oxa-1-azaspiro[3.3]heptanyl, 6-oxa-1- azaspiro[3.4]octanyl). In an embodiment, R1is oxetanyl. In an embodiment, R1is tetrahydropyranyl. In an embodiment, R1is tetrahydrofuranyl. In an embodiment, R1is azetidinyl. In an embodiment, the azetidinyl is optionally substituted (e.g., substituted with 0 or 1 instances of –F or –Me). In an embodiment, R1is pyrrolidinyl. In an embodiment, R1is piperidinyl. In an embodiment, R1is piperazinyl. In an embodiment, R1is morpholinyl. In an embodiment, R1is azepanyl. In an embodiment, R1is 6-oxa-1-azaspiro[3.3]heptanyl. In an embodiment, R1is 6-oxa-1-azaspiro[3.4]octanyl.

[0377] In an embodiment, R1is –C6-C10aryl (e.g., phenyl, naphthyl). In an embodiment, R1is phenyl (e.g., phenyl substituted with 0 or 1 instances of halo (e.g., –Cl, –F)). In an embodiment, R1is -2-Cl-phenyl.

[0378] In an embodiment, R1is –ORa1wherein each Ra1is as defined in any of the embodiments described herein (e.g., hydroxy (–OH), methoxy, difluoromethoxy (–OCHF2), trifluoromethoxy (–OCF3), –OCH(CH3)CF3, –OCH2CF3, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclobutyloxy, –OCH2CH(CH3)3). In an embodiment, R1is hydroxy. In an embodiment, R1is methoxy. In an embodiment, R1is ethoxy. In an embodiment, R1is propoxy. In an embodiment, R1is isopropoxy. In an embodiment R1is difluoromethoxy (– OCHF2). In an embodiment, R1is trifluoromethoxy (–OCF3). In an embodiment, R1is – OCH(CH3)CF3. In an embodiment, R1is –OCH2CF3. In an embodiment, R1is cyclopropyloxy. In an embodiment R1is –OCH2CH(CH3)3.

[0379] In an embodiment, R1is –N(Ra1)2wherein each Ra1is as defined in any of the embodiments described herein (e.g., –NH2, –NHRa1, –N(CH3)Ra1). In an embodiment, R1is – NH2. In an embodiment, R1is –NHRa1(e.g., –NHMe, –NHEt, –NHPr, –NHiPr, –NHcyclopropyl, –NHcyclobutyl). In an embodiment, R1is –N(CH3)Ra1(e.g., –NMe2, – N(CH3)Et, –N(CH3)Pr, –N(CH3)iPr, –N(CH3)cyclopropyl, –N(CH3)cyclobutyl).

[0380] In an embodiment, R1is –C(=O)Ra1or –C(=O)ORa1wherein each Ra1is as defined in any of the embodiments described herein. In an embodiment, R1is –C(=O)Ra1wherein Ra1is as described herein. In an embodiment, R1is –C(=O)alkyl. In an embodiment, R1is – C(O)CH3, –C(O)cyclopropyl, –C(O)cyclobutyl, –C(O)tBu, –C(O)iPr, –C(O)Pr, –C(O)iBu, or –C(=O)OMe. In an embodiment, R1is acetyl (–C(=O)Me). In an embodiment, R1is – C(=O)ORa1. In an embodiment, R1is –COOH. In an embodiment, R1is COOMe.

[0381] In an embodiment, R1is –NRa1C(=O)Ra1wherein each Ra1is as defined in any of the embodiments described herein. In an embodiment, R1is –NHC(=O)Ra1(e.g., –NH, – NHC(=O)Me, –NH, –NHC(=O)Et, –NH, –NHC(=O)Pr, –NH, –NHC(=O)iPr, –NH, – NHC(=O)Bu, –NH, –NHC(=O)tBu, –NH, –NHC(=O)Cyclopropyl, –NH, – NHC(=O)Cyclobutyl). In an embodiment, R1is –N(CH3)C(=O)Ra1(e.g., –N(CH3)C(=O)Me, –N(CH3)C(=O)Et, –N(CH3)C(=O)Pr, –N(CH3)C(=O)iPr, –N(CH3)C(=O)Bu, – N(CH3)C(=O)tBu, –N(CH3)C(=O)Cyclopropyl, –N(CH3)C(=O)Cyclobutyl).

[0382] In an embodiment, R1is –NRa1C(=O)ORa1wherein each Ra1is as defined in any of the embodiments described herein. In an embodiment, R1is –NHC(=O)ORa1(e.g., –NH, – NHC(=O)OMe, –NH, –NHC(=O)OEt, –NH, –NHC(=O)OPr, –NHC(=O)OiPr, – NHC(=O)OBu, –NHC(=O)OtBu, –NHC(=O)OCyclopropyl, –NHC(=O)OCyclobutyl). In an embodiment, R1is –N(CH3)C(=O)ORa1(e.g., –N(CH3)C(=O)OMe, –N(CH3)C(=O)OEt, – N(CH3)C(=O)OPr, –N(CH3)C(=O)OiPr, –N(CH3)C(=O)OBu, –N(CH3)C(=O)OtBu, – N(CH3)C(=O)OCyclopropyl, –N(CH3)C(=O)OCyclobutyl).

[0383] In an embodiment, R1is –C(=O)N(Ra1)2wherein each Ra1is as defined in any of the embodiments described herein(e.g., –C(=O)NH2, –C(=O)NHRa1, –C(=O)N(CH3)Ra1). In an embodiment, R1is –C(=O)NH2. In an embodiment, R1is –C(=O)NHRa1(e.g., –C(=O)NHMe, –C(=O)NHEt, –C(=O)NHPr, –C(=O)NHiPr, –C(=O)NHBu, –C(=O)NHtBu, – C(=O)NHCyclopropyl, –C(=O)NHCyclobutyl). In an embodiment, R1is –C(=O)N(CH3)Ra1(e.g., –C(=O)NMe2, –C(=O)N(CH3)Et, –C(=O)N(CH3)Pr, –C(=O)N(CH3)iPr, – C(=O)N(CH3)Bu, –C(=O)N(CH3)tBu, –C(=O)N(CH3)Cyclopropyl, – C(=O)N(CH3)Cyclobutyl).

[0384] In an embodiment, R1is –OC(=O)N(Ra1)2wherein each Ra1is as defined in any of the embodiments described herein. In an embodiment, R1is –OC(=O)NHRa1(e.g., – OC(=O)NHMe, –OC(=O)NHEt, –OC(=O)NHPr, –OC(=O)NHiPr, –OC(=O)NHBu, – OC(=O)NHtBu, –OC(=O)NHCyclopropyl, –OC(=O)NHCyclobutyl). In an embodiment, R1is –OC(=O)N(CH3)Ra1(e.g., –OC(=O)NMe2, –OC(=O)N(CH3)Et, –OC(=O)N(CH3)Pr, – OC(=O)N(CH3)iPr, –OC(=O)N(CH3)Bu, –OC(=O)N(CH3)tBu, – OC(=O)N(CH3)Cyclopropyl, –OC(=O)N(CH3)Cyclobutyl).

[0385] In an embodiment, R1is -S(=O)Ra1wherein each Ra1is as defined in any of the embodiments described herein. In an embodiment, R1is –S(=O)alkyl (e.g., –S(=O)Me, – S(=O)Et, –S(=O)Pr, –S(=O)iPr). In an embodiment, R1is –S(=O)cycloalkyl (e.g., – S(=O)cyclopropyl, –S(=O)cyclobutyl, –S(=O)cyclopentyl, –S(=O)cyclohexyl).

[0386] In an embodiment, R1is -S(=O)2Ra1. In an embodiment, R1is –S(=O)2alkyl (e.g., – S(=O)2Me, –S(=O)2Et, –S(=O)2Pr, –S(=O)2iPr). In an embodiment, R1is –S(=O)2cycloalkyl (e.g., –S(=O)2cyclopropyl, –S(=O)2cyclobutyl, –S(=O)2cyclopentyl, –S(=O)2cyclohexyl). In an embodiment, R1is S(=O)2aryl (e.g., S(=O)2phenyl).

[0387] In an embodiment, R1is –SRa1wherein each Ra1is as defined in any of the embodiments described herein. In an embodiment, R1is –Salkyl (e.g., –SMe, –SEt, –SPr, – SiPr). In an embodiment, R1is –Scycloalkyl (e.g., –Scyclopropyl, –Scyclobutyl, – Scyclopentyl, –Scyclohexyl). In an embodiment, R1is –Saryl (e.g., Sphenyl).

[0388] In an embodiment, R1is -S(=O)(=NRa1)Ra1wherein each Ra1is as defined in any of the embodiments described herein. In an embodiment, R1is –S(=O)(=NH)Ra1(e.g., – S(=O)(=NH)Me, –S(=O)(=NH)Et, –S(=O)(=NH)Pr, –S(=O)(=NH)iPr, –S(=O)(=NH)Bu, – S(=O)(=NH)tBu, –S(=O)(=NH)Cyclopropyl, –S(=O)(=NH)Cyclobutyl). In an embodiment, R1is –S(=O)(=NCH3)Ra1(e.g., –S(=O)(=NCH3)Me, –S(=O)(=NCH3)Et, –S(=O)(=NCH3)Pr, –S(=O)(=NCH3)iPr, –S(=O)(=NCH3)Bu, –S(=O)(=NCH3)tBu, –S(=O)(=NCH3)Cyclopropyl, –S(=O)(=NCH3)Cyclobutyl).

[0389] In an embodiment, R1is –NRa1S(=O)2Ra1wherein each Ra1is as defined in any of the embodiments described herein. In an embodiment, R1is –NHS(=O)2alkyl (e.g., – NHS(=O)2Me, –NHS(=O)2Et, –NHS(=O)2Pr, –NHS(=O)2iPr). In an embodiment, R1is – NHS(=O)2cycloalkyl (e.g., –NHS(=O)2cyclopropyl, –NHS(=O)2cyclobutyl, – NHS(=O)2cyclopentyl, –NHS(=O)2cyclohexyl). In an embodiment, R1is – N(CH3)S(=O)2alkyl (e.g., –N(CH3)S(=O)2Me, –N(CH3)S(=O)2Et, –N(CH3)S(=O)2Pr, – N(CH3)S(=O)2iPr). In an embodiment, R1is –N(CH3)S(=O)2cycloalkyl (e.g., – N(CH3)S(=O)2cyclopropyl, –N(CH3)S(=O)2cyclobutyl, –N(CH3)S(=O)2cyclopentyl, – N(CH3)S(=O)2cyclohexyl).

[0390] In an embodiment, R1is -S(=O)2N(Ra1)2wherein each Ra1is as defined in any of the embodiments described herein (e.g., –S(=O)2NH2, –S(=O)2NHRa1, –S(=O)2N(CH3)Ra1). In an embodiment, R1is -S(=O)2NH2. In an embodiment, R1is -S(=O)2NHRa1(e.g., –S(=O)2NHMe, –S(=O)2NHEt, –S(=O)2NHPr, –S(=O)2NHiPr, –S(=O)2NHcyclopropyl, – S(=O)2NHcyclobutyl). In an embodiment, R1is -S(=O)2N(CH3)Ra1(e.g., –S(=O)2NMe2, – S(=O)2N(CH3)Et, –S(=O)2N(CH3)Pr, –S(=O)2N(CH3)iPr, –S(=O)2N(CH3)cyclopropyl, – S(=O)2N(CH3)cyclobutyl).

[0391] As generally defined herein, each Ra1is independently selected from the group consisting of H, –C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl and 3-7 membered heterocyclyl, wherein each hydrogen atom of each alkyl, cycloalkyl heterocyclyl can be replaced by deuterium; or two instances of Ra1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O.

[0392] In an embodiment, each Ra1is independently selected from H, –C1–C6alkyl (e.g., – Me, –Et, –Pr, –iPr, –nBu, –sec-Bu, –iso-Bu, –tBu), –heteroC1-C4alkyl, –C1–C6haloalkyl (e.g., –CF3, –CHF2, –CH2CF3, –CH(CH3)CF3) and C3–C9cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl). In an embodiment, each Ra1is selected from H, –C1– C6alkyl (e.g., –Me, –Et, –Pr, –iPr, –nBu, –sec-Bu, –iso-Bu, –tBu), –C1–C6haloalkyl (e.g., – CF3, –CHF2, –CH2CF3, –CH(CH3)CF3) and –C3–C9cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl).

[0393] In an embodiment, each Ra1is independently H.

[0394] In an embodiment, each Ra1is independently –C1–C6alkyl (e.g., –Me, –Et, –Pr, –iPr, –nBu, –tBu, –sec-Bu, –iso-Bu). In an embodiment, each Ra1is independently –Me. In an embodiment, each Ra1is independently –Et. In an embodiment, each Ra1is independently – Pr. In an embodiment, each Ra1is independently –iPr.

[0395] In an embodiment, each Ra1is independently –heteroC1-C4alkyl. In an embodiment, each Ra1is independently methoxymethyl (–CH2OCH3). In an embodiment, each Ra1is independently aminomethyl (e.g., –CH2NH2, –CH2NHCH3, –CH2N(CH3)2.

[0396] In an embodiment, each Ra1is independently –C1–C6haloalkyl (e.g., –CF3, –CHF2, – CF2CH3, –CH2CF3). In an embodiment, each Ra1is independently trifluoromethyl (–CF3). In other embodiments, each Ra1is independently difluoromethyl (–CHF2). In an embodiment, each Ra1is –CH(CH3)CF3. In an embodiment, each Ra1is –CH2CF3.

[0397] In an embodiment, each Ra1is independently –C3–C9cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl). In an embodiment, each Ra1is independently cyclopropyl. In an embodiment each Ra1is independently cyclobutyl. In an embodiment, each Ra1is independently cyclopentyl. In an embodiment, each Ra1is independently cyclohexyl.

[0398] In an embodiment, each Ra1is independently 3-10 membered heterocyclyl (e.g., oxetanyl, tetrahydropyranyl, tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl).

[0399] As generally defined herein, each R2is independently selected from the group consisting of –D, halo, –CN, –C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, –C6-C10aryl, –ORa2, – N(Ra2)2, –C(=O)Ra2, –C(=O)ORa2, –NRa2C(=O)Ra2, –NRa2C(=O)ORa2, –C(=O)N(Ra2)2, – OC(=O)N(Ra2)2, –S(=O)Ra2, –S(=O)2Ra2, –SRa2, –S(=O)(=NRa2)Ra2, –NRa2S(=O)2Ra2and – S(=O)2N(Ra2)2, wherein each alkyl, cycloalkyl, heterocyclyl and aryl of R2can be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, –OH– and –CH3, wherein each Ra2is as defined in any of the embodiments described herein.

[0400] In an embodiment each R2is independently selected from H, –D, halo, –CN, –C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, –C6-C10aryl, –ORa2and –N(Ra2)2, wherein each aryl, alkyl, cycloalkyl and heterocyclyl is substituted with 0, 1 or 2 substituents selected from –F, –Cl, – OH– and –CH3.

[0401] In an embodiment, each R2is independently selected from –C1–C6alkyl and ORa2.

[0402] In an embodiment, each R2is independently selected from –CH3, –OH, –OCH3, – OCD3and –OCHF2.

[0403] In an embodiment, each R2is independently selected from –OCH3, –OCD3, –OCH2F and –OCHF2.

[0404] In an embodiment, R2is H. In an embodiment R2is –D.

[0405] In an embodiment, R2is halo (e.g., fluoro, chloro, bromo, iodo). In an embodiment, R2is –Cl. In an embodiment, R2is –F. In an embodiment, R2is –Br. In an embodiment, R2is –I.

[0406] In an embodiment, R2is –CN.

[0407] In an embodiment, R2is –C1–C6alkyl (e.g., –Me, –Et, –Pr, –iPr, –nBu, –sec-Bu, –iso- Bu, –tBu, –C(CH3)CH2CH3,). In an embodiment, R2is –Me. In an embodiment, R2is –Et. In an embodiment R2is –Pr. In an embodiment, R2is –iPr. In an embodiment, R2is - C(CH3)CH2CH3.

[0408] In an embodiment, R2is –heteroC1-C4alkyl. In an embodiment, R2is methoxymethyl (–CH2OCH3). In an embodiment, R2is aminomethyl (e.g., –CH2NH2, –CH2NHCH3, – CH2NHCH2CH3, –CH2N(CH3)2). In an embodiment, R2is –CH2N(CH3)CH2CH3. In an embodiment, R2is –CH2N(CH3)CH2CF3.

[0409] In an embodiment, R2is –C1–C6haloalkyl (e.g., –CF3, –CHF2, –CF2CH3, –CH2CF3). In an embodiment, R2is trifluoromethyl (–CF3). In other embodiments, R2is difluoromethyl (–CHF2). In other embodiments, R2is –CH2CF3. In an embodiment, R2is –CF2CH3.

[0410] In an embodiment, R2is –C1–C6hydroxyalkyl (e.g., –CH2OH, –CH(OH)CH3, – C(OH)(CH3)2). In an embodiment, R2is hydroxymethyl (–CH2OH).

[0411] In an embodiment, R2is optionally substituted –C3–C10cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl). In an embodiment, R2is optionally substituted cyclopropyl (e.g., substituted with 0 or 1 instance of –CN). In an embodiment R2is cyclobutyl. In an embodiment, R2is cyclopentyl. In an embodiment, R2is cyclohexyl.

[0412] In an embodiment, R2is an optionally substituted 3-10 membered heterocyclyl (e.g., oxetanyl, tetrahydropyranyl, tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl, 6-oxa-1-azaspiro[3.3]heptanyl, 6-oxa-1- azaspiro[3.4]octanyl). In an embodiment, R2is oxetanyl. In an embodiment, R2is tetrahydropyranyl. In an embodiment, R2is tetrahydrofuranyl. In an embodiment, R2is azetidinyl. In an embodiment, the azetidinyl is optionally substituted (e.g., substituted with 0 or 1 instances of –F or –Me). In an embodiment, R2is pyrrolidinyl. In an embodiment, R2is piperidinyl. In an embodiment, R2is piperazinyl. In an embodiment, R2is morpholinyl. In an embodiment, R2is azepanyl. In an embodiment, R2is 6-oxa-1-azaspiro[3.3]heptanyl. In an embodiment, R2is 6-oxa-1-azaspiro[3.4]octanyl.

[0413] In an embodiment, R2is –C6-C10aryl (e.g., phenyl, naphthyl). In an embodiment, R2is optionally substituted phenyl (e.g., phenyl substituted with 0 or 1 instances of halo (e.g., – Cl, –F)). In an embodiment, R2is –2-Cl-phenyl.

[0414] In an embodiment, R2is –ORa2wherein each Ra2is as defined in any of the embodiments described herein (e.g., hydroxy (–OH), methoxy, –OCD3, difluoromethoxy (– OCHF2), trifluoromethoxy (–OCF3), –OCH(CH3)CF3, –OCH2CF3, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclobutyloxy, –OCH2CH(CH3)3). In an embodiment, R2is hydroxy. In an embodiment, each R2is independently selected from –OCH3, –OCD3, – OCH2F and –OCHF2. In an embodiment, each R2is independently selected from –OCH3, – OCD3and –OCHF2. In an embodiment, each R2is independently selected from –OCH3and – OCD3.

[0415] In an embodiment, R2is –OMe. In an embodiment, R2is –OCD3. In an embodiment, R2is ethoxy. In an embodiment, R2is propoxy. In an embodiment, R2is isopropoxy. In an embodiment R2is difluoromethoxy (–OCHF2). In an embodiment R2is fluoromethoxy (– OCH2F). In an embodiment, R2is trifluoromethoxy (–OCF3). In an embodiment, R2is –OCH(CH3)CF3. In an embodiment, R2is –OCH2CF3. In an embodiment, R2is cyclopropyloxy. In an embodiment R2is –OCH2CH(CH3)3.

[0416] In an embodiment, R2is –N(Ra2)2wherein each Ra2is as defined in any of the embodiments described herein (e.g., –NH2, –NHRa2, –N(CH3)Ra2). In an embodiment, R2is – NH2. In an embodiment, R2is –NHRa2(e.g., –NHMe, –NHEt, –NHPr, –NHiPr, – NHcyclopropyl, –NHcyclobutyl). In an embodiment, R2is –N(CH3)Ra2(e.g., –NMe2, – N(CH3)Et, –N(CH3)Pr, –N(CH3)iPr, –N(CH3)cyclopropyl, –N(CH3)cyclobutyl).

[0417] In an embodiment, R2is –C(=O)Ra2or –C(=O)ORa2wherein each Ra2is as defined in any of the embodiments described herein. In an embodiment, R2is –C(=O)Ra2wherein Ra2is as described herein. In an embodiment, R2is –C(=O)alkyl. In an embodiment, R2is – C(O)CH3, –C(O)cyclopropyl, –C(O)cyclobutyl, –C(O)tBu, –C(O)iPr, –C(O)Pr, –C(O)iBu, or –C(=O)OMe. In an embodiment, R2is acetyl (–C(=O)Me). In an embodiment, R2is – C(=O)ORa2. In an embodiment, R2is –COOH. In an embodiment, R2is COOMe.

[0418] In an embodiment, R2is –NRa2C(=O)Ra2wherein each Ra2is as defined in any of the embodiments described herein. In an embodiment, R2is –NHC(=O)Ra2(e.g., –NHC(=O)Me, –NHC(=O)Et, –NHC(=O)Pr, –NHC(=O)iPr, –NHC(=O)Bu, –NHC(=O)tBu, – NHC(=O)Cyclopropyl, –NHC(=O)Cyclobutyl). In an embodiment, R2is –N(CH3)C(=O)Ra2(e.g., –N(CH3)C(=O)Me, –N(CH3)C(=O)Et, –N(CH3)C(=O)Pr, –N(CH3)C(=O)iPr, – N(CH3)C(=O)Bu, –N(CH3)C(=O)tBu, –N(CH3)C(=O)Cyclopropyl, – N(CH3)C(=O)Cyclobutyl).

[0419] In an embodiment, R2is –NRa2C(=O)ORa2. In an embodiment, R2is –NHC(=O)ORa2(e.g., –NHC(=O)OMe, –NHC(=O)OEt, –NHC(=O)OPr, –NHC(=O)OiPr, –NHC(=O)OBu, – NHC(=O)OtBu, –NHC(=O)OCyclopropyl, –NHC(=O)OCyclobutyl). In an embodiment, R2is –N(CH3)C(=O)ORa2(e.g., –N(CH3)C(=O)OMe, –N(CH3)C(=O)OEt, –N(CH3)C(=O)OPr, –N(CH3)C(=O)OiPr, –N(CH3)C(=O)OBu, –N(CH3)C(=O)OtBu, – N(CH3)C(=O)OCyclopropyl, –N(CH3)C(=O)OCyclobutyl).

[0420] In an embodiment, R2is –C(=O)N(Ra2)2wherein each Ra2is as defined in any of the embodiments described herein (e.g., –C(=O)NH2, –C(=O)NHRa2, –C(=O)N(CH3)Ra2). In an embodiment, R2is –C(=O)NH2. In an embodiment, R2is –C(=O)NHRa2(e.g., –C(=O)NHMe, –C(=O)NHEt, –C(=O)NHPr, –C(=O)NHiPr, –C(=O)NHBu, –C(=O)NHtBu, – C(=O)NHCyclopropyl, –C(=O)NHCyclobutyl). In an embodiment, R2is –C(=O)N(CH3)Ra2(e.g., –C(=O)NMe2, –C(=O)N(CH3)Et, –C(=O)N(CH3)Pr, –C(=O)N(CH3)iPr, – C(=O)N(CH3)Bu, –C(=O)N(CH3)tBu, –C(=O)N(CH3)Cyclopropyl, – C(=O)N(CH3)Cyclobutyl).

[0421] In an embodiment, R2is –OC(=O)N(Ra2)wherein each Ra2is as defined in any of the embodiments described herein. In an embodiment, R2is –OC(=O)NHRa2(e.g., – OC(=O)NHMe, –OC(=O)NHEt, –OC(=O)NHPr, –OC(=O)NHiPr, –OC(=O)NHBu, – OC(=O)NHtBu, –OC(=O)NHCyclopropyl, –OC(=O)NHCyclobutyl). In an embodiment, R2is –OC(=O)N(CH3)Ra2(e.g., –OC(=O)NMe2, –OC(=O)N(CH3)Et, –OC(=O)N(CH3)Pr, – OC(=O)N(CH3)iPr, –OC(=O)N(CH3)Bu, –OC(=O)N(CH3)tBu, – OC(=O)N(CH3)Cyclopropyl, –OC(=O)N(CH3)Cyclobutyl).

[0422] In an embodiment, R2is -S(=O)Ra2wherein each Ra2is as defined in any of the embodiments described herein. In an embodiment, R2is –S(=O)alkyl (e.g., –S(=O)Me, – S(=O)Et, –S(=O)Pr, –S(=O)iPr). In an embodiment, R2is –S(=O)cycloalkyl (e.g., – S(=O)cyclopropyl, –S(=O)cyclobutyl, –S(=O)cyclopentyl, –S(=O)cyclohexyl).

[0423] In an embodiment, R2is -S(=O)2Ra2. In an embodiment, R2is –S(=O)2alkyl (e.g., – S(=O)2Me, –S(=O)2Et, –S(=O)2Pr, –S(=O)2iPr). In an embodiment, R2is –S(=O)2cycloalkyl (e.g., –S(=O)2cyclopropyl, –S(=O)2cyclobutyl, –S(=O)2cyclopentyl, –S(=O)2cyclohexyl). In an embodiment, R2is S(=O)2aryl (e.g., S(=O)2phenyl).

[0424] In an embodiment, R2is –SRa2wherein each Ra2is as defined in any of the embodiments described herein. In an embodiment, R2is –Salkyl (e.g., –SMe, –SEt, –SPr, – SiPr). In an embodiment, R2is –Scycloalkyl (e.g., –Scyclopropyl, –Scyclobutyl, – Scyclopentyl, –Scyclohexyl). In an embodiment, R2is –Saryl (e.g., Sphenyl).

[0425] In an embodiment, R2is -S(=O)(=NRa2)Ra2wherein each Ra2is as defined in any of the embodiments described herein. In an embodiment, R2is –S(=O)(=NH)Ra2(e.g., – S(=O)(=NH)Me, –S(=O)(=NH)Et, –S(=O)(=NH)Pr, –S(=O)(=NH)iPr, –S(=O)(=NH)Bu, – S(=O)(=NH)tBu, –S(=O)(=NH)Cyclopropyl, –S(=O)(=NH)Cyclobutyl). In an embodiment, R2is –S(=O)(=NCH3)Ra2(e.g., –S(=O)(=NCH3)Me, –S(=O)(=NCH3)Et, –S(=O)(=NCH3)Pr, –S(=O)(=NCH3)iPr, –S(=O)(=NCH3)Bu, –S(=O)(=NCH3)tBu, –S(=O)(=NCH3)Cyclopropyl, –S(=O)(=NCH3)Cyclobutyl).

[0426] In an embodiment, R2is –NRa2S(=O)2Ra2wherein each Ra2is as defined in any of the embodiments described herein. In an embodiment, R2is –NHS(=O)2alkyl (e.g., – NHS(=O)2Me, –NHS(=O)2Et, –NHS(=O)2Pr, –NHS(=O)2iPr). In an embodiment, R2is – NHS(=O)2cycloalkyl (e.g., –NHS(=O)2cyclopropyl, –NHS(=O)2cyclobutyl, – NHS(=O)2cyclopentyl, –NHS(=O)2cyclohexyl). In an embodiment, R2is – N(CH3)S(=O)2alkyl (e.g., –N(CH3)S(=O)2Me, –N(CH3)S(=O)2Et, –N(CH3)S(=O)2Pr, – N(CH3)S(=O)2iPr). In an embodiment, R2is –N(CH3)S(=O)2cycloalkyl (e.g., –N(CH3)S(=O)2cyclopropyl, –N(CH3)S(=O)2cyclobutyl, –N(CH3)S(=O)2cyclopentyl, – N(CH3)S(=O)2cyclohexyl).

[0427] In an embodiment, R2is -S(=O)2N(Ra2)2wherein each Ra2is as defined in any of the embodiments described herein (e.g., –S(=O)2NH2, –S(=O)2NHRa2, –S(=O)2N(CH3)Ra2). In an embodiment, R2is -S(=O)2NH2. In an embodiment, R2is -S(=O)2NHRa2(e.g., – S(=O)2NHMe, –S(=O)2NHEt, –S(=O)2NHPr, –S(=O)2NHiPr, –S(=O)2NHcyclopropyl, – S(=O)2NHcyclobutyl). In an embodiment, R2is -S(=O)2N(CH3)Ra2(e.g., –S(=O)2NMe2, – S(=O)2N(CH3)Et, –S(=O)2N(CH3)Pr, –S(=O)2N(CH3)iPr, –S(=O)2N(CH3)cyclopropyl, – S(=O)2N(CH3)cyclobutyl).

[0428] As generally defined herein, each Ra2is independently selected from the group consisting of H, –C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl and 3-7 membered heterocyclyl, wherein each hydrogen atom of each alkyl, cycloalkyl heterocyclyl can be replaced by deuterium; or two instances of Ra2on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O.

[0429] In an embodiment, each Ra2is independently selected from H, –C1–C6alkyl (e.g., – Me, –Et, –Pr, –iPr, –nBu, –sec-Bu, –iso-Bu, –tBu), –heteroC1-C4alkyl, –C1–C6haloalkyl (e.g., –CF3, –CHF2, –CH2CF3, –CH(CH3)CF3) and C3–C9cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl). In an embodiment, each Ra2is selected from H, –C1– C6alkyl (e.g., –Me, –Et, –Pr, –iPr, –nBu, –sec-Bu, –iso-Bu, –tBu), –C1–C6haloalkyl (e.g., – CF3, –CHF2, –CH2CF3, –CH(CH3)CF3) and –C3–C9cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl).

[0430] In an embodiment, each Ra2is independently selected from the group consisting of H, –C1-C6alkyl and –C1-C6haloalkyl wherein each hydrogen atom of the alkyl can be independently replaced with deuterium.

[0431] In an embodiment, each Ra2is independently selected from the group consisting of – C1-C6alkyl and –C1-C6haloalkyl wherein each hydrogen atom of the alkyl can be independently replaced with deuterium.

[0432] In an embodiment, each Ra2is independently selected from the group consisting of – CH3, –CD3,–Et, –CHF2and –CH2F.

[0433] In an embodiment, each Ra2is independently selected from the group consisting of – CH3, –CD3and –CHF2.

[0434] In an embodiment, each Ra2is independently selected from the group consisting of H, –CH3, –CD3.

[0435] In an embodiment, each Ra2is independently H.

[0436] In an embodiment, each Ra2is independently –C1–C6alkyl herein each hydrogen atom of the alkyl can be replaced by deuterium (e.g., –Me, –CD3, –Et, –Pr, –iPr, –nBu, –tBu, –sec- Bu, –iso-Bu). In an embodiment, each Ra2is independently selected from the group consisting of –CH3and –CD3. In an embodiment, each Ra2is independently –CH3. In an embodiment, each Ra2is independently –CD3. In an embodiment, each Ra2is independently – Et. In an embodiment, each Ra2is independently –Pr. In an embodiment, each Ra2is independently –iPr.

[0437] In an embodiment, each Ra2is independently –heteroC1-C4alkyl. In an embodiment, each Ra2is independently methoxymethyl (–CH2OCH3). In an embodiment, each Ra2is independently aminomethyl (e.g., –CH2NH2, –CH2NHCH3, –CH2N(CH3)2.

[0438] In an embodiment, each Ra2is independently –C1–C6haloalkyl (e.g., –CF3, –CHF2, – CF2CH3, –CH2CF3). In an embodiment, each Ra2is independently trifluoromethyl (–CF3). In other embodiments, each Ra2is independently difluoromethyl (–CHF2). In other embodiments, each Ra2is independently fluoromethyl (–CH2F). In an embodiment, each Ra2is –CH(CH3)CF3. In an embodiment, each Ra2is –CH2CF3.

[0439] In an embodiment, each Ra2is independently –C3–C9cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl). In an embodiment, each Ra2is independently cyclopropyl. In an embodiment each Ra2is independently cyclobutyl. In an embodiment, each Ra2is independently cyclopentyl. In an embodiment, each Ra2is independently cyclohexyl.

[0440] In an embodiment, each Ra2is independently 3-10 membered heterocyclyl (e.g., oxetanyl, tetrahydropyranyl, tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl).

[0441] In an embodiment, the compound is of Formula (I-b)Formula (I-b);wherein Ring A, Ring B, L, Rc, Rc’, Ra2, RA, RB, RC, RE, n and p are as defined in any of the embodiments described herein.

[0442] In an embodiment, the compound is of Formula (I-c)the embodiments described herein.

[0443] In an embodiment, the compound is of Formula (I-d)Formula (I-d); wherein L, Rc, Rc’, Ra2, RA, RC, RE, RB, n and p are as defined in any of the embodiments described herein.

[0444] In an embodiment, the compound is of Formula (I-d-1)Formula (I-d-1); wherein L, Rc, Rc’, Ra2, RC, RE, RB, and p are as defined in any of the embodiments described herein.

[0445] In an embodiment, the compound is of Formula (I-e)wherein X3, L, Rc, Rc’, Ra2, RA, RC, RB, REand n are as defined in any of the embodiments described herein.

[0446] In an embodiment, the compound is of Formula (I-f)Formula (I-f); wherein L, Rc, Rc’, Ra2, RA, RC, RB, REand n are as defined in any of the embodiments described herein.

[0447] In an embodiment, the compound is of Formula (I-f-1)Formula (I-f-1); wherein L, Rc, Rc’, Ra2, RC, RBand REare as defined in any of the embodiments described herein.

[0448] In an embodiment, the compound is selected from the compounds of Table 1.

[0449] In an embodiment, provided is a pharmaceutical composition comprising a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof as defined herein and a pharmaceutically acceptable carrier. In an embodiment, the pharmaceutical composition further comprises a second therapeutic agent.

[0450] In various embodiments, the Compounds of the Disclosure are USP1 inhibitors that reduce the level of USP1 protein and / or inhibit or reduce at least one biological activity of USP l protein.

[0451] In an embodiment, the Compounds of the Disclosure specifically bind to USP1 protein. In an embodiment, the Compounds of the Disclosure specifically bind to USP1 protein in a USP1-UAF1 complex. In an embodiment, the Compounds of the Disclosure specifically bind to USP1 mRNA. In an embodiment, the Compounds of the Disclosure specifically bind to USP1 protein (alone or in a USP1-UAF1 complex) or USP1 mRNA. In an embodiment, the Compounds of the Disclosure specifically bind to UAF1 (alone or in a USP1-UAF1 complex) and inhibit or reduces formation or activity of the USP1-UAF1 complex.

[0452] In an embodiment, the Compounds of the Disclosure decrease the formation of the USP1-UAF1 complex. In an embodiment, the Compounds of the Disclosure decrease the activity of the USP1-UAF1 complex. In an embodiment, the Compounds of the Disclosure decrease the deubiquitinase activity of USP1. In an embodiment, the Compounds of the Disclosure increase mono-ubiquitinated PCNA. In an embodiment, the Compounds of the Disclosure increase mono-ubiquitinated FANCD2. In an embodiment, the Compounds of the Disclosure increase mono- ubiquitinated FANCI.

[0453] In an embodiment, the Compounds of the Disclosure do not bind to other deubiquitinases, other USP proteins, or other UAF1 complexes (e.g., USP46-UAF1) or bind deubiquitinases, other USP proteins, or other UAF1 complexes (e.g., USP46-UAF1) with at least 5-fold, at least 10-fold, at least 20-fold, or at least 100-fold reduced affinity compared to the affinity for USP1 (i.e., the KDof the USP1 inhibitor for other deubiquitinases, other USP proteins, or other UAF1 complexes (e.g., USP46-UAF1) is at least 5 -fold, at least 10-fold, at least 20 fold, least 50 fold, at least 100 fold.

[0454] Certain compounds of the disclosure were assessed for USP1-UAF1 activity in a Ubiquitin Rhodamine assay as described in Biology Example 1.

[0455] Table 1 indicates IC50values (μM) against USP1-UAF1 for exemplary compounds (column 4). For column 4, “a” indicates an IC50value lower than 30 nM, “b” indicates an IC50value equal to or greater than 30 nM and lower than 100 nM, “c” indicates an IC50value equal to or greater than 100 nM but lower than 5 µM, and “d” indicates an IC50value equal to or greater than 5 µM in the assay described in Biology Example 1

[0456] Table 1 also indicates IC50values in a viability assay for a non-isogenic pair of BRCA1 mutant (column 5- MDA-MB-436) and BRCA1 WT (column 6 – HCC1954) celllines. These values indicate the effect of treatment with compound on cell survival. In columns 5 and 6, a value of “aa” and “aaa” indicates an IC50of less than 100 nM in the mutant and wild-type cell lines, respectively; a value of “bb” and ”bbb” indicates an IC50equal to or greater than 100 nM but less than 250 nM in the mutant and wild-type cell lines, respectively; a value of “cc” and “ccc” indicates an IC50equal to or greater than 250 nM but less than 5 µM in the mutant and wild-type cell lines, respectively; a value of “dd” and “ddd” indicates an IC50greater than or equal to 5 µM in the mutant and wild-type cell lines, respectively, in the assay described in Biology Example 2.

[0457] Table 1 also indicates IC50values for exemplary compounds in an AlphaLISA assay measuring monoubiquitinated PCNA in a BRCA1 mutant cell line (MDA-MB-436; column 7). In column 7, a value of “A” indicates an IC50of less than 100 nM, a value of “B” indicates an IC50equal to or greater than 100 nM but less than 250 nM, a value of “C” indicates an IC50equal to or greater than 250 nM but less than 5 µM, a value of “D” indicates an IC50greater than or equal to 5 µM, in the assay described in Biology Example 3.

[0458] Unless otherwise indicated, the absolute stereochemistry of all chiral atoms is as depicted. Compounds marked with (OR) or (rel) are single enantiomers wherein the absolute stereochemistry was arbitrarily assigned (e.g., based on chiral SFC elution as described in the Examples section). Compounds marked with (and) or (rac) are mixtures of enantiomers wherein the relative stereochemistry is as shown. Compounds marked with (abs) are single enantiomers wherein the absolute stereochemistry is as indicated. Table 1. Exemplary compounds and biological dataO N N N O N F N F 2 a aa ddd A NFO N N N O 17 a aa ddd AO N N N S N F 38 a aa ddd A N FAlternative Embodiments

[0459] In an alternative embodiment, compounds described herein may also comprise one or more isotopic substitutions. For example, hydrogen may be2H (D or deuterium) or3H (T or tritium); carbon may be, for example,13C or14C; oxygen may be, for example,18O; nitrogen may be, for example,15N, and the like. In other embodiments, a particular isotope (e.g.,3H,13C,14C,18O, or15N) can represent at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 99.9% of the total isotopic abundance of an element that occupies a specific site of the compound. Pharmaceutical Compositions

[0460] In an embodiment, provided is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound described herein (e.g., a compound of Formula (I), (II) or a compound of Table 1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0461] The term “pharmaceutically acceptable carrier or adjuvant” refers to a carrier or adjuvant that may be administered to a patient, together with a compound provided herewith, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.

[0462] Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions provided herewith include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d–α-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene polyoxypropylene block polymers, polyethylene glycol and wool fat. Cyclodextrins such as α–, β–, and γ- cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2 and 3 hydroxypropyl-β-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.

[0463] When employed as pharmaceuticals, the compounds provided herein are typically administered in the form of a pharmaceutical composition. Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.

[0464] In an embodiment, with respect to the pharmaceutical composition, the carrier is a parenteral carrier, oral or topical carrier.

[0465] In an embodiment, provided is a compound described herein (e.g., a compound of Formula (I), (II) or a compound of Table 1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof) (or pharmaceutical composition thereof) for use as a pharmaceutical or a medicament (e.g., a medicament for the treatment of a disease or disorder associated with USP1 in a subject in need thereof). In an embodiment, the disease is a proliferating disease. In a further embodiment, the disease is cancer. In an embodiment, the cancer is breast cancer (e.g., triple negative breast cancer), ovarian cancer (e.g., platinum-resistant ovarian cancer, platinum-refractory ovarian cancer), prostate cancer, pancreatic cancer or lung cancer (e.g., non-small cell lung cancer (NSCLC)).

[0466] In an embodiment, provided is a compound described herein (e.g., a compound of Formula (I), (II) or a compound of Table 1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof) (or pharmaceutical composition thereof) for use in the treatment of a disease or disorder associated with USP1 in a subject in need thereof. In an embodiment, the disease is a proliferating disease. In a further embodiment, the disease is cancer. In an embodiment, the cancer is breast cancer (e.g., triple negative breast cancer), ovarian cancer (e.g., platinum-resistant ovarian cancer, platinum-refractory ovarian cancer), prostate cancer, pancreatic cancer or lung cancer (e.g., non-small cell lung cancer (NSCLC)).

[0467] In an embodiment, provided is a compound described herein (e.g., a compound of Formula (I), (II) or a compound of Table 1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof) (or pharmaceutical composition thereof) for use in the manufacturing of a medicament (e.g., a medicament for the treatment of a disease or disorder associated with USP1 in a subject in need thereof). In an embodiment, the disease is a proliferating disease. In a further embodiment, the disease is cancer. In an embodiment, the cancer is breast cancer (e.g., triple negative breast cancer), ovarian cancer (e.g., platinum-resistant ovarian cancer, platinum-refractory ovarian cancer), prostate cancer, pancreatic cancer or lung cancer (e.g., non-small cell lung cancer (NSCLC)). Generally, the compounds provided herein are administered in a therapeutically effective amount. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient’s symptoms, and the like.

[0468] The pharmaceutical compositions provided herewith may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection. The pharmaceutical compositions provided herewith may contain any conventional nontoxic pharmaceutically acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.

[0469] The compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term “unit dosage forms” refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include prefilled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions. In such compositions, the compound is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.

[0470] Liquid forms suitable for oral administration may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like. Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0471] Injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art. As before, the active compound in such compositions is typically a minor component, often being from about 0.05 to 10% by weight with the remainder being the injectable carrier and the like. The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3–butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer’s solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono– or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are naturalpharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens or Spans and / or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

[0472] Transdermal compositions are typically formulated as a topical ointment or cream containing the active ingredient(s), generally in an amount ranging from about 0.01 to about 20% by weight, preferably from about 0.1 to about 20% by weight, preferably from about 0.1 to about 10% by weight, and more preferably from about 0.5 to about 15% by weight. When formulated as an ointment, the active ingredients will typically be combined with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with, for example, an oil-in-water cream base. Such transdermal formulations are well-known in the art and generally include additional ingredients to enhance the dermal penetration of stability of the active ingredients or the formulation. All such known transdermal formulations and ingredients are included within the scope provided herein.

[0473] The compounds provided herein can also be administered by a transdermal device. Accordingly, transdermal administration can be accomplished using a patch either of the reservoir or porous membrane type, or of a solid matrix variety.

[0474] The pharmaceutical compositions provided herewith may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound provided herewith with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.

[0475] The pharmaceutical compositions provided herewith may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and / or other solubilizing or dispersing agents known in the art.

[0476] The above-described components for orally administrable, injectable or topically administrable, rectally administrable and nasally administrable compositions are merely representative. Other materials as well as processing techniques and the like are set forth in Part 8 of Remington’s Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference.

[0477] The compounds disclosed herein can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can be found in Remington’s Pharmaceutical Sciences.

[0478] When the compositions provided herewith comprise a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds provided herewith. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds provided herewith in a single composition.

[0479] Also provided are pharmaceutically acceptable acid addition salt of a compound described herein (e.g., compound of Formula (I), (II) or a compound of Table 1).

[0480] The acid which may be used to prepare the pharmaceutically acceptable salt is that which forms a non-toxic acid addition salt, i.e., a salt containing pharmacologically acceptable anions such as the hydrochloride, hydroiodide, hydrobromide, nitrate, sulfate, bisulfate, phosphate, acetate, lactate, citrate, tartrate, succinate, maleate, fumarate, benzoate, para-toluenesulfonate, and the like.

[0481] The compounds described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.5 to about 100 mg / kg of body weight, alternatively dosages between 1 mg and 1000 mg / dose, every 4 to 120 hours, or according to the requirements of the particular drug. The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions provided herewith will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage formwill vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w / w). Alternatively, such preparations contain from about 20% to about 80% active compound.

[0482] Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient’s disposition to the disease, condition or symptoms, and the judgment of the treating physician.

[0483] Upon improvement of a patient’s condition, a maintenance dose of a compound, composition or combination provided herewith may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Patients may, however, require intermittent treatment on a long term basis upon any recurrence of disease symptoms. Methods of Treatment and Use

[0484] In an embodiment, the compounds described herein can be used to inhibit the activity of a USP1 protein. For example, in an embodiment, a method of inhibiting a USP1 protein comprises contacting the USP1 protein with a compound disclosed herein. The contacting can occur in vitro or in vivo.

[0485] In an embodiment, the compounds described herein can be used to treat a "USP1 protein mediated” disorder (e.g., a USP1 protein mediated cancer), a “USP1 associated” disorder (e.g., a USP1 associated cancer), or a disorder “associated with USP1” (e.g., a cancer associated with USP1). A “USP1 protein mediated”, “USP1 associated” disorder or a disorder “associated with USP1”, is any pathological condition in which a USP1 protein is known to play a role, including any cancers that require USP1 for cell proliferation and survival. In an embodiment, “USP1 protein mediated”, “USP1 associated” disorder or a disorder “associated with USP1” is a proliferative disease such as cancer. The method comprises administering to a patient in need of a treatment for a USP1 protein mediated disorder an effective amount of a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate,solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceutically acceptable excipient.

[0486] In an embodiment, provided is a method of treating a disease or disorder associated with modulation of USP1. The method comprises administering to a patient in need of a treatment for diseases or disorders associated with modulation of ubiquitin specific protease 1 (USP1) an effective amount of a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceutically acceptable excipient. In an embodiment the disease or disorder is cancer. In an embodiment, the compound or composition is administered in combination with a second therapeutic agent.

[0487] In an embodiment, provided is a method of treating or preventing cancer. The method comprises administering to a patient in need of a treatment for cancer an effective amount of a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof or a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof and a pharmaceutically acceptable excipient.

[0488] In an embodiment, provided is a method of treating cancer. The method comprises administering to a patient in need thereof of a treatment for cancer an effective amount of a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof or a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof and a pharmaceutically acceptable excipient.

[0489] In an embodiment, provided is a method of treating or preventing a disease or disorder associated with DNA damage. The method comprises administering to a patient in need of a treatment for diseases or disorders associated with DNA damage an effective amount of a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof or a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate,prodrug, tautomer or stereoisomer thereof and a pharmaceutically acceptable excipient. In an embodiment the disease is cancer.

[0490] In an embodiment, provided is a method of treating a disease or disorder associated with DNA damage. The method comprises administering to a patient in need of a treatment for diseases or disorders associated with DNA damage an effective amount of a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof or a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof and a pharmaceutically acceptable excipient.

[0491] In an embodiment, provided is a method of inhibiting, modulating or reducing DNA repair activity exercised by USP1. The method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof or a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof and a pharmaceutically acceptable excipient.

[0492] In an embodiment, provided is (a) a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or (b) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof and a pharmaceutically acceptable excipient, for use as a medicament.

[0493] In an embodiment, provided is (a) a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or (b) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof and a pharmaceutically acceptable excipient for use in the treatment or prevention of a disease sensitive to the inhibition of USP1. In an embodiment the disease is cancer.

[0494] In an embodiment, provided is (a) a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof, or (b) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptablesalt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof and a pharmaceutically acceptable excipient for use in the treatment of a disease or disorder sensitive to the inhibition of USP1.

[0495] In an embodiment, provided is (a) a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof, or (b) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof and a pharmaceutically acceptable excipient for use in the treatment or prevention of cancer.

[0496] In an embodiment, provided is (a) a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof, or (b) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer or stereoisomer thereof and a pharmaceutically acceptable excipient for use in the treatment of cancer.

[0497] In an embodiment, provided is (a) a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or (b) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceutically acceptable excipient for use in the treatment or prevention of a disease or disorder associated with DNA damage. In an embodiment the disease or disorder is cancer.

[0498] In an embodiment, provided is (a) a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or (b) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceutically acceptable excipient for use in the treatment of a disease or disorder associated with DNA damage. In an embodiment the disease or disorder is cancer.

[0499] In an embodiment, provided is (a) a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or (b) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceuticallyacceptable excipient for use in a method of inhibiting or reducing DNA repair activity modulated by USP1.

[0500] In an embodiment, provided is a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutical composition comprising a compound of Formula (I), (II) or a compound of Table 1 and a pharmaceutically acceptable carrier used for the treatment of cancers.

[0501] In an embodiment, provided is the use of (a) a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or (b) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceutically acceptable excipient in the manufacture of a medicament for treating or preventing a disease sensitive to the inhibition of USP1. In an embodiment the disease or disorder is cancer.

[0502] In an embodiment, provided is the use of (a) a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or (b) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceutically acceptable excipient in the manufacture of a medicament for treating or preventing cancer.

[0503] In an embodiment, provided is the use of (a) a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or (b) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceutically acceptable excipient in the manufacture of a medicament for treating or preventing a disease or disorder associated with DNA damage. In an embodiment, the disease or disorder is cancer.

[0504] In an embodiment, provided is the use of (a) a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or (b) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereofand a pharmaceutically acceptable excipient in the manufacture of a medicament for treating a disease or disorder associated with DNA damage. In an embodiment, the disease or disorder is cancer.

[0505] In an embodiment, provided is the use of (a) a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or (b) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceutically acceptable excipient in the manufacture of a medicament for inhibiting or reducing DNA repair activity modulated by USP1.

[0506] In an embodiment, provided is a pharmaceutical composition comprising a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceutically acceptable carrier. The pharmaceutical acceptable carrier may further include an excipient, diluent, or surfactant.

[0507] In an embodiment, provided are methods of treating a disease or disorder associated with modulation of USP1 including, but not limited to, cancer comprising, administering to a patient suffering from at least one of said diseases or disorder (a) an effective amount (e.g., a therapeutically effective amount) of a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or (b) a pharmaceutical composition comprising an effective amount (e.g., a therapeutically effective amount) of a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceutically acceptable excipient; and one or more additional anti-cancer agent(s).

[0508] In an embodiment, the compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof) and the other anti-cancer agent(s) is generally administered sequentially in any order by infusion or orally. The dosing regimen may vary depending upon the stage of the disease, physical fitness of the patient, safety profiles of the individual drugs, and tolerance of the individual drugs, as well as other criteria well-known to the attending physician and medical practitioner(s) administering the combination. The compound disclosed herein and other anti-cancer agent(s) may be administered within minutes of each other, hours, days, or even weeks apart depending upon the particular cycle being used for treatment. In addition, the cycle could include administration of one drug moreoften than the other during the treatment cycle and at different doses per administration of the drug.

[0509] In an embodiment, provided are kits that include one or more of the compounds disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof) and a second therapeutic agent as disclosed herein are provided. Representative kits include (a) a compound disclosed herein or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof), (b) at least one other therapeutic agent, e.g., as indicated above, whereby such kit may comprise a package insert or other labeling including directions for administration.

[0510] In an embodiment of the methods and uses described herein, the cancer is selected from adrenocortical carcinoma, AIDS-related lymphoma, AIDS-related malignancies, anal cancer, cerebellar astrocytoma, extrahepatic bile duct cancer, bladder cancer, osteosarcoma / malignant fibrous histiocytoma, brain stem glioma, ependymoma, visual pathway and hypothalamic gliomas, breast cancer, bronchial adenomas / carcinoids, carcinoid tumors, gastrointestinal carcinoid tumors, carcinoma, adrenocortical, islet cell carcinoma, primary central nervous system lymphoma, cerebellar astrocytoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, clear cell sarcoma of tendon sheaths, colon cancer, colorectal cancer, cutaneous t-cell lymphoma, endometrial cancer, ependymoma, esophageal cancer, Ewing’s sarcoma / family of tumors, extracranial germ cell tumors, extragonadal germ cell tumors, extrahepatic bile duct cancer, eye cancers, including intraocular melanoma, and retinoblastoma, gallbladder cancer, gastrointestinal carcinoid tumor, ovarian germ cell tumor, gestational trophoblastic tumor, hairy cell leukemia, head and neck cancer, Hodgkin’s disease, hypopharyngeal cancer, Kaposi’s sarcoma, laryngeal cancer, acute lymphoblastic leukemia, acute myeloid leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, non-Hodgkin’s lymphoma, Waldenstrom’s macroglobulinemia, malignant mesothelioma, malignant thymoma, medulloblastoma, melanoma, Merkel cell carcinoma, metastatic squamous neck cancer with occult primary, multiple endocrine neoplasia syndrome, multiple myeloma / plasma cell neoplasm, mycosis fungoides, myelodysplastic syndrome, chronic myelogenous leukemia, myeloid leukemia, multiple myeloma, myeloproliferative disorders, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cancer, oral cavity and lip cancer, oropharyngealcancer, osteosarcoma / malignant fibrous histiocytoma of bone, ovarian cancer, ovarian low malignant potential tumor, pancreatic cancer, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pheochromocytoma, pituitary tumor, pleuropulmonary blastoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, transitional cell cancer (e.g., renal pelvis and ureter), retinoblastoma, rhabdomyosarcoma, salivary gland cancer, malignant fibrous histiocytoma of bone, soft tissue sarcoma, Sezary syndrome, skin cancer, small intestine cancer, stomach (gastric) cancer, supratentorial primitive neuroectodennal and pineal tumors, cutaneous t-cell lymphoma, testicular cancer, malignant thymoma, thyroid cancer, gestational trophoblastic tumor, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and Wilms’ tumor. In other embodiments, the cancer is a non-small cell lung cancer.

[0511] In any of the embodiments, the cancer can be any cancer in any organ, for example, a cancer is selected from the group consisting of glioma, thyroid carcinoma, breast carcinoma, small-cell lung carcinoma, non-small-cell carcinoma, gastric carcinoma, colon carcinoma, gastrointestinal stromal carcinoma, pancreatic carcinoma, bile duct carcinoma, CNS carcinoma, ovarian carcinoma, endometrial carcinoma, prostate carcinoma, renal carcinoma, anaplastic large-cell lymphoma, leukemia, multiple myeloma, mesothelioma, and melanoma, and combinations thereof.

[0512] In an embodiment, the cancer to be treated with a compound disclosed herein is selected from the group consisting of bone cancer, including osteosarcoma and chondrosarcoma; brain cancer, including glioma, glioblastoma, astrocytoma, medulloblastoma, and meningioma; soft tissue cancer, including rhabdoid and sarcoma; kidney cancer; bladder cancer; skin cancer, including melanoma; and lung cancer, including non-small cell lung cancer; colon cancer, uterine cancer; nervous system cancer; head and neck cancer; pancreatic cancer; and cervical cancer.

[0513] In other embodiments, the cancer is selected from liposarcoma, neuroblastoma, glioblastoma, bladder cancer, adrenocortical cancer, multiple myeloma, colorectal cancer, non- small cell lung cancer, Human Papilloma Virus-associated cervical, oropharyngeal, penis, anal, thyroid or vaginal cancer or Epstein-Barr Virus-associated nasopharyngeal carcinoma, gastric cancer, rectal cancer, thyroid cancer, Hodgkin lymphoma and diffuse large B-cell lymphoma.

[0514] In an embodiment, the cancer is selected from breast cancer (e.g., triple negative breast cancer (TNBC)), ovarian cancer (e.g., platinum-resistant ovarian cancer, platinum- refractory ovarian cancer), prostate cancer, pancreatic cancer and lung cancer (e.g., non-smallcell lung cancer (NSCLC)). In an embodiment, the cancer is selected from breast cancer (e.g., triple negative breast cancer (TNBC)), ovarian cancer (e.g., platinum-resistant ovarian cancer, platinum-refractory ovarian cancer), prostate cancer and lung cancer (e.g., non-small cell lung cancer (NSCLC)). In an embodiment, the cancer is breast cancer. In an embodiment the cancer is triple negative breast cancer (TNBC). In an embodiment the cancer is prostate cancer. In an embodiment the cancer is lung cancer. In an embodiment the cancer is non- small cell lung cancer (NSCLC).

[0515] In an embodiment of the methods described herein, the cancer is a dedifferentiated ID-driven cancer. In other embodiments, the cancer is a cancer that is sensitive to USP1 inhibition. In yet other embodiments, the cancer is a cancer that is sensitive to USP1 inhibition due to DNA damage pathway deficiency.

[0516] In an embodiment of the methods and uses described herein, the cancer is selected from the group consisting of a hematological cancer, a lymphatic cancer, and a DNA damage repair pathway deficient cancer.

[0517] In an embodiment, a compound disclosed herein is used to treat a cancer, wherein the cancer is a homologous recombination deficient cancer. In an embodiment, a compound disclosed herein is used to treat a cancer that does not have a defect in the homologous recombination pathway.

[0518] In an embodiment, the cancer is a DNA damage repair pathway deficient cancer. In an embodiment, the DNA damage repair pathway deficient cancer is selected from the group consisting of lung cancer, non-small cell lung cancer (NSCLC), colon cancer, bladder cancer, osteosarcoma, ovarian cancer (e.g., platinum-resistant ovarian cancer, platinum-refractory ovarian cancer), and breast cancer (e.g., triple negative breast cancer (TNBC). In an embodiment, the cancer is non-small cell lung cancer (NSCLC). In an embodiment, the cancer is colon cancer. In an embodiment, the cancer is bladder cancer. In an embodiment, the cancer is ovarian cancer or breast cancer. In an embodiment, the cancer is ovarian cancer. In an embodiment, the cancer is platinum-resistant ovarian cancer. In some embodiments, the cancer is platinum-refractory ovarian cancer. In an embodiment, the cancer is breast cancer. In an embodiment, the cancer is triple negative breast cancer.

[0519] In an embodiment, the cancer is a HRR (homologous recombination repair) gene mutant cancer. In an embodiment, the cancer is a HRR (homologous recombination repair) gene mutant cancer selected from the group consisting of ATM, NBN, FANCA, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutant cancer. In an embodiment, the cancer isan ATM mutant cancer. In an embodiment, the cancer is an NBN mutant cancer. In an embodiment, the cancer is a FANCA mutant cancer. In an embodiment, the cancer is an BARD1 mutant cancer. In an embodiment, the cancer is an BRCA1 mutant cancer. In an embodiment, the cancer is an BRCA2 mutant cancer. In an embodiment, the cancer is an BRIP1 mutant cancer. In an embodiment, the cancer is an CDK12 mutant cancer. In an embodiment, the cancer is an CHEK1 mutant cancer. In an embodiment, the cancer is an CHEK2 mutant cancer. In an embodiment, the cancer is an FANCL mutant cancer. In an embodiment, the cancer is an PALB2 mutant cancer. In an embodiment, the cancer is an PPP2R2A mutant cancer. In an embodiment, the cancer is an RAD51B mutant cancer. In an embodiment, the cancer is an RAD51C mutant cancer. In an embodiment, the cancer is an RAD51D mutant cancer. In an embodiment, the cancer is an RAD54L mutant cancer.

[0520] In an embodiment, the cancer is a BRCA1 mutant cancer. In an embodiment, the BRCA1 mutation is a germline mutation. In an embodiment, the BRCA1 mutation is a somatic mutation. In an embodiment, the BRCA1 mutation leads to BRCA1 deficiency. In an embodiment, the cancer is a BRCA2 mutant cancer. In an embodiment, the BRCA2 mutation is a germline mutation. In an embodiment, the BRCA2 mutation is a somatic mutation. In an embodiment, the BRCA2 mutation leads to BRCA2 deficiency. In an embodiment, the cancer is a BRCA1 mutant cancer and a BRCA2 mutant cancer. In an embodiment, the cancer is a BRCA1 deficient cancer. In an embodiment, the cancer is a BRCA2 deficient cancer. In an embodiment, the cancer is a BRCA1 deficient cancer and a BRCA2 deficient cancer. In an embodiment, the cancer is not a BRCA1 mutant cancer or a BRCA2 mutant cancer. In an embodiment, the cancer is a BRCA1 deficient cancer and a BRCA2 mutant cancer. In an embodiment, the BRCA1 or BRCA2 mutant or BRCA1 or BRCA2 deficient cancer is selected from non-small cell lung cancer (NSCLC), osteosarcoma, prostate cancer, pancreatic cancer, ovarian cancer, and breast cancer. In an embodiment, the BRCA1 mutant, BRCA2 mutant, BRCA1 deficient or BRCA 2 deficient cancer as described herein is ovarian cancer, breast cancer, prostate cancer or pancreatic cancer. In an embodiment, the cancer is ovarian cancer. In an embodiment, the cancer is platinum-resistant ovarian cancer. In some embodiments, the cancer is platinum-refractory ovarian cancer. In an embodiment, the cancer is breast cancer. In an embodiment, the cancer is a triple negative breast cancer. In an embodiment, the cancer is prostate cancer. In an embodiment, the cancer is homologous recombination deficient. Homologous recombination deficiency can be measured by BRCA1 / 2 mutation, or genomic instability (positive homologous recombination deficiency (HRD) score) without BRCA1 / 2 mutations.

[0521] In an embodiment, the cancer is a Poly (ADP-ribose) polymerase ("PARP") inhibitor refractory or resistant cancer. In an embodiment, the cancer is a PARP inhibitor resistant or refractory BRCA1, BRCA2, or BRCA1 and BRCA2 mutant cancer. In an embodiment, the cancer is a PARP inhibitor resistant or refractory BRCA1, BRCA2, or BRCA1 and BRCA2- deficient cancer. In an embodiment, the PARP inhibitor refractory or resistant cancer is selected from the cancers described herein. In an embodiment, the PARP inhibitor refractory or resistant cancer is selected from breast cancer (e.g., triple negative breast cancer (TNBC), ovarian cancer (e.g., platinum-resistant ovarian cancer, platinum-refractory ovarian cancer), pancreatic cancer and prostate cancer).

[0522] In an embodiment, the cancer has a mutation in the gene encoding ataxia telangiectasia mutated (ATM) protein kinase or loss of ATM protein expression. In an embodiment, the cancer to be treated with a compound disclosed herein is a cancer (e.g., a cancer selected from the cancers described herein) that comprises cancer cells with a loss of function mutation in a gene encoding ATM. In an embodiment the ATM mutation is a germline mutation. In an embodiment the ATM mutation is a somatic mutation. In an embodiment, the cancer is not an ATM mutant cancer. In an embodiment the cancer is an ATM-deficient cancer. In an embodiment, the ATM-deficient cancer is selected from breast cancer (e.g., triple negative breast cancer (TNBC)), ovarian cancer (e.g., platinum-resistant ovarian cancer, platinum-refractory ovarian cancer), colorectal cancer, stomach cancer, endometrial cancer, urothelial cancer, cervical cancer, melanoma, esophageal cancer, head and neck cancer, mantle cell lymphoma, sarcoma, prostate cancer, pancreatic cancer, and lung cancer (e.g., non-small cell lung cancer (NSCLC)).

[0523] In an embodiment, the cancer comprises cancer cells with elevated levels of translesion synthesis. This includes cancers that exhibit elevated PCNA monoubiquitination, with or without elevated levels of RAD18 and / or UBE2K and / or PCNA. In an embodiment, the elevated levels of RAD18 and / or UBE2K and / or PCNA are elevated RAD18 and / or UBE2K and / or PCNA protein levels. In an embodiment, the elevated levels of RAD18 and / or UBE2K and / or PCNA are elevated RAD18 and / or UBE2K and / or PCNA mRNA levels. In an embodiment, elevated levels of RAD18 and / or UBE2K and / or PCNA (e.g., RAD18 and / or UBE2K and / or PCNA protein and / or RAD18 and / or UBE2K and / or PCNA mRNA) have been detected (e.g., in a cancer sample obtained from the subject) prior to the administration. Elevated translesion synthesis can also be measured by PCNA monoubiquitination without elevated RAD18 and / or UBE2K and / or PCNA levels. In an embodiment, a subject’s cancer has been tested for RAD18 and / or UBE2K and / or PCNA levels protein or mRNA, or PCNAmonoubiquitination prior to beginning treatment with a USP1 inhibitor. In an embodiment, the cancer is a breast cancer (e.g., triple negative breast cancer), an ovarian cancer, a lung cancer (e.g., non-small cell lung cancer (NSCLC)), or a prostate cancer.

[0524] In an embodiment, the cancer is a BRCA1 and / or BRCA2 mutant cancer, wherein the cancer comprises cells with increased translesion synthesis, as exemplified by elevated PCNA monoubiquitination with or without elevated RAD18 and / or UBE2K and / or PCNA levels. In an embodiment, the cancer is a breast cancer (e.g., triple negative breast cancer), an ovarian cancer or a prostate cancer that is a BRCA1 and / or BRCA2 mutant cancer.

[0525] In an embodiment, the cancer is selected from the group consisting of bone cancer, including osteosarcoma and chondrosarcoma; brain cancer, including glioma, glioblastoma, astrocytoma, medulloblastoma, and meningioma; soft tissue cancer, including rhabdoid and sarcoma; kidney cancer; bladder cancer; skin cancer, including melanoma; and lung cancer, including non-small cell lung cancer; colon cancer, uterine cancer; nervous system cancer; head and neck cancer; pancreatic cancer; and cervical cancer. Combination therapies

[0526] In an embodiment, the compounds of the disclosure are administered in therapeutically effective amounts in a combination therapy with one or more therapeutic agents (pharmaceutical combinations) or modalities, e.g. non-drug therapies. For example, synergistic effects can occur with other anti-proliferative, anti-cancer, immunomodulatory or anti-inflammatory substances. Where the compounds of the disclosure are administered in conjunction with other therapies, dosages of the co-administered compounds will vary depending on the type of co-drug employed, on the specific drug employed, on the condition being treated and so forth.

[0527] In an embodiment, provided are methods of treatment of a disease or disorder associated with the USP1 with a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof) in combination with a second therapeutic agent. In an embodiment, provided are methods of treatment of a disease or disorder associated with USP1 with a compound of Formula (I), (II) or a compound of Table 1 or pharmaceutically acceptable salts thereof in combination with a second therapeutic agent and a third therapeutic agent. In an embodiment, provided are methods of treatment of a disease or disorder associated with the USP1 with a compound of Formula (I), (II) or a compound of Table 1, or pharmaceutically acceptable salts thereof) incombination with a second therapeutic agent, a third therapeutic agent, and a fourth therapeutic agent.

[0528] The term “Combination” refers to either a fixed combination in one dosage unit form, or a combined administration where a compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof) and a combination partner (e.g., another drug as explained below, also referred to as “therapeutic agent” or “co-agent”) may be administered independently at the same time or separately within time intervals, especially where these time intervals allow that the combination partners show a cooperative, e.g., synergistic effect. The single components may be packaged in a kit or separately. One or both of the components (e.g., powders or liquids) may be reconstituted or diluted to a desired dose prior to administration. The terms “co-administration” or “combined administration” or the like as utilized herein are meant to encompass administration of the selected combination partner to a single subject in need thereof (e.g., a patient), and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time. The term “pharmaceutical combination” as used herein means a product that results from the mixing or combining of more than one therapeutic agent and includes both fixed and non–fixed combinations of the therapeutic agents. The term “fixed combination” means that the therapeutic agents, e.g., a compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof) and a combination partner, are both administered to a patient simultaneously in the form of a single entity or dosage. The term “non-fixed combination” means that the therapeutic agents, e.g., a compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof) and a combination partner, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient. The latter also applies to cocktail therapy, e.g., the administration of three or more therapeutic agent.

[0529] The term "combination therapy" refers to the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of activeingredients. Alternatively, such administration encompasses co-administration in multiple, or in separate containers (e.g., tablets, capsules, powders, and liquids) for each active ingredient. Powders and / or liquids may be reconstituted or diluted to a desired dose prior to administration. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner, either at approximately the same time or at different times.

[0530] In an embodiment, compounds disclosed herein are combined with other therapeutic agents, including, but not limited to, other anti-cancer agents, anti-allergic agents, anti-nausea agents (or anti-emetics), pain relievers, cytoprotective agents, and combinations thereof.

[0531] In an embodiment, provided is a method of treating a disease or disorder associated with USP1 (e.g., cancer) comprising administering or coadministering, in any order, to a patient in need thereof a compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or pharmaceutically acceptable salts thereof) and a general chemotherapeutic agent selected from anastrozole (Arimidex®), bicalutamide (Casodex®), bleomycin sulfate (Blenoxane®), busulfan (Myleran®), busulfan injection (Busulfex®), capecitabine (Xeloda®), N4-pentoxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin (Paraplatin®), carmustine (BiCNU®), chlorambucil (Leukeran®), cisplatin (Platinol®), cladribine (Leustatin®), cyclophosphamide (Cytoxan® or Neosar®), cytarabine, cytosine arabinoside (Cytosar-U®), cytarabine liposome injection (DepoCyt®), dacarbazine (DTIC- Dome®), dactinomycin (Actinomycin D, Cosmegan), daunorubicin hydrochloride (Cerubidine®), daunorubicin citrate liposome injection (DaunoXome®), dexamethasone, docetaxel (Taxotere®), doxorubicin hydrochloride (Adriamycin®, Rubex®), etoposide (Vepesid®), fludarabine phosphate (Fludara®), 5-fluorouracil (Adrucil®, Efudex®), flutamide (Eulexin®), tezacitibine, Gemcitabine (difluorodeoxycitidine), hydroxyurea (Hydrea®), Idarubicin (Idamycin®), ifosfamide (IFEX®), irinotecan (Camptosar®), L- asparaginase (ELSPAR®), leucovorin calcium, melphalan (Alkeran®), 6-mercaptopurine (Purinethol®), methotrexate (Folex®), mitoxantrone (Novantrone®), mylotarg, paclitaxel (Taxol®), nab–paclitaxel (Abraxane®), phoenix (Yttrium90 / MX-DTPA), pentostatin, polifeprosan 20 with carmustine implant (Gliadel®), tamoxifen citrate (Nolvadex®), teniposide (Vumon®), 6–thioguanine, thiotepa, tirapazamine (Tirazone®), topotecan hydrochloride for injection (Hycamptin®), vinblastine (Velban®), vincristine (Oncovin®), and vinorelbine (Navelbine®).

[0532] In an embodiment, provided is a method of treating a disease or disorder associated with USP1 (e.g., cancer) comprising administering or coadministering, in any order, to apatient in need thereof a compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or pharmaceutically acceptable salts thereof) and an EGFR- inhibitor(e.g., cetuximab, panitumimab, erlotinib, gefitinib and EGFRi NOS). In an embodiment, provided is a method of treating a disease or disorder associated with USP1 (e.g., cancer) comprising administering or coadministering, in any order, to a patient in need thereof a compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or pharmaceutically acceptable salts thereof) and a MAPK-pathway inhibitor (e.g., BRAFi, panRAFi, MEKi, ERKi) In an embodiment, provided is a method of treating a disease or disorder associated with USP1 (e.g., cancer) comprising administering or coadministering, in any order, to a patient in need thereof a compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or pharmaceutically acceptable salts thereof) and a PI3K-mTOR pathway inhibitor (e.g., alpha-specific PI3Ki, pan-class I PI3Ki and mTOR / PI3Ki, particularly everolimus and analogues thereof).

[0533] In an embodiment, provided is a method of enhancing the chemotherapeutic treatment of cancer in a mammal undergoing treatment with an anti-cancer agent, which method comprises co-administering to the mammal an effective amount of a compound disclosed herein. In an embodiment, provided is a method of treating a disease or disorder associated with USP1 (e.g., cancer) comprising administering or coadministering, in any order, to a patient in need thereof a compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or pharmaceutically acceptable salts thereof) and a DNA damaging agent (e.g., actinomycin, amsacrine, anthracyclines, bleomycin, busulfan, camptothecin, carboplatin, chlorambucil, cisplatin, cyclophosphamide, Cytoxan, dactinomycin, daunorubicin, doxorubicin, epirubicin, hexamethylmelamineoxaliplatin, iphosphamide, melphalan, merchlorehtamine, mitomycin, mitoxantrone, nitrosourea, plicamycin, procarbazine, taxol, taxotere, tenyposide, triethylenethiophosphoramide and etoposide). In a preferred embodiment, the DNA damaging agent is cisplatin. In an embodiment, the DNA damaging agent is radiation or a biotherapeutic agent (e.g., an antibody).

[0534] In an embodiment, the anti-cancer agent is selected from reversible DNA binders (e.g., topotecan hydrochloride, irinotecan (CPT11 – Camptosar), rubitecan, exatecan, nalidixic acid, TAS-103, etoposide, acridines (e.g., amsacrine, aminocrine), actinomycins (e.g., actinomycin D), anthracyclines (e.g., doxorubicin, daunorubicin), benzophenainse, XR 11576 / MLN 576, benzopyridoindoles, Mitoxantrone, AQ4, Etoposide, Teniposide, epipodophyllotoxins, and bisintercalating agents such as triostin A and echinomycin), DNA alkylators (e.g., sulfur mustard, the nitrogen mustards (e.g., mechlorethamine), chlorambucil,melphalan, ethyleneimines (e.g., triethylenemelamine, carboquone, diaziquone), methyl methanesulfonate, busulfan, CC-1065, duocarmycins (e.g., duocarmycin A, duocarmycin SA), metabolically activated alkylating agents such as nitrosoureas (e.g., carmustine, lomustine, (2-chloroethyl)nitrosoureas), triazine antitumor drugs such as triazenoimidazole (e.g., dacarbazine), mitomycin C and leinamycin), DNA strand breakers (e.g., doxorubicin and daunorubicin (which are also reversible DNA binders), other anthracyclines, bleomycins, tirapazamine, enediyne antitumor antibiotics such as neocarzinostatin, esperamicins, calicheamicins, dynemicin A, hedarcidin, C-1027, N1999A2, esperamicins and zinostatin), and disruptors of DNA replication (e.g., 5-fluorodeoxyuridine).

[0535] In an embodiment, the DNA damaging agent is radiation (e.g., radiation that induces a DNA cross-linking in a cell when applied to the cell, (e.g., ionizing radiation and ultraviolet (UV) radiation)). Ionizing radiation consists of subatomic particles or electromagnetic waves that are sufficiently energetic to cause ionization by detaching electrons from atoms or molecules. Ionization depends on the energy of the impinging individual particles or waves. In general, ionizing particles or photons with energies above a few electron volts can be ionizing. Non-limiting examples of ionizing particles are alpha particles, beta particles, and neutrons. The ability of photons to ionize an atom or molecule depends on its frequency. Short-wavelength radiation such as high frequency ultraviolet, x-rays, and gamma rays, is ionizing. Ionizing radiation comes from radioactive materials, x-ray tubes, and particle accelerators.

[0536] In an embodiment, the anticancer agent targets a USP1 independent mechanism of DNA repair. Non-limiting examples of suitable DNA repair inhibitors are poly (ADP-ribose) polymerase (PARP) inhibitors, DNA-dependent protein kinase (DNA-PK) inhibitors, ataxia telangiectasia and Rad3-related protein (ATR) inhibitors, ataxia-telangiectasia mutated (ATM) inhibitors, checkpoint kinase 1 (CHK1) inhibitors, checkpoint kinase 2 (CHK2) inhibitors, and Wee1 inhibitors. It has been reported that BRCA1 / 2 status predicts the efficacy of PARP inhibitors in the clinic (Audeh et al. Lancet (2010) 376 (9737), 245-51). In general, BRCA1 / 2 mutant cancers have increased sensitivity to USP1 inhibitors. Accordingly, in an embodiment, a In an embodiment, provided is a method of treating a disease or disorder associated with USP1 (e.g., cancer) comprising administering or coadministering, in any order, to a patient in need thereof a compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or pharmaceutically acceptable salts thereof) and a PARP inhibitor (e.g., olaparib, rucaparib, niraparib, talazoparib, and veliparib).

[0537] In an embodiment, the anticancer or DNA damaging agent can be a biotherapeutic. Non-limiting examples of suitable biotherapeutics include rInterferon-a2a, rlnterferon-oi2b, rInterleukin-2, rG-CSF, rGM-CSF, and rErythropoietin.

[0538] In an embodiment, the anticancer agent can be an antibody, such as a monoclonal antibody. Non-limiting examples of suitable therapeutic monoclonal antibodies for use in the methods described herein include trastuzumab, an anti-ErbB2 / HER2 for breast cancer, cetuximab, an anti-ErbBl / EGFR for colorectal cancer, and bevacizumab, an anti-VEGF for colorectal, breast and lung cancers (G. Adams et al., Nature Biotechnology 23: 1147-57 (2005)). Multitarget inhibitors, such as Sutent which inhibits TK activity of VEGFR, PDGFR and FGFR, are also suitable for use in the inventive method.

[0539] In an embodiment, the anticancer agent can be a proteasome inhibitor, such as bortezomib.

[0540] Administration of the compounds disclosed herein can be accomplished via any mode of administration of therapeutic agents including systemic or local administration such as oral, nasal, parenteral, transdermal, subcutaneous, vaginal, buccal, rectal or topical administration modes.

[0541] Some patients may experience allergic reactions to the compounds disclosed herein and / or other anti-cancer agent(s) during or after administration; therefore, anti-allergic agents are often administered to minimize the risk of an allergic reaction. In an embodiment, provided is a method of treating a disease or disorder associated with USP1 (e.g., cancer) comprising administering or coadministering, in any order, to a patient in need thereof a compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or pharmaceutically acceptable salts thereof) and an anti-allergic agent(e.g., corticosteroids, including, but not limited to, dexamethasone (e.g., Decadron®), beclomethasone (e.g., Beclovent®), hydrocortisone (also known as cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate, and sold under the tradenames Ala–Cort®, hydrocortisone phosphate, Solu–Cortef®, Hydrocort Acetate® and Lanacort®), prednisolone (sold under the tradenames Delta–Cortel®, Orapred®, Pediapred® and Prelone®), prednisone (sold under the tradenames Deltasone®, Liquid Red®, Meticorten® and Orasone®), methylprednisolone (also known as 6–methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, sold under the tradenames Duralone®, Medralone®, Medrol®, M- Prednisol® and Solu–Medrol®); antihistamines, such as diphenhydramine (e.g., Benadryl®), hydroxyzine, and cyproheptadine; and bronchodilators, such as the beta-adrenergic receptor agonists, albuterol (e.g., Proventil®), and terbutaline (Brethine®)).

[0542] Some patients may experience nausea during and after administration of the compound disclosed herein and / or other anti-cancer agent(s); therefore, anti–emetics are used in preventing nausea (upper stomach) and vomiting. In an embodiment, provided is a method of treating a disease or disorder associated with USP1 (e.g., cancer) comprising administering or coadministering, in any order, to a patient in need thereof a compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or pharmaceutically acceptable salts thereof) and an anti-emetic(e.g., aprepitant (Emend®), ondansetron (Zofran®), granisetron HCl (Kytril®), lorazepam (Ativan®. dexamethasone (Decadron®), prochlorperazine (Compazine®), casopitant (Rezonic® and Zunrisa®), and combinations thereof).

[0543] Medication to alleviate the pain experienced during the treatment period is often prescribed to make the patient more comfortable. In an embodiment, provided is a method of treating a disease or disorder associated with USP1 (e.g., cancer) comprising administering or coadministering, in any order, to a patient in need thereof a compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or pharmaceutically acceptable salts thereof) and an analgesic (e.g., an over-the-counter analgesics, (e.g., Tylenol®), an opioid analgesic (e.g., hydrocodone / paracetamol or hydrocodone / acetaminophen (e.g., Vicodin®), morphine (e.g., Astramorph® or Avinza®), oxycodone (e.g., OxyContin® or Percocet®), oxymorphone hydrochloride (Opana®), and fentanyl (e.g., Duragesic®)).

[0544] In an effort to protect normal cells from treatment toxicity and to limit organ toxicities, cytoprotective agents (such as neuroprotectants, free-radical scavengers, cardioprotectors, anthracycline extravasation neutralizers, nutrients and the like) may be used as an adjunct therapy. In an embodiment, provided is a method of treating a disease or disorder associated with USP1 (e.g., cancer) comprising administering or coadministering, in any order, to a patient in need thereof a compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or pharmaceutically acceptable salts thereof) and a cytoprotective agent (e.g., Amifostine (Ethyol®), glutamine, dimesna (Tavocept®), mesna (Mesnex®), dexrazoxane (Zinecard® or Totect®), xaliproden (Xaprila®), and leucovorin (also known as calcium leucovorin, citrovorum factor and folinic acid)).

[0545] The structure of the active compounds identified by code numbers, generic or trade names may be taken from the actual edition of the standard compendium “The Merck Index” or from databases, e.g., Patents International (e.g., IMS World Publications).

[0546] The above-mentioned compounds, which can be used in combination with a compound disclosed herein, can be prepared and administered as described in the art, including, but not limited to, in the documents cited above.

[0547] In an embodiment, provided are pharmaceutical compositions comprising at least one compound disclosed herein (e.g., a USP1 inhibitor, e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof together with a pharmaceutically acceptable carrier suitable for administration to a human or animal subject, either alone or together with other anti- cancer agents.

[0548] In an embodiment, provided are methods of treating human or animal subjects having or having been diagnosed with a disease or disorder associated with USP1 (e.g., cancer) comprising administering to the subject in need thereof a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof in combination with a second therapeutic agent.

[0549] In an embodiment, provided are methods of treating a disease or disorder associated with USP1 (e.g., cancer) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof in combination with a second therapeutic agent.

[0550] In particular, compositions will either be formulated together as a combination therapeutic or administered separately.

[0551] In combination therapy, the compound disclosed herein and other anti-cancer agent(s) may be administered either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient.

[0552] A compound disclosed herein (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof) may also be used in combination with known therapeutic processes, for example, the administration of hormones or especially radiation. A compound disclosed herein may in particular be used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.

[0553] In certain instances, compounds disclosed herein are combined with other therapeutic agents, including, but not limited to, other anti-cancer agents, anti–allergic agents, anti- nausea agents (or anti-emetics), pain relievers, cytoprotective agents, and combinations thereof. Patient Selection and Monitoring Determining whether a subject will respond to treatment with USP1 inhibitors

[0554] In an embodiment, provided is a method of determining if a subject having or having been diagnosed with a cancer (e.g., a cancer associated with USP1) (i.e., a cancer patient (e.g., a USP1-associated cancer patient)) will respond to therapeutic treatment with a USP1 inhibitor (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof), comprising the steps of: a) detecting levels of RAD18 and / or UBE2K and / or PCNA (e.g., RAD18 and / or UBE2K and / or PCNA protein and / or RAD18 and / or UBE2K and / or PCNA mRNA) in a test cancer sample (e.g., in a cancer test sample obtained from the subject); b) comparing the test cancer sample with reference cells (e.g., a reference sample taken from a non-cancerous or normal control subject), wherein elevated levels of RAD18 and / or UBE2K and / or PCNA in said test cancer sample indicates that the subject will respond to therapeutic treatment with a USP1 inhibitor (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof).

[0555] In an embodiment, provided is a method of determining if a subject having or having been diagnosed with a cancer (e.g., a cancer associated with USP1) (i.e., a cancer patient (e.g., a USP1-associated cancer patient)) will respond to therapeutic treatment with a USP1 inhibitor (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof), comprising the steps of: a) detecting levels of translesion synthesis (e.g., detecting PCNA monoubiquitination levels) in a test cancer sample (e.g., in a cancer test sample obtained from the subject); b) comparing the test cancer sample with reference cells (e.g., a reference sample taken from a non-cancerous or normal control subject), wherein elevatedtranslesion synthesis (e.g., increased PCNA monoubiquitination levels) in said test cancer sample indicates that the subject will respond to therapeutic treatment with a USP1 inhibitor (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof).

[0556] In an embodiment, provided is a method of determining if a subject having or having been diagnosed with a cancer (e.g., a cancer associated with USP1) (i.e., a cancer patient (e.g., a USP1-associated cancer patient)) will respond to therapeutic treatment with a USP1 inhibitor (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof), comprising the steps of: a) detecting mutations in a gene encoding ATM (i.e., loss function mutations) in a test cancer sample (e.g., in a cancer test sample obtained from the subject); b) wherein presence of mutations in a gene encoding ATM in said test cancer sample indicates that the subject will respond to therapeutic treatment with a USP1 inhibitor (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof).

[0557] In an embodiment, provided is a method of determining if a subject having or having been diagnosed with a cancer (e.g., a cancer associated with USP1) (i.e., a cancer patient (e.g., a USP1-associated cancer patient)) will respond to therapeutic treatment with a USP1 inhibitor (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof), comprising the steps of: a) detecting germline or somatic mutations in a gene encoding BRCA1 (e.g., a loss of function mutation) in a subject test sample (e.g., in a cancer test sample or blood test sample obtained from the subject); b) wherein presence of mutations in a gene encoding BRCA1 in said test sample indicates that the subject will respond to therapeutic treatment with a USP1 inhibitor (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof).

[0558] In an embodiment, provided is a method of determining if a subject having or having been diagnosed with a cancer (e.g., a cancer patient) will respond to therapeutic treatmentwith a USP1 inhibitor (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof), comprising the steps of: a) detecting germline or somatic mutations in a gene encoding BRCA2 (e.g., a loss of function mutation) in a subject test sample (e.g., in a cancer test sample or blood test sample obtained from the subject); b) wherein presence of mutations in a gene encoding BRCA2 in said test sample indicates that the subject will respond to therapeutic treatment with a USP1 inhibitor (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof).

[0559] In an embodiment, provided is a method of determining if a subject having or having been diagnosed with a cancer (e.g., a cancer associated with USP1) (i.e., a cancer patient (e.g., a USP1-associated cancer patient)) will respond to therapeutic treatment with a USP1 inhibitor (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof), comprising the steps of: a) detecting deficiency in homologous recombination (e.g., as measured by a positive homologous recombination deficiency (HRD) score) in a subject test sample (e.g., in a cancer sample or blood sample obtained from the subject) b) wherein presence of homologous recombination deficiency (e.g., a positive homologous recombination deficiency (HRD) score) in said test sample indicates that the subject will respond to therapeutic treatment with a USP1 inhibitor (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof).

[0560] In an embodiment, the cancer is a cancer selected from the cancers disclosed herein. In an embodiment, the cancer is pancreatic cancer, breast cancer (e.g., triple negative breast cancer (TNBC)), ovarian cancer (e.g., platinum-resistant ovarian cancer, platinum-refractory ovarian cancer), prostate cancer, lung cancer (e.g., non-small cell lung cancer (NSCLC)). In an embodiment, the cancer is breast cancer (e.g., triple negative breast cancer (TNBC)), ovarian cancer (e.g., platinum-resistant ovarian cancer, platinum-refractory ovarian cancer), prostate cancer, lung cancer (e.g., non-small cell lung cancer (NSCLC)). Determining if a cancer will respond to treatment with a USP1 inhibitor

[0561] In an embodiment, provided is a method of determining if a cancer (e.g., a cancer associated with USP1) will respond to therapeutic treatment with a USP1 inhibitor (e.g., a compound of Formula (I), (II) or a compound of Table 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof), comprising the steps of: a) detecting levels of RAD18 and / or UBE2K and / or PCNA (e.g., RAD18 and / or UBE2K and / or PCNA protein and / or RAD18 and / or UBE2K and / or PCNA mRNA) a cancer test sample (e.g., in a cance...

Claims

Claims What is claimed is:

1. A compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof; wherein:; X1and X2are each independently CH or N; Ring A is selected from the group consisting of:wherein X3is CH or N and wherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B; L is selected from the group consisting of –O– and –S–; Ring B is a 5-10 membered heteroaryl or a 3-10 membered heterocyclyl; each RAis independently selected from the group consisting of –D, oxo, halo, – CN, –C1–C6alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, –ORA1and – N(RA1)2; each RA1is independently selected from the group consisting of H, –C1–C6alkyl, – C1–C6haloalkyl and C3–C9cycloalkyl wherein each hydrogen atom of each alkyl andcycloalkyl can be replaced by deuterium; or two instances of RA1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O; each RBis independently selected from the group consisting of halo, –CN, –C1–C6alkyl, –C1–C6alkenyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, C3-C9cycloalkylalkyl, –ORB1, –N(RB1)2, – C(=O)RB1, –C(=O)ORB1, –NRB1C(=O)RB1, –NRB1C(=O)ORB1, –C(=O)N(RB1)2, – OC(=O)N(RB1)2, –S(=O)RB1, –S(=O)2RB1, –SRB1, –S(=O)(=NRB1)RB1, –NRB1S(=O)2RB1and –S(=O)2N(RB1)2, wherein each alkyl, alkenyl, cycloalkyl, heterocyclyl and cycloalkylalkyl of RBcan be partially or fully deuterated and can be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, –OH– and –CH3; each RB1is independently selected from the group consisting of H, –C1–C6alkyl, – heteroC1-C4alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl and 3-7 membered heterocyclyl wherein each hydrogen atom of each alkyl, cycloalkyl and heterocyclyl can be replaced by deuterium; or two instances of RB1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O; each RCis independently selected from the group consisting of H, –D, oxo, halo, – CN, –ORC1, –SRC1–NRC12, –C1–C6alkyl, –C1–C6hydroxyalkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl, 3-10 member heterocyclyl and –heteroC1-C4alkyl wherein each alkyl, cycloalkyl and heterocyclyl of RCcan partially or fully deuterated and can be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, –OH– and –CH3; each RC1is independently selected from the group consisting of H and –C1–C6alkyl, wherein each hydrogen atom of the alkyl can be independently replaced by deuterium; or two instances of RC1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O; each RDis independently selected from the group consisting of –D, halo, –CN, – C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, –C6-C10aryl, –ORD1, –N(RD1)2, –C(=O)RD1, – C(=O)ORD1, –NRD1C(=O)RD1, –NRD1C(=O)ORD1, –C(=O)N(RD1)2, –OC(=O)N(RD1)2, – S(=O)RD1, –S(=O)2RD1, –SRD1, –S(=O)(=NRD1)RD1, –NRD1S(=O)2RD1and –S(=O)2N(RD1)2,wherein each alkyl, cycloalkyl, heterocyclyl and aryl of RDcan be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, –OH– and –CH3; each RD1is independently selected from the group consisting of H, –C1–C6alkyl, – heteroC1-C4alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl and 3-7 membered heterocyclyl, wherein each hydrogen atom of each alkyl, cycloalkyl and heterocyclyl can be replaced by deuterium; or two instances of RD1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O; REis selected from H, –D, halo, –CN, –C1–C6alkyl, –C1-C6alkynyl, –heteroC1–C6alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, –C6-C10aryl, 5-10 member heteroaryl, heterocyclylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkyl, –ORE1, –SRE1, –N(RE1)2, –C1–C6alkylene–NRE1C(=O)ORE1, – C(=O)RE1, –C(=O)ORE1, –NRE1C(=O)RE1, –NRE1C(=O)ORE1, –C(=O)N(RE1)2, and – OC(=O)N(RE1)2, wherein each alkyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl is optionally substituted at any available position; each RE1is independently selected from H, –C1–C6alkyl (wherein each hydrogen can be independently replaced by deuterium), –heteroC1–C6alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl, 3-7 membered heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, 5-6 membered heteroaryl, arylalkyl and heteroarylalkyl wherein each alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl is optionally substituted at any available position; each Rcand Rc’is independently selected from the group consisting of H, –D, – C1–C6alkyl, –heteroC1-C4alkyl and –C1–C6haloalkyl or Rcand Rc’can be taken together with the atom to which they are attached to form a –C3–C9cycloalkyl; n is 0, 1, 2, 3 or 4; m is 0, 1, 2 or 3; and p is 0, 1, 2 or 3.

2. The compound of claim 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein REis selected from H, halo, –CN, –C1–C6alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, 5-10 member heteroaryl, –ORE1, –SRE1, –N(RE1)2, –C1–C6alkylene– NRE1C(=O)ORE1and –C(=O)N(RE1)2wherein each alkyl, haloalkyl, cycloalkyl, heterocyclyland heteroaryl is substituted at any available position with 0 or 1 substituents independently selected from –CN, –OH, –NCH3, –NH2, –CF3and –F.

3. The compound of claim 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RE1is independently selected from – C1–C6alkyl (wherein each hydrogen can be independently replaced with deuterium), –C1–C6haloalkyl, –heteroC1-C4alkyl, –C3-C9cycloalkyl, 3-7 membered heterocyclyl, cycloalkylalkyl, heterocyclylalkyl and arylalkyl, wherein each alkyl, haloalkyl, heteroalkyl, cycloalkyl, heterocyclyl, cycloalkylalkyl and arylalkyl is independently substituted at any available position with 0 or 1 substituents independently selected from –NH2and –CF3.

4. The compound of claim 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RE1is independently selected from the group consisting of –Me, –CD3, –Et, –iPr, CH2CHF2, –CF3, –CHF2, –CH2F, Bn, cyclopropyl, oxetan-3-yl, tetrahydrofuran-3-yl, CH2-1-CF3-cyclopropyl, CH2CH(NH2)CF3, ,–CH2CH2CH2OMe and –CH2CH2OMe.

5. The compound of claim 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein REis selected from H, –D, halo, –C1–C6alkyl (substituted with 0 or 1 instances of –CN), –C1–C6haloalkyl (substituted with 0 or 1 instances of –NH2or –NHCH3), heteroC1–C4alkyl, –C1–C6hydroxyalkyl (substituted with 0 or 1 instances of –CF3), –C1–C6alkylene–NHC(=O)O(C1-C6alkyl), –C3–C10cycloalkyl (substituted with 0 or 1 instances of –CF3), 3-10 member heterocyclyl (substituted with 0 or 1 instances of –F), 5-10 member heteroaryl, –CH2-heterocyclyl, –NH2, –NH(C1-C6alkyl), – N(C1-C6alkyl)2, –NH(heteroC1–C4alkyl), –OH, –S(C1–C6alkyl), –Ocycloalkylalkyl (substituted with 0 or 1 instances of –CF3), -Oarylalkyl, –O(C1–C6haloalkyl) and –O(C1–C6alkyl) (wherein each hydrogen can be independently replaced by deuterium).

6. The compound of claim 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein REis selected from H, –D, –F, –Cl, –Me, –Et, –iPr, –tBu, –CHF2, –CH2CF3, –CH2CHF2, –CF3, –CH2OMe, –CH(CF3)NH2, – CH(CF3)NHCH3, –CH(OH)CF3, –C(OH)(CH3)2, –CH(OH)CH3, –CH2CN,–C(CN)(CH3)2, – CH2CH2CH2NHC(=O)OC(CH3)3, cyclopropyl, 1-CF3-cyclopropyl, cyclobutyl, cyclopentyl, 3-F-oxetan-3-yl, tetrahydrofuran-3-yl,, , , ,Ocyclopropyl, –O-oxetan-3-yl, –O-tetrahydrofuran-3-yl, –OCH2CH(NH2)CF3, –OCF3, – OCH2CHF2, –OCH2F, –OCHF2, –OCH2CF3, –OMe, –OCD3, –OEt and –OiPr.

7. The compound of claim 1 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein REis selected from H, –D, –CN, –F, –Cl, –Me, –Et, –Pr, –iPr, –nBu, –tBu, –CF3, –CHF2, –C(=O)NH2, –OH and –OMe.

8. The compound of any one of claims 1-7 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RCis independently selected from the group consisting of H, –ORC1, –SRC1, –C1-C6alkyl including partially or fully deuterated alkyl, –C1-C6haloalkyl –C1-C6hydroxyalkyl and C3-C9cycloalkyl.

9. The compound of any one of claims 1-7 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RCis independently selected from the group consisting of H, –C1-C3alkyl including partially or fully deuterated alkyl and –C1-C3hydroxyalkyl .

10. The compound of any one of claims 1-9 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RC1is independently selected from the group consisting of H, –CH3, –Et and –CD3.

11. The compound of any one of claims 1-7or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RCis independently selected from the group consisting of H, –CH3, –Et, –iPr, –CF3, CH2OH, –CH(OH)CH3, –OMe, –SMe and cyclopropyl.

12. The compound of any one of claims 1-7 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RCis independently selected from the group consisting of H, –CH3, CH2OH and –CH(OH)CH3.

13. The compound of any one of claims 1-12 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein X1and X2are both N.

14. The compound of any one of claims 1 to 13 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RDis independently selected from the group consisting of –C1-C6alkyl, –ORD1and C3-C10cycloalkyl.

15. The compound of any one of claims 1 to 13 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RDis independently selected from the group consisting of –ORD1and C3-C10cycloalkyl.

16. The compound of any one of claims 1 to 15 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RD1is independently selected from the group consisting of –C1-C3alkyl and –C1-C3haloalkyl wherein each hydrogen atom of the alkyl can be independently replaced with deuterium.

17. The compound of any one of claims 1 to 15 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RD1is independently –C1-C3alkyl wherein each hydrogen atom of the alkyl can be independently replaced with deuterium.

18. The compound of any one of claims 1 to 15 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RD1is independently selected from the group consisting of –CH3, –Et, –CD3, –CH2F and –CHF2.

19. The compound of any one of claims 1 to 13 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RDis independently selected from the group consisting of –n-Pr, –iPr, –OCH3, –OCD3, –OEt, – OCHF2, –OCH2F and cyclopropyl.

20. The compound of any one of claims 1 to 13 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RDis independently selected from the group consisting of –OCH3, –OCD3, –OEt, –OCHF2, – OCH2F and cyclopropyl.

21. The compound of any one of claims 1 to 13 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RDis independently selected from the group consisting of –OCH3and cyclopropyl.

22. The compound of any one of claims 1 to 21 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein m is 1 or 2.

23. The compound of any one of claims 1-21 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the moiety represented asis selected from the group consistingwherein: each R1is independently selected from the group consisting of –D, halo, –CN, –C1–C6alkyl, –heteroC1-C4alkyl, –C1–C6haloalkyl, –C1–C6hydroxyalkyl, –C3–C10cycloalkyl, 3-10 membered heterocyclyl, –C6-C10aryl, –ORa1, –N(Ra1)2, –C(=O)Ra1, –C(=O)ORa1, – NRa1C(=O)Ra1, –NRa1C(=O)ORa1, –C(=O)N(Ra1)2, –OC(=O)N(Ra1)2, –S(=O)Ra1, –S(=O)2Ra1, –SRa1, –S(=O)(=NRa1)Ra1, –NRa1S(=O)2Ra1and –S(=O)2N(Ra1)2 , wherein each alkyl, cycloalkyl, heterocyclyl and aryl of R1can be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, –OH– and –CH3; each Ra1is independently selected from the group consisting of H, –C1–C6alkyl, – heteroC1-C4alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl and 3-7 membered heterocyclyl, wherein each hydrogen atom of each alkyl, cycloalkyl heterocyclyl can be replaced by deuterium; or two instances of Ra1on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O; each R2is independently selected from the group consisting of –D, halo, –CN, – C1–C6 alkyl, –heteroC1-C4 alkyl, –C1–C6 haloalkyl, –C1–C6 hydroxyalkyl, –C3–C10 cycloalkyl, 3-10 membered heterocyclyl, –C6-C10aryl, –ORa2, –N(Ra2)2, –C(=O)Ra2, – C(=O)ORa2, –NRa2C(=O)Ra2, –NRa2C(=O)ORa2, –C(=O)N(Ra2)2, –OC(=O)N(Ra2)2, – S(=O)Ra2, –S(=O)2Ra2, –SRa2, –S(=O)(=NRa2)Ra2, –NRa2S(=O)2Ra2and –S(=O)2N(Ra2)2, wherein each alkyl, cycloalkyl, heterocyclyl and aryl of R2can be substituted at any available position with 0, 1 or 2 substituents selected from –F, –Cl, –OH– and –CH3; each Ra2is independently selected from the group consisting of H, –C1–C6alkyl, – heteroC1-C4alkyl, –C1–C6haloalkyl, –C3–C9cycloalkyl and 3-7 membered heterocyclyl, wherein each hydrogen atom of each alkyl, cycloalkyl heterocyclyl can be replaced by deuterium; or two instances of Ra2on a nitrogen atom can be taken together with the nitrogen to which they are attached to form a 4-6 member monocyclic heterocycle containing one nitrogen atom and 0-1 additional heteroatoms selected from N and O.

24. The compound of claim 23 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each R1is independently selected from halo, –C1–C6alkyl, phenyl substituted with 0 to 1 instances of halo, –C1–C6haloalkyl, –C1–C6hydroxyalkyl and –C3–C10cycloalkyl.

25. The compound of claim 23 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each R1is independently selected from –iPr and cyclopropyl.

26. The compound of any one of claims 23-25 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each R2is independently ORa2.

27. The compound of any one of claims 23-26 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each Ra2is independently selected from the group consisting of –C1-C6alkyl and –C1-C6haloalkyl wherein each hydrogen atom of the alkyl can be independently replaced with deuterium.

28. The compound of any one of claims 23-26 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each Ra2is independently selected from the group consisting of –CH3, –CD3,–Et, –CHF2and –CH2F.

29. The compound of any one of claims 23-28 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each R2is independently selected from –OCH3, –OCD3, –OCH2F and –OCHF2.

30. The compound of any one of claims 1-21 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the moiety represented as31. The compound of any one of claims 1-21 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the moiety represented as32. The compound of any one of claims 1-21 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the moiety represented as33. The compound of any one of claims 1-21 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound is of Formula (I-b)Formula (I-b); wherein Ra2is selected from the group consisting of CH3, –CHF2and –CD3.

34. The compound of any one of claims 1 to 33 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein L is –O–.

35. The compound of any one of claims 1 to 33 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein L is –S–.

36. The compound of any one of claims 1 to 35 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rcand Rc’are eachindependently selected from H, –Me, –CF3and –CHF2or are taken together to form a cyclopropyl.

37. The compound of any one of claims 1 to 36 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ring A is selected from the group consisting ofwherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

38. The compound of any one of claims 1 to 36 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ring A iswherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

39. The compound of any one of claims 1 to 38 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein n is 1 or 2.

40. The compound of any one of claims 1 to 38 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein n is 0 or 1.

41. The compound of any one of claims 1 to 40 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RAis independently selected from C1-C6alkyl, C1-C6haloalkyl, –OC1-C3alkyl, and halo.

42. The compound of any one of claims 1 to 40 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RAis independently halo.

43. The compound of any one of claims 1 to 40 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RAis independently selected from –F, –Cl, –CH3, –Et,–CH2CF3, –OCH3and –OEt.

44. The compound of any one of claims 1 to 40 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the moiety representedselected from the group consisting of, ,wherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

45. The compound of any one of claims 1 to 40 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the moiety represented (RA)nis selected from the group consisting of, ,wherein the left-side attachment point connects to CRcRc’and the right attachment point connects to Ring B.

46. The compound of any one of claims 1 to 40 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound is of Formula (I-c)Formula (I-c); wherein Ra2is selected from the group consisting of CH3, –CHF2and –CD3.

47. The compound of any one of claims 1 to 40 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound is of Formula (I-d)Formula (I-d); wherein Ra2is selected from the group consisting of CH3, –CHF2and –CD3.

48. The compound of any one of claims 1 to 40 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound is of Formula (I-d-1)Formula (I-d-1); wherein Ra2is selected from the group consisting of CH3, –CHF2 and –CD3.

49. The compound of any one of claims 1-46 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ring B is a 5-6 member monocyclic heteroaryl containing 1-3 heteroatoms selected from O, N and S.

50. The compound of any one of claims 1-46 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ring B is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxadiazolyl and triazolyl.

51. The compound of any one of claims 1-46 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ring B is selected from the group consisting of pyridinyl, pyrazolyl and imidazolyl.

52. The compound of any one of claims 1-46 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ring B is selected from the group consisting of pyrazolyl and imidazolyl.

53. The compound of any one of claims 1-46 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ring B is selected from the groupconsisting of pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, pyrazin-2-yl, pyrazin-3-yl, pyridazin-3-yl, pyridazin-4-yl, pyridazin-5-yl, pyridazin-6-yl, pyrrol-2-yl, pyrazol-1-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol- 2-yl, thiazol-4-yl, thiazol-5-yl, thiadiazol-3-yl, thiadiazol-5-yl, oxadiazol-3-yl, oxadiazol-5-yl, 1,2,3 triazol-1-yl and 1,2,5 thiazol-4-yl.

54. The compound of any one of claims 1-46 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ring B is selected from the group consisting of pyridin-2-yl, pyrazol-1-yl and imidazol-2-yl.

55. The compound of any one of claims 1-46 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ring B is selected from the group consisting of pyrazol-1-yl and imidazol-2-yl.

56. The compound of any one of claims 1-55 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein p is 1, 2 or 3.

57. The compound of any one of claims 1-56 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RBis independently selected from the group consisting of halo, –CN, –C1-C6alkyl (including partially or fully deuterated alkyl), –C1-C6haloalkyl, –C1-C6hydroxyalkyl, C3-C10cycloalkyl, ORB1, –C(O)(NRB1)2and – C(O)ONRB1.

58. The compound of any one of claims 1-56 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RBis independently selected from the group consisting of halo, –C1-C6alkyl (including partially or fully deuterated alkyl), –C1-C6alkenyl, –C1-C6haloalkyl, -heteroC1-C4alkyl, –C3-C10cycloalkyl (substituted with 0, 1 or 2 instances of F), 4-7 member heterocyclyl (substituted with 0 or 1 instances of methyl), C3-C10cycloalkylalkyl and ORB1.

59. The compound of any one of claims 1-58 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RB1is independently –C1– C6alkyl.

60. The compound of any one of claims 1-58 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RB1is independently selected from the group consisting of –Me and –Et.

61. The compound of any one of claims 1-56 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RBis independently selected from the group consisting of –Cl, –CH3, –CD3,–Et, –iPr,–CH=CHCH3, –CH2CF3,– CH(CH3)CF3, –CF3, –CHF2, –OCH3, –OEt, cyclopropyl, 2,2-difluorocyclopropyl, 1-Me-azetidin-3-yl, oxetan-3-yl, tetrahydropyran-4-yl, –CH2CH2OCH3,–OCH(CH3)CH2OCH3, – CH2-cyclopropyl.

62. The compound of any one of claims 1-56 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RBis independently selected from the group consisting of –Cl, –CD3,–CH3, –Et, –iPr, –CF3, –OCH3and cyclopropyl.

63. The compound of any one of claims 1-56 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RBis independently selected from the group consisting of –Cl, –CH3, –Et, –iPr, –CF3, –OCH3and cyclopropyl.

64. The compound of any one of claims 1-56 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each RBis independently selected from the group consisting of –CH3, –Et, –iPr, –CF3and cyclopropyl.

65. The compound of any one of claims 1-46 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the moiety represented by66. The compound of any one of claims 1-46 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the moiety represented byselected from the group consisting,67. The compound of any one of claims 1-36 and 39-43 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound is of Formula (I-e)wherein RAis F; Ra2is selected from the group consisting of CH3,iPr, –CHF2and –CD3; and RBis selected from the group consisting of –Me, –Et and cyclopropyl.

68. The compound of any one of claims 1-36 and 39-43 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound is of Formula (I-f)Formula (I-f); wherein Ra2is selected from the group consisting of CH3, –CHF2and –CD3; and RBis selected from the group consisting of –Me, –Et and cyclopropyl.

69. The compound of any one of claims 1-36 and 39-43 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound is of Formula (I-f-1)Formula (I-f-1); wherein Ra2is selected from the group consisting of CH3, –CHF2and –CD3; and RBis selected from the group consisting of –Me, –Et and cyclopropyl.

70. The compound of any one of claims 1 to 69 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the compound is selected from:.

71. A pharmaceutical composition comprising a compound of any one of claims 1 to 70 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceutically acceptable carrier.

72. The pharmaceutical composition of claim 71, further comprising a second therapeutic agent.

73. A compound of any one of claims 1 to 70 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition of claim 71 or 72 for use in a method for treating or preventing a disease or disorder associated with the inhibition of USP1 comprising administering to a patient in need thereof a therapeutically effective amount of the compound or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

74. A compound of any one of claims 1 to 70 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition of claim 71 or 72 for use in a method of treating a disease or disorder associated with the inhibition of USP1 comprising administering to a patient in need thereof a therapeutically effective amount of the compound or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

75. A compound of any one of claims 1 to 70 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition of claim 71 or 72 for use in a method for inhibiting USP1 comprising administering to a patient in need thereof an effective amount of the compound or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

76. A compound of any one of claims 1 to 70 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition of claim 71 or 72 for use in a method for treating or preventing cancer in a patient in need thereof comprising administering to the patient in need thereof a therapeutically effective amount of the compound or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

77. A compound of any one of claims 1 to 70 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition of claim 71 or 72 for use in a method for treating cancer in a patient in need thereof comprising administering to the patient in need thereof a therapeutically effective amount of the compound or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

78. The compound or composition for use of any one of claims 76 or 77, wherein the cancer is a cancer that is sensitive to USP1 inhibition.

79. The compound or composition for use of any one of claims 76 to 78, wherein the cancer is a cancer that is sensitive to USP1 inhibition due to a dysfunctional DNA-repair pathway.

80. The compound or composition for use of any one of claims 76 to 79, wherein the cancer is a HRR (homologous recombination repair) gene mutant cancer.

81. The compound or composition for use of any one of claims 76 to 80, wherein the cancer is a HRR (homologous recombination repair) gene mutant cancer selected from the group consisting of ATM, NBN, FANCA, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, or RAD54L mutant cancer.

82. The compound or composition for use of any one of claims 76 to 81, wherein the cancer is characterized by a positive homologous recombination deficiency (HRD) score.

83. The compound or composition for use of any one of claims 76 to 82, wherein the cancer is a BRCA1 and / or a BRCA2 mutant cancer.

84. The compound or composition for use of any one of claims 76 to 83, wherein the cancer is a BRCA1 and / or a BRCA2 deficient cancer.

85. The compound or composition for use of any one of claims 76 to 84, wherein the cancer is a PARP inhibitor resistant or refractory cancer.

86. The compound or composition for use of any one of claims 76 to 85, wherein the cancer is selected from adrenocortical carcinoma, AIDS-related lymphoma, AIDS-related malignancies, anal cancer, cerebellar astrocytoma, extrahepatic bile duct cancer, bladder cancer osteosarcoma / malignant fibrous histiocytoma, brain stem glioma, ependymoma, visualpathway and hypothalamic gliomas, breast cancer, bronchial adenomas / carcinoids, carcinoid tumors, gastrointestinal carcinoid tumors, carcinoma, adrenocortical, islet cell carcinoma, primary central nervous system lymphoma, cerebellar astrocytoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, clear cell sarcoma of tendon sheaths, colon cancer, colorectal cancer, cutaneous t-cell lymphoma, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma / family of tumors, extracranial germ cell tumors, extragonadal germ cell tumors, extrahepatic bile duct cancer, eye cancers, including intraocular melanoma, and retinoblastoma, gallbladder cancer, gastrointestinal carcinoid tumor, ovarian germ cell tumor, gestational trophoblastic tumor, hairy cell leukemia, head and neck cancer, Hodgkin's disease, hypopharyngeal cancer, hypothalamic and visual pathway glioma, intraocular melanoma, Kaposi's sarcoma, laryngeal cancer, acute lymphoblastic leukemia, acute myeloid leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, non-Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, malignant mesothelioma, malignant thymoma, medulloblastoma, melanoma, intraocular melanoma, merkel cell carcinoma, metastatic squamous neck cancer with occult primary, multiple endocrine neoplasia syndrome, multiple myeloma / plasma cell neoplasm, mycosis fungoides, myelodysplastic syndrome, chronic myelogenous leukemia, myeloid leukemia, multiple myeloma, myeloproliferative disorders, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cancer, oral cavity and lip cancer, oropharyngeal cancer, osteosarcoma / malignant fibrous histiocytoma of bone, ovarian cancer, ovarian low malignant potential tumor, pancreatic cancer, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pheochromocytoma, pituitary tumor, pleuropulmonary blastoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, transitional cell cancer (e.g., renal pelvis and ureter), retinoblastoma, rhabdomyosarcoma, salivary gland cancer, malignant fibrous histiocytoma of bone, soft tissue sarcoma, Sezary syndrome, skin cancer, small intestine cancer, stomach (gastric) cancer, supratentorial primitive neuroectodennal and pineal tumors, cutaneous t-cell lymphoma, testicular cancer, malignant thymoma, thyroid cancer, gestational trophoblastic tumor, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and Wilms' tumor.

87. The compound or composition for use of any one of claims 76 to 85, wherein the cancer is selected from breast cancer, ovarian cancer, pancreatic cancer, prostate cancer and lung cancer.

88. The compound or composition for use of any one of claims 76 to 85, wherein the method further comprises administering to the patient a second therapeutic agent.

89. The compound or composition for use of any one of claims 76 to 85, wherein the second therapeutic agent is a PARP inhibitor.

90. A compound of any one of claims 1 to 70 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition of claim 71 or 72 for use in a method for treating or preventing a disease or disorder associated with DNA damage.

91. The compound or composition for use of claim 90, wherein the disease is cancer.

92. A compound of any one of claims 1 to 70 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition of claim 71 or 72 for use in a method for treating a disease or disorder associated with DNA damage.

93. A compound of any one of claims 1 to 70 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition of claim 71 or 72 for use in a method of inhibiting, modulating or reducing DNA repair activity exercised by USP1 comprising administering to a patient in need thereof an effective amount of the compound or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

Citation Information

Patent Citations

  • Usp1 inhibitors for the treatment of cancer

    US62857986P0

  • Inhibitors of the USP1 / UAF1 deubiquitinase complex and uses thereof

    US9802904B2

  • Expression monitoring by hybridization to high density oligonucleotide arrays

    WO1997010365A1

  • Small molecule inhibitors of USP1 deubiquitinating enzyme activity

    WO2011137320A2

  • Purinones as ubiquitin-specific protease 1 inhibitors

    WO2017087837A1

Cited By

  • Ubiquitin specific processing protease 1 (USP1) compounds

    WO2025096539A1